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Abstract 
 
This work is concerned with the design and synthesis of the cheap, late first row 
transition metal complexes of Schiff base ligand systems. The prepared complexes 
readily afford systematic variation in order to probe potency and understand the role of 
metal, chelating ligands and anionic ligands when carrying out their cytotoxic effect. 
This study has lead to a better understanding of the action of these classes of complex 
and will be used to direct the design of new anti-cancer metallopharmaceuticals going 
forward. 
 
This thesis details the synthesis of a library of Schiff base macroacyclic ligands and 
their novel late first row transition metal complexes with varying anionic counterparts. 
The creation of a library with several degrees of variability provides a wide array of 
parameters to afford subtle variation in structure and chemistry e.g. denticity, co-
ordination mode, chelate hole size, metal centred redox potentials, hydrolysis rates, co-
ordinative saturation, lipophilicity, solubility and more. 
 
Complexation of the ligands was carried out by the free ligand and a novel macroacyclic 
metal template approach using the cheap late first row transition metal salts of  Cobalt 
(II), Nickel (II), Copper (II) and Zinc (II) plus one Ru (III) complex. Structural studies 
of the 80 generated complexes was carried out by vibrational spectroscopy, elemental 
analysis, mass spectrometry, magnetic susceptibility and NMR.   
 
Single crystal X-ray structures have been determined with 20 reported in this thesis. All 
ligands act as tridentate ligands in all except one case to form monomeric distorted 
trigonal-bipyramidal, square-pyramidal or octahedral structures. In the case of zinc 
nitrate, the ligand L
2
PhMe acts as a tetradentate ligand to give a distorted octahedral 
structure. Paramagnetic NMR and solution magnetic susceptibility of paramagnetic 
complexes was achieved by the Evans NMR method and analysis of the solution NMR 
showed that L
2
R and L
3
R ligands display 2-fold symmetry and are likely either 
tetradentate in solution or a fast exchange between imine N-donar sites is occurring 
even down to -65°C. 
 
The majority of the resulting complexes of L
1
R were screened against a panel of three 
cancer cell lines. Several categories of complex were able to afford structure activity 
relationships. It was discovered that the ligand is indeed essential for activity of the 
metal salts against the panel of cell lines and it was largely discovered that the variation 
in ‘tail group’ and anionic coordinating ligands played little role in providing a dramatic 
variation in activity of the metal salt. In general all L
1
R complexes displayed moderate 
cytotoxicity showing a trend in activity with respect to the metal in the order 
Ru
III≈CoII>CuII≈ZnII>NiII, over a 6 day exposure to the three cell panel RuIII was shown 
to be the most potent metal of the L
1
R series providing IC50 values of 4.6 (0.7) and 7.5 
(1.2) μM against the DLD-1 and H460 cell lines respectively, which is Ca. 4.6 and 15 
  
iii 
times less potent than cisplatin to the same cell panel respectively. Ru
III
 was also 
discovered to be the only metal to provide an IC50 value from a 1 hour exposure to the 
DLD-1 cell panel. The value of 20.4 (3.5) μM is a moderate figure but again Ca. 10 fold 
less potent than cisplatin for the same test.  
 
The L
2
R and L
3
R complexes could not be screened by the same comprehension due to 
their low solubilities. However the lone screen that was possible from the very sparingly 
soluble complex [CuCl2(L
3
Bu
i
)] gave the most exciting result and most potent complex 
of this thesis. After a 6 day exposure, [CuCl2(L
3
Bu
i
)] gave IC50 values of 4.3 (0.1) and 
2.9 (0.1) μM against the DLD-1 and H460 cell lines respectively. These values are 
merely 4 and 6 fold more than Cisplatin to the same cell lines respectively and 
demonstrates the potential of this class of complex as cytostatic agents. 
 
Further studies utilising a semi-quantitative DNA damaging assay, demonstrated that all 
first row complexes can damage DNA when in the presence of hydrogen peroxide, with 
the exception of Zn
II
 complexes. Co
II
 appeared to afford the greatest DNA damage with 
the most intsense bands for double strand breaks and the Cu
II
 complex of the ligand 
L
3
Bu
i
 also demonstrated a greater DNA damage as opposed to its L
1
Bu
i
 analogue. 
 
Key Words 
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1. Introduction 
 
1.1. Natural History of Cancer 
 
In the body, the birth and death of normal cells are carefully regulated: in a young 
animal, the rate of cell multiplication exceeds that of cell death; in adults, the rate of cell 
multiplication and death is balanced at a steady state. Occasionally, these controls 
breakdown and cells continue to grow when no longer needed. Descendants of these 
cells inherit the characteristics of uncontrolled growth, which results in a mass of cells 
that continues to grow indefinitely, forming a tumour.
1
  
 
Benign tumours are localised and closely resemble the normal ‘parent’ cells from which 
they arose; such tumours are normally encased in a fibrous capsule and pose little threat 
to life.
2
 In general, benign tumours can be surgically removed and will not spread to 
other tissues (by virtue of their encapsulation). Benign tumours are only problematic if 
their size hinders the function of normal tissue or if they secrete excess amounts of 
chemical (e.g. hormones), which the body becomes unable to cope with.
3
 
 
Unlike benign tumours, malignant tumours are not localised or encapsulated. These 
tumours have the ability to spread (metastasise);
4
 they can invade neighbouring tissue or 
enter the circulatory system and appear as new tumours at sites remote to the tissue of 
origin.  
 
The term ‘cancer’ is generally used to describe a malignant growth and will be used in 
this thesis. It is rarely possible to determine exactly how a malignancy began, although 
  
2 
some cancer risk factors have been identified. For further information on cancer and it’s 
molecular features, refer to the excellent review by Hanahan et al.
1
  
 
1.1.1. Carcinogenesis 
 
A normal cell can be transformed into a malignant cell by the expression of one or more 
oncogenes. Oncogenes are genes that encode proteins (oncoproteins) that are able to 
induce cancer in animals, or transform cells in culture, and are responsible for the 
breakdown of normal cell regulation. Most oncogenes are derived from normal genes; 
these precursors are known as proto-oncogenes and are often important for normal cell 
function. Oncogenes may give rise to mutant forms of the protein coded for by the 
proto-oncogene, leading to malignant transformation, or may code for the same protein 
as the proto-oncogene (here, malignancy occurs by virtue of an overexpression of the 
protein or expression where the protein is normally absent).
1
 
 
Five classes of protein have been identified which are involved in the regulation of cell 
growth. These are growth factors, growth factor receptors, intracellular signal 
transducers, nuclear transcription factors and cell-cycle control proteins. Genes for each 
class of protein are known to give rise to one or more oncogenes, further demonstrating 
that regulation of cell growth is inherently linked to the initiation of malignancy. 
Oncogenes often act together to cause malignancy, no one oncogene has been shown to 
be capable of inducing malignant transformation on its own. It may take some time for a 
cell to acquire enough alterations to induce malignancy; this could account for the long 
periods of time that may pass between exposure to carcinogen and development of 
cancer. 
1
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Oncogenes are transformed by, or carried into cells, by one of three main types of 
transforming agents: viruses, chemical carcinogens and radiation. Each transforming 
agent is briefly discussed in the following sections.  
 
The other set of growth regulatory proteins are the tumour suppressor genes (anti-
ocnogenes), which can be deactivated. If DNA is damaged in a normal cell, there are 
cellular ‘policemen’ that can detect damage and block DNA replication. This gives the 
cell time to repair the damaged DNA before the next cell division. If repair does not 
prove possible, the cell commits suicide (apoptosis).5 Tumour suppressor genes are 
genes which code for proteins that are involved in these processes of checking, repair 
and suicide. TP53 is an important example of such a gene and codes for the protein of 
the same name (p53). If the TP53 gene is damaged, the repair mechanisms become less 
efficient, defects are carried forward from one cell generation to another and as the 
damage increases, the chances of the cell becoming cancerous increase. 
 
Genetic defects can lead to the following cellular defects, all of which are associated 
with cancer: 
 Abnormal signalling pathways 
 Insensitivity to growth-inhibitory signals 
 Abnormalities in cell cycle regulation 
 Evasion of programmed cell death (apoptosis) 
 Limitless cell division (immortality) 
 Ability to develop new blood vessels (angiogenesis) 
 Tissue invasion and metastasis 
  
4 
It is thought that most, if not all, of these conditions have to be met before a defective 
cell can spawn life-threatening malignant growth. Thus, a single defect can be kept 
under control by a series of safeguards. This can explain why cancers may take many 
years to develop after exposure to a damaging mutagen such as asbestos or coal dust. 
That first exposure may have caused mutations in some cells, but cellular chemistry has 
the control systems in place to cope and to keep the cells in check. A lifetime’s 
exposure to other damaging mutagens such as tobacco smoke, however, results in 
further genetic damage which overwhelm the safeguards one by one until the abnormal 
cell finally breaks free of its shackles and becomes cancerous. 
 
The various hurdles and safeguards that a potential cancer cell has to overcome explain 
why cancers are relatively rare early on in life and are more common in later years. This 
also helps to explain why cancer is so difficult to treat once it does appear. Since so 
many cellular safeguards have already been overcome, it is unlikely that tackling one 
specific cellular defect is going to be totally effective. As a result, traditional anticancer 
drugs have tended to be highly toxic agents and act against a variety of cellular targets 
by different mechanisms.
6
 Unfortunately, since they are potent cellular poisons, they 
also affect normal cells and produce serious side effects. Such agents are said to be 
cytotoxic, and dose levels have to be chosen which are high enough to affect the tumour 
but are bearable to the patient. 
7
 
 
In recent years, anticancer drugs have been developed which target specific 
abnormalities in a cancer cell, allowing them to be more selective and have less serious 
side effects. However, bearing in mind the number of defects in a cancer cell, it is 
unlikely that a single agent of this kind will be totally effective and it is more likely that 
  
5 
these new agents will be most effective when they are used in combination with other 
drugs having different mechanisms of action, or with surgery and radiotherapy.
8
 
1.1.1.1. Tumour Viruses 
 
There are two types of tumour virus that can act as transforming agents: RNA-
containing viruses (retroviruses) and DNA-containing viruses. The tumour viruses 
achieve malignancy by integrating their own genetic information into the DNA of the 
host cell. This can lead to chronic expression/over-expression of oncoproteins, which 
cause the cell to go out of control. 
1.1.1.2. Chemical Carcinogens 
 
Most of the known chemical carcinogens do not share a common chemical structure. 
However, there are two (very broad) categories of chemical carcinogens, direct-acting 
and indirect-acting.
9
 
 
Direct-acting carcinogens are highly reactive electrophiles, of which there are only a 
few (e.g. some nitrosamines and certain alkylating agents). N-methylnitrosourea is a 
direct-acting carcinogen that can form the methyldiazonium ion (Figure 1), which can 
then form adducts with DNA causing malignancy. Other nitrosamines require metabolic 
activation to form the methyldiazonium ion and, therefore, cannot be classified as 
direct-acting. Nitrogen mustard is an example of an alkylating agent that can function as 
a direct-acting carcinogen. As nitrogen mustard is bifunctional (Figure 1), it can form 
inter- and intrastrand crosslinks with adjacent bases in DNA and is direct-acting because 
its chlorine groups are sufficiently electrophilic to interact with nucleophiles, without 
metabolic activation.
10
  
  
6 
Figure 1. Examples of direct-acting carcinogens.
10
 
 
 
 
Indirect-acting carcinogens (e.g. polycyclic aromatic hydrocarbons, aromatic amines) 
require metabolic activation and the introduction of electrophilic centres, in order to 
become ultimate carcinogens and therefore carcinogenic. Enzymes in the body, 
particularly those in the liver, carry out metabolic activation. These activation processes 
serve to detoxify chemicals, adding hydrophilic groups to insoluble compounds and, 
thus, allowing them to be easily excreted by the body. The metabolic activation process 
is catalysed by the cytochrome P450 family of proteins and can lead to highly reactive 
electrophiles (e.g. epoxides) that are ultimate carcinogens. Figure 2 shows the activation 
of benzopyrene, an indeirect-acting carcinogen. 
 
 
 
 
 
 
 
NO
NH
2
O
N
N
+
N-methylnitrosourea methyldiazonium ion
N
Cl
Cl
nitrogen mustard
  
7 
Figure 2. Example of indirect-acting carcinogens – metabolic activation of 
benzopyrene.
10
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Thus, the ultimate carcinogens and the direct-acting carcinogens can form covalent 
bonds with many different negative charged centres, including DNA, RNA and 
proteins, by virtue of their electrophilic nature. However, it is only the DNA-adducts 
which are thought to be related to the development of malignancy; such adducts alter 
the sequence of the DNA and thus, are mutagens. This is not to say that all mutagens are 
carcinogens, sometimes, mutagenicity can result in immediate cell death, rather than an 
increased growth rate of cells. 
 
The International Agency for Research on Cancer (IACR has developed a classification 
system for describing the carcinogenic risk to humans of such agents, mixtures and 
exposure circumstances. Table 1 summarises the IACR classification system of 
chemical carcinogen. 
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Table 1. IACR classification of chemical carcinogens
10, 11 
Group Risk 
Chemicals 
(no. in group) 
Exposure circumstances 
1 Carcinogenic 
Benzene, nitrogen 
mustard (28) 
Tobacco smoking 
2A 
Probably 
carcinogenic 
Benzo(a)pyrene, 
dimethylsulfoxide (63) 
Petroleum industry 
 
2B Possibly carcinogenic 
Aziridine, chloroform 
(235) 
Dry cleaning 
3 Unclassifiable 
Aniline, bromoethane 
(483) 
Leather goods 
manufacture 
4 
Probably not 
carcinogenic 
Caprolactam (1)  
 
1.1.1.3. Radiation 
 
Humans are exposed to radiation from many sources and several types of radiation are 
responsible for causing certain cancers, as summarised in Table 2. 
 
Table 2. Types and sources of radiation that cause cancer in humans.
10
  
Radiation type Source Related cancer 
Ultraviolet Exposure to sunlight Skin 
X-ray Medical procedures Leukaemia, thyroid 
Atomic particle Military weapons All types 
Radon Mining, building materials Lung 
 
Ultraviolet (UV) radiation and ionising radiations (X-rays and atomic particles are 
particularly dangerous. UV radiation has only limited penetration and consequently, 
mainly affects the skin. UV radiation does not break chemical bonds in DNA; rather it 
excites other molecules and makes them more reactive. These excited species can then 
bond to DNA and once bound they can form covalent bonds between pyrimidine bases, 
producing dimers. These dimers interfere with DNA transcription and replication and if 
they are not quickly repaired, can cause carcinogenisis. Ionising radiation causes single- 
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and double-strand breaks in DNA, resulting in chromosome deletions and 
rearrangements. 
1.1.1.4. Reactive Oxygen Species 
 
Reactive free radicals are routinely generated during normal metabolic pathways. These 
reactive species are capable of oxidising nucleic acids and lipids, causing alterations in 
DNA, interfering with DNA repair mechanisms and activating signal transduction 
pathways. Cells come under oxidative attack numerous times a day, but mostly the 
damage is repaired. Occasionally, base changes are not repaired and can contribute to 
carcinogenisis. The main culprits here are reactive oxygen species, the major source of 
which is oxidative phosphorylation, although reactive nitrogen species can also cause 
problems.
10
 The predominant forms of reactive oxygen are the superoxide radical and 
its conjugate acid the hydroperoxy radical (the most reactive and therefore most 
dangerous) and hydrogen peroxide (which, although is not an actual radical, is a 
precursor to the hydroxyl radical).
12
 Cells contain various species capable of 
inactivating reactive oxygen species, such as proteins, glutathione and certain 
vitamins.
13
 
1.1.2. Risk Factors Associated with an Increased Incidence of Cancer 
 
The previous sections outlined agents that are known to promote carcinogenesis. 
However, there are certain lifestyle factors that are associated with an increasd risk of 
developing cancers. Epidemiological analysis of the five main cancers in both men and 
women (see Table 3) has identified four factors (tobacco smoking, diet, sex hormones 
and family history) which were associated most frequently with the prevalent cancers 
and these are discussed in the proceeding sections.  
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Table 3. Incidence of the five main cancers in the USA and their risk factors.
10
  
Cancer Percentage of all cases Risk factors 
Men   
Prostate 36 
Sex hormones 
Diet 
Lung 13 Tobacco Smoking 
Colorectal 12 
Diet 
Family history 
Urinary tract 9 Smoking 
Leukaemia/lymphoma 7 Non identified 
Women   
Breast 33 
Sex hormones 
Family history 
Diet 
Lung 13 Smoking 
Colorectal 12 
Family history 
Diet 
Leukaemia/lymphoma 6 Non identified 
Ovary 5 
Ovulation 
Family history 
 
1.1.2.1. Smoking 
 
Tobacco smoking is widely known to be a risk factor in lung cancer, but it is also 
implicated in a number of other cancers, including those of the mouth, bladder and 
kidney. More than 40 potential carcinogens have been isolated from tobacco smoke and 
there is a clear close relationship between the number of cigarettes smoked and cancer 
risk. 
1.1.2.2. Diet 
 
Diet has the most effect in areas of the body that come into direct contact with food (e.g. 
the gastrointestinal tract); however, diet is also implicated in other areas, such as the 
breast and lung. It is difficult to conclude exactly which foods are ‘good’ and ‘bad’ in 
terms of cancer risk, as the modern diet is varied. A diet high in fruit and vegetables is 
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thought to be beneficial in terms of decreasing the risk of cancer, because of the 
presence of antioxidants that are able to counteract the DNA-damaging effects of 
reactive oxygen species. Saturated fat, meat, salt and alcohol are all considered to be 
dietary risk factors and are implicated in a number of cancers (stomach, colon and 
breast cancer). 
1.1.2.3. Sex Hormones 
 
Sex hormones are implicated in the most common smoking-unrelated cancers, in both 
men and women (prostate and breast cancer, respectively). Chemical or surgical 
castration of men dramatically reduces the incidence of prostate cancer, while removal 
of the ovaries reduces the risk of breast cancer. These hormones influence proliferation 
of their target cells and hence, increase the risk of cancer at these sites. 
1.1.2.4. Familial Cancers 
 
The majority of cancers (>90%) are sporadic and no evidence exists to suggest that the 
disease may be inherited from family members. A small percentage of cancers (5-10%) 
have some degree of familial involvement, including breast and colon cancer. A very 
small percentage of cancer (approximately 0.1%), have a strong familial link, including 
retinoblastoma and Wilm’s tumour of the kidney. 
 
1.2. The Global Burden of Cancer 
 
Cancer is an indiscriminate, collection of diseases, affecting millions of people 
worldwide. The global number of new cancer cases reported in 2000 was 10.1 million, 
(excluding cases of non-malignant skin cancer)
14
 and in 2006 in the UK alone 293,601 
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people were diagnosed with cancer.
15
 The most commonly occurring cancer in 2000 
was that of the lung, with 1.2 million new cases and 1.1 million lung-cancer related 
deaths reported. Lung cancer was once rare, but today incidence of the disease has 
reached epidemic proportions.
16
 North America and Europe have the highest incidence 
of lung cancer, with one of the highest rates occurring here in the UK. Clearly, there is 
an urgent need for new, effective treatments for this and many other cancers. 
1.2.1. Cancer Management 
1.2.1.1. Surgery 
 
The majority of patients with solid tumours will require surgical intervention at some 
point in their treatment programme. A large proportion of patients will undergo an 
initial diagnostic biopsy before treatment starts. Surgery and subsequent pathological 
examination of excised tissue, is used to determine the stage to which the disease has 
progressed, allowing suitable treatment to be chosen and defining the risk of relapse. If 
a tumour is localised and displays limited spread to the regional nodes or metastases, a 
complete surgical cure may be achieved. During surgery, the lymph nodes are often 
removed, providing information on disease progression and helping to prevent 
recurrence. Distant metastases are sometimes removed, although these are commonly 
dealt with by non-surgical means. Surgery alone is rarely able to provide a cure once the 
disease has metastasised, as there is a risk of recurrent disease at the primary site, in 
conjunction with the fact that micrometastases may continue to grow. In these cases, a 
cure is more likely to be achieved by a combination of surgery with chemotherapy 
and/or radiotherapy. Surgery is also used in palliative care, but careful consideration is 
given to whether the proposed benefits outweigh the possible trauma and discomfort of 
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a surgical procedure. Prophylactic surgeries are carried out, typically mastectomy on 
women with a family history of breast cancer.  
1.2.1.2. Radiotherapy 
 
Ionising radiation induces DNA damage in normal and tumour cells; if DNA damage is 
not repaired, apoptosis (programmed cell death) results. Radiotherapy can be 
administered as one single dose but it is more commonly given in multiple doses, with 
rest periods between treatments. This is because cells are only radiosensitive during 
certain phases of the cell cycle. Therefore, administering the treatment in cycles allows 
normal cells to recover from the effects of the radiation and allows tumour cells to 
become re-oxygenated. This is important, as hypoxic cells are resistant to ionising 
radiation.    
 
Radiotherapy is routinely used to treat a number of cancers, including head and neck, 
cervical, bladder, lung, lymph and oesophageal. As with surgery, radiotherapy can be 
used effectively at a variety of stages in the treatment programme. Radiotherapy is 
commonly used as an adjuvant therapy (to help in local disease control) or in 
neoadjuvant therapy (to reduce tumour mass prior to surgery). Post-operative 
radiotherapy is also carried out, particularly when residual disease is present. Finally, 
radiotherapy can be used in palliative care to improve quality of life. 
1.2.1.3. Chemotherapy 
 
Chemical agents are used in a variety of ways, throughout the treatment programme. 
Cancers are rarely cured by chemotherapy alone, although there are a limited number of 
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malignancies that can be managed this way. More often, chemotherapy is used as part of 
a treatment regimen or to alleviate symptoms and improve quality of life. 
 
The main ways that chemical agents are used in cancer treatment are: as neoadjuvant 
therapy prior to surgery; as adjuvant therapy following surgical removal of the tumour; 
as palliative therapy to improve quality of life; and as prophylactic treatment in high-
risk groups (e.g. tamoxifen in women with a family history of breast cancer). Curative 
chemotherapy, in particular, tends to be aggressive and side effects are severe. 
 
There are several groups of chemical agents used in cancer chemotherapy. Table 4 
provides an overview of the types of drugs used, their mechanism of action, the tumours 
that they are used to treat and their major side effects. This list is not exhaustive but it 
serves to illustrate the major groups of chemotherapeutic agents that are available. The 
reader is refered to the textbook by Tannock and Hill,
17
 for a more complete list of 
chemotherapeutic agents. 
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Table 4. The different groups of chemical agents used in cancer therapy. 
Type of agent 
Mechanism of 
action 
Example Target tumours Major toxicity 
Alkylating 
agents 
Most 
bifunctional 
agents, which 
form inter- and 
intrastrand 
crosslinks with 
DNA double 
helix and cause 
disruption of 
DNA synthesis 
Cisplatin 
Ovarian 
Testicular 
Nausea 
Renal 
dysfunction 
Neural effects 
Antimetabolites 
Inhibit the 
synthesis of 
nucleic acid 
5-fluorouracil 
Breast 
Stomach 
Bone marrow 
effects 
Natural 
products 
Various 
mechanisms 
Taxol 
Leukaemia 
Ovarian 
Testicular 
Bone marrow 
effects 
Hormone 
therapy 
Deprive 
tumour of the 
hormone 
required for 
proliferation 
Tamoxifen Breast 
Gastrointestinal 
effects 
Menstrual 
irregularities 
  
There are a number of problems with chemotherapeutic drugs, not least the many 
adverse events that are common to cytotoxic agents (including acute effects, such as 
nausea and vomiting, myelosuppression and alopecia, and long-term complications, 
such as secondary malignancies and infertility). Adverse events occur because these 
drugs are systemic therapies; they have potential to effect cells anywhere in the body. 
These adverse events can seriously impair quality of life and so there is a need for less 
toxic (i.e. tumour selective) drugs. The onset of structure-based drug design may help to 
increase tumour selectivity and, thus, reduce the severity of side effects. Another major 
problem with chemotherapy is drug resistance; a fraction of a tumour may become 
resistant to a drug (or class of drug) that it has previously responded to, causing relapse 
of the tumour.
18
 The development of drugs that have a unique mode of action has been 
proposed as a possible route to overcome drug resistance. 
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There is clearly plenty of scope for major improvements on traditional 
chemotherapeutic agents, because: 
 
 The common tumours, such as those of the colon, breast and lung, do not 
respond well to existing therapies 
 The majority of drugs:- 
o Are toxic to normal cells 
o Have a low therapeutic index 
o Preferentially kill rapidly-dividing cells 
 Drug resistance is a problem 
 
There is an urgent need to devlop cytotoxic drugs that are selective for malignant cells, 
thus reducing side effects, increasing the therapeutic index and removing the need for 
prolonged cycles of treatment (which can lead to drug resistance). The development of 
selective antitumour drugs is one of the main aims in current cancer research. 
 
1.3. Development of new chemotherapeutic agents 
 
Historically new drugs were found by random screening of compounds against 
experimental models, in the hope that an effective agent would be found by chance. 
This empirical method of drug discovery is still valid, although it is usually restricted to 
the screening of natural products. The US National Cancer Institute (NCI) 60 human 
tumour cell line anticancer drug screen (NCI60) was developed in the late 1980s as an 
in vitro drug-discovery tool intended to supplant the use of transplantable animal 
tumours in anticancer drug screening. This screening model was rapidly recognized as a 
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rich source of information about the mechanisms of growth inhibition and tumour-cell 
kill. Recently, its role has changed to that of a service screen supporting the cancer 
research community. New methods, such as target orientated drug screening and 
rational drug design are rapidly superseding the traditional methods, fuelled by a growth 
in our understanding of tumour biology. As medicinal technology has advanced, new 
targets involved in carcinogenesis and cancer biology have been discovered. 
Identification of these new target molecules is one step towards broadening the type and 
range of chemotherapeutic agents, bringing new choices for treatement and helping to 
overcome resistance to the traditional chemotherapies. New approaches currently in 
development include: interfering with signal transduction pathways that are upregulated 
in cancer cells; preventing new tumour blood vessel formation (angiogenesis);
18
 gene 
therapy;
19
 and immunotherapy.
20
 
Twenty-first century drug development (particularly in the pharmaceutical industry) 
focuses upon the development of therapeutic strategies designed to interfere with 
specific target molecules, with the aim of producing selective agents.  
 
1.4. Aim of Project 
 
As mentioned in the previous sections, in medicine new drugs are often sought to 
improve upon or find novel areas of application that previous drug developments could 
not manage. In many cases drug resistance can become a big issue and severe side 
effects triggered by less selective drugs can cause drugs to fail or serious discomfort in 
the patient. To try and improve upon the drugs on the market, novel compounds with 
novel modes of action or PKPD profiles are most likely to give results. However even 
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by a rational drug design approach, this discovery is not a guarantee and serendipity 
finds its way into finding new leads.   
 
Our interest in the Schiff base complexes in this study has been brought about by the 
desire to discover new generations of anticancer metallopharmaceuticals, which have 
been eagerly sought since that of cisplatin as described by many books and reviews.
21-24
 
The particular Schiff base systems of this study were initially developed as 
polymerisation precatalysts,
25
 and show similar chemistry in many respects to known 
anticancer metallopharmaceuticals, cisplatin and the metallocene dihalides and have yet 
to be investigated in anticancer drug applications or any other medicinal application. 
The initial investigation into this class of complex focused on the Schiff base complexes 
[CoCl2(L
1
Ph)] and [CuCl2(L
3
Ph)]. These were prepared and  tested for their ability to 
bind to calf thymus DNA by measuring DNA melting temperatures in the presence of 
such compounds.
26
 These particular complexes showed very promising results and so it 
is from those discoveries which this research stems. 
 
The aim of this research was to identify the potential and to understand the role these 
systems would play as cytostatic agents. Possible model experiments were also an area 
of interest and would provide an opportunity in identifying biomolecular targets and 
their drug binding sites and modes, with the prospect of identifying an initial 
mechanism of action for these potential anticancer metallopharmaceuticals.  
 
Since our initial lead stems from pure speculative insight and some promising results 
arising from it, there was no real rationale other than the compound similarities to 
known anti-cancer metallopharmaceuticals. It has also been discovered in the following 
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review that besides cisplatin, antiproliferative activity has been detected during the past 
30 years for numerous other non-platinum group metal compounds. This means that 
anti-tumour activity is not limited to platinum complexes, but includes numerous other 
organometallic and inorganic compounds of transition metals and main group elements. 
In fact it turns out to be most advantageous that the spectrum of activity and pattern of 
toxicity of most non-platinum group metal anti-tumour agents do not resemble those 
induced by cytostatic platinum drugs. This observation qualifies non-platinum group 
metal antitumour compounds to be independent groups of antiproliferative agents and 
justifies the hope the class of complex and their metal salts in this study may actually 
improve the prognosis of patients suffering from certain cancer diseases in the future.   
 
In order to design complexes in a study such as this, it is always sensible to have a 
fundamental understanding of the role such agents play in carrying out their task. 
Knowledge of potential modes of action can give good ideas as to what chemistry 
should be probed or tuned within a compound to provide the desired affect. The 
following section provides a review of anti-cancer metallopharmaceuticals, their co-
ordination chemistry and provides the proposed mechanisms of action on which the 
later drug design in this thesis is based. 
 
1.5. Review of Anticancer Metallodrugs 
 
After the discovery and success of cisplatin 1, as an anticancer agent, many 
investigations have been driven towards finding more metallodrugs with improved 
anticancer properties. Although the progression has been rather slow a handful of 
anticancer metallodrugs have made it through the rigorous clinical trials to be used in 
clinical treatments of cancer today. Numerous platinum complexes of the second 
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generation have been developed; about 10 of them entered clinical studies in the late 
1970’s.27 The main compounds that represent these second generation platinum 
complexes are diammine(cyclobutane-1,1-dicarboxylato)platinum
II
 (carboplatin, 2) and 
aquo {1,1-bis(aminomethyl)cyclohexane](sulfato)-platinum
II
 (spiroplatin,3), which like 
cisplatin are four-coordinate, planar complexes, and bis(isopropylamine)-cis-dichloro-
trans-dihydroxoplatinum
IV
 (iproplatin, 4), which in contrast contains platinum
IV
 in an 
octahedral coordination sphere.
28
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Not only platinum complexes exhibit antitumour properties; many complexes 
containing platinum group metals such as ruthenium, rhodium, or palladium are 
characterised by cytostatic activity. The problem with the rhodium and palladium 
complexes being their toxicity. Keppler and co-workers have shown amine and imine 
complexes of Ru
III
, to have antitumour properties, namely cis-[Cl2(NH3)4Ru]Cl, 5 and 
(HIm)[trans-[(Im)2Cl4Ru] (NAMI-A), 6 which are both octahedral complexes with cis 
chloro ligands and are highly water soluble. In addition  Mestroni and co-workers have 
shown DMSO analogues to have activity against certain tumours.
29
 These complexes 
and their analogues have shown inhibition of DNA replication and transcription along 
with inhibition of cellular DNA repair mechanisms. The complexes have too shown a 
direct correlation between cytotoxicity along with DNA binding, the binding has been 
shown to be primarily single and double stranded binding to the N7 of guanine bases as 
with cisplatin, but in the case of the octahedral Ru complexes with trans chloro ligands, 
interstrand binding is more of a possibility.  
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Other Ruthenium complexes to have shown promise are the polyamino and 
polycarboxylates, which are six coordinate, octahedral and highly water soluble. One 
example is the Ru
IV
 complex [Cl2(cdta)Ru
IV
], 7 where the chlorides are cis- to one 
another and the carboxylates appear to be labile. The Ru centre has a high reduction 
potential for these complexes and the compound is expected to be reduced to the Ru
II
 
compound in vivo. The Ru
III
 metal ion has a high affinity for transferrin  (Tf), and has 
been proposed to be transported to cells by this iron transport protein. The active species 
in vivo has also been proposed to be the Ru
II
 metal (vide infra). 
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The isomer of cis-[Cl2(azpy)2Ru] (azpy = 2-(phenylazo)pyridine), 8 with C2 symmetry 
exhibits substantial activity against several cell lines.
30
 Possible reasons for this are, (1) 
the decrease in the rate of chloride aquation due to the π-acceptor effect of the imine 
ligands increasing the effective charge on the metal ion so that the hydrolysis rates are 
in the range of cisplatin; (2) increased hydrophobic or intercalative interactions with 
DNA, which may facilitate covalent binding; (3) geometric effects exerted by the 
ligands, which may facilitate (or inhibit) protein binding to the nucleic acid. 
N
Ru
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Gallium salts were the first main-group compounds for which antiproliferative activity 
was described (in 1975).
31
 Gallium trinitrate is one metallodrug that has shown good 
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anticancer properties and it is used against some soft tissue cancers and bone cancers.
31
 
Ga(NO3)3 is a salt and not a metal complex and possibly for that reason it is not 
considered to kill tumour cells by binding to DNA. But it has been proposed that the 
compound binds to transferrin and therefore inhibits the corporation of iron into tumour 
cells, which is an essential metal; used in DNA replication. Other important main group 
cytostatics contain metals neighbouring gallium, i.e. germanium and tin. Presently there 
are two main representatives of antitumour germanium compounds: the monomeric 8,8-
diethyl-2-[3-(N-dimethylamino)-propyl]-2-aza-8-germaspiro[4.5]decane 
(spirogermanium, 9),
32
 and the polymeric bis[(carboxyethyl)germanium] trioxide 
(germanium sesquioxide, Ge-132, 10),
28
 and the third group of antitumour main-group 
metal complexes detected so far is represented by diorganotin
IV
 derivatives such as 
octahedral diorganotin dihalide complexes R2SnX2L
2
 [R=alkyl, phenyl; X= F, Cl, Br, I, 
NCS; L= unidentate ligand (e.g. pyridine); L
2= bidentate chelating ligand (e.g. 2,2’- 
bipy), 11 and di- and triorganotin complexes of nitrogenous bases and amino acids, e.g. 
R2Sn [adeninate(1-)]2 and R2Sn[L-cysteinate(2-)].
33
 Their antiproliferative activity was 
detected in 1980 and later against p388 leukaemia. Though this activity is strong 
comparable to that of 1, further studies showed that there is obviously no activity 
against other experimental tumour systems.
28
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Antitumour compounds of transition metals other than platinum-group metals either 
contain early transition metals like titanium and vanadium, medium transition metals 
like iron, or late transition metals like copper and gold. Early transition metal 
compounds showing tumour inhibiting efficacy are mainly represented by metallocene 
complexes of type 12 (M = Ti, V, Nb, Mo; e.g., X = Cl). These are organometallic 
complexes, the cyclopentadienyl ring ligands being bound to the central metal ion M by 
carbon-metal bonds. Metallocene complexes 12 have shown antiproliferative activity 
against experimental tumours. The antitumour activity of metallocene dihalide 
complexes is dependent upon the metal ion with M = Ti, V, Nb, Mo, showing marked 
activity, Ta and W, exhibiting marginal effectiveness and Zr and Hf, being inactive. The 
diagonal relationship between the active metal ions (Ti-Nb and V-Mo) suggests that 
active complexes fall within a window of size and substitution reactivity of the metal 
ion. The most successful of these agents being Cl2Cp2Ti which subsequently made 
phase II clinical trials. Whilst these compounds were initially tested as possible 
analogues of cisplatin, the effectiveness of Cl2Cp2Ti against platinum-resistant cell lines 
indicates a different mechanism of action.
34
 The metal ion has been shown to 
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accumulate in cellular regions rich in nucleic acids with highest concentrations in the 
chromatin. The compound Cl2Cp2Ti has also been shown to bind strongly to the Fe
III
 
binding sites in Tf, which may provide a transport mechanism into the tumours.
35
 Later 
studies indicated that metallocene dihalides do not bind strongly to DNA at neutral pH 
and do not suppress DNA-processing enzymes, so that it is unlikely that their activity 
involves nucleic acids.
36
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Other antitumour titanium complexes are the six co-ordinate 
bis(benzylacetonato)titanium
IV
 dihalides and bis(alkoxides), 13 (R = CH3, R’ = C6H5, X 
= F,Cl, Br, OC2H5) and some similar zirconium and hafnium complexes have also been 
found to show activity. Budotitane an example of this class of compound cis-
[(CH3CH2O)2(bzac)2Ti
IV
], where bzac = 1-phenylbutane-1,3-diketonate, was the first 
non-platinum transition-metal anticancer agent to be tested in clinical trials.
37
 In the 
series cis-[X2(bzac)2Ti
IV
], activity varies in the order Ti ~ Zr > Hf > Mo > Sn > Ge,
37
 
which is roughly inverse to the rates of X dissociating from the metal ion. Little is 
known about the mechanism of budotitane except that it is distinct from that of 
cisplatin.
38
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Whereas the antitumour metallocene dihalides, 12 are neutral compounds, the 
cytostatically active medium transition metal agents are saltlike metallocenium 
complexes, 14 (M = Fe, Co; e.g., X = FeCl4
-
), containing in the cation the co-
ordinatively saturated central metal atom interposed between two parallel 
cyclopentadienyl ring ligands. Thus, metallocenium compounds are also organometallic 
complexes. Their antitumour activity was detected in 1984 against Ehrlich ascites 
tumour.
39
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Regarding late transition metal antitumour agents, numerous compounds of copper are 
known that contain organic ligands exhibiting antiproliferative activity by themselves. 
Prominent examples of this type of cytostatic compounds are bleomycin- and 
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thiosemicarbazone-copper complexes. Besides these, many other copper complexes 
containing e.g. ligands of the Schiff base type have shown antiproliferative activity. 
Thus, efficacy against experimental animal tumours was revealed for the neutral 
complex trans-bis(salicylaldoximato)copper
II
 as well as for copper
II
 complex salt 15 of 
the macrocyclic ligand tetrabenzo[b,f,j,n]-1,5,9,13-tetraazacyclohexadecene. 
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From certain gold
I
 complexes like auranofin it is known that they are clinically well 
approved therapeutic drugs against rheumatoid arthritis. Reports of in vivo antitumour 
activity of gold complexes, however are comparably rare. Complexes for which in vivo 
antitumour activity has been described are gold
I
 phosphine complexes such as the 
neutral binuclear 16, containing a bridging dithiolate ligand and the saltlike, 
mononuclear, tetrahedral chelate complex, 17 comprised of two bidentate 1,2-
bis(diphenylphosphino)ethane ligands. They effected antiproliferative activity against 
P388 leukemia, M5076 reticulum cell sarcoma, and mammary adenocarcinoma 16 / c. 
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1.6. The Likely Fate of Metallodrugs on Entering the Body 
 
As mentioned before the majority of research into anti cancer metallopharmaceuticals is 
undoubtedly for that of cisplatin and some of the proposed concepts are therefore based 
on the findings of cisplatin research. Some concepts maybe based on research into other 
metallopharmaceuticals, but to a lesser extent.  
1.6.1. Transport 
 
It has been proposed that following injection into the bloodstream cisplatin encounters a 
relatively high concentration of chloride ions (100 mM) that suppress hydrolysis and 
maintains the compound in the neutral state. The limiting factor for accumulating 
platinum in cells is its concentration, and the uptake of cisplatin is not saturable.
40, 41
 
  
30 
Cisplatin uptake does not have a pH optimum nor is it inhibited by structural analogues 
such as carboplatin, suggesting that the transport is not carrier-mediated.
42
 These results 
suggest that cisplatin enters cells by passive diffusion, although there is some evidence 
that uptake may in part occur by an active transport mechanism.
43
  
 
Other metal ion complexes are similar in size to iron
III
 and mimic some of the chemistry 
of iron in that they bind to transferrin (Tf) and can enter cells through transferrin 
receptors (TfR), as well as by routes that do not require transferrin. This also depends 
on the affinity of the metal ions for binding to Tf. For instance Ga(NO3)3 a non platinum 
chemotherapeutic agent has a similar size and a high affinity for binding to Tf.
44
 The 
uptake of the metal ions into cells is largely dependent on the TfR density on the 
exterior of cells, and cellular iron deprivation results in enhanced sensitivity of the cells 
to gallium.
45
 As the enhanced requirements for nutrients of neoplastic cells from their 
generally higher metabolism compared to normal healthy cells, leads to higher TfR 
densities, the uptake of gallium into the tumour cells is generally higher than in other 
tissues. This can account for the selectivity of the metal ion for tumour cells over 
normal healthy cells. It is also thought that other metal complexes are transported in the 
same way, such as titanocene dichloride
46
 and other metallodrugs may even be 
transported by other serum proteins such as albumins.
47-49
 
1.6.2. Tumour cell Specificity 
 
Because tumour cells are highly proliferating their elevated requirements for nutrients 
coupled with their higher membrane permeability results in both specific and non-
specific uptake of metallodrugs. But for cisplatin and many other cytotoxic 
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chemotherapeutics this still results in healthy cells being affected and many unwanted 
side effects. 
1.6.3. Metal complex activation 
 
The reaction mechanism of many anticancer metallodrugs with DNA has been shown to 
involve activation of the metallodrug by aquation.
50
 For platinum
II
 complexes the 
tendency of a ligand to leave the complex correlates with the affinity for binding to 
platinum
II
, decreasing in the order: 
 
CN
-
 > NH3 ~ Guo, Ado, OH
-
 > I
-
 > SCN
-
 > Br
-
 > Cl
-
 ~ phosphate, carboxylate > H2O > 
NO3
-
,SO4
2-
, ClO4
-
. 
 
A platinum
II
 complex co-ordinated with water or any ligand beyond water in this series 
may be called “activated”. The drug administered is not the active drug and is actually a 
prodrug since it is activated to a different compound in vivo. For cisplatin which is 
thought to be transported to the cell by passive diffusion it experiences a drop of 
chloride ion concentration from 100 mM to ~20 mM in the cell, which facilitates 
activation. Activation in biological reactions occurs by hydrolysis. For different 
complexes, rate constants of hydrolysis depend on the geometry of co-ordination and on 
the chemistry of the conserved ligands. 
 
Another method of activation of metallodrugs is by reduction, a hypothesis that came to 
light more than two decades ago. It has been suggested that Ru
III 
complexes may serve 
as prodrugs, which are activated by reduction in vivo to co-ordinate more rapidly to 
biomolecules.
51, 52
 Indeed, glutathione and a number of redox proteins are capable of 
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reducing Ru
III
 complexes in vivo.
53
 The low dioxygen content (hypoxia) and lower pH 
should favour Ru
II
, which is generally more actively binding than Ru
III
, and thus 
provide for selective toxicity. It has also been suggested that octahedral platinum
IV
 
complexes are reduced to the square planar platinum
II
 compound before binding to 
DNA in vivo.
54
  
 
As reduction of Ru
III
 to Ru
II
 fills the d orbitals, those ligands that -donate are no 
longer able to do so and bind less strongly (Figure 3). In the case of Ru (II) am(m)ine 
complexes, acido ligands are lost fairly rapidly. 
 
Figure 3. a) Shows σ bonding between the filled sp hybrid orbital of F- and the empty eg 
orbitals of Ru(II) and (III). b) Shows π bonding between the filled py orbital of F
-
 and 
the empty t2g dπ orbitals of Ru(III), whereas Ru(II) has no empty dπ orbitals to form π 
bonds with the π donor F- (acido ligand).55 
F FRu(III) Ru(II)
a
b
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1.6.4. Cellular Targets 
 
Once the metal complex is activated it can then form adducts with biomolecular targets 
forming lesions and altering various ways in which these biomolecules function. 
Because there are many biomolecules in the body, there are numerous targets for 
metallodrugs, namely, DNA, RNA, nucleotides, nucleosides, amino acids, proteins, 
oligopeptides, phospholipids and others, all which contain donor functions for the 
metallodrugs, O, N, P, S donors and charged secies which can bind co-valantly or 
electrostatically or through weaker hydrogen bonding to the metal centres or to ligands 
in the primary co-ordination sphere.   
 
From work carried out on cisplatin there is some evidence to suggest that non-DNA 
targets may be involved, and this topic has been reviewed.
56
 Cisplatin interacts with 
phospholipids and phosphatidylserine in membranes,
57, 58
 disrupts the cytoskeleton,
59
 
and affects the polymerisation of actin, presumably because of conformational changes 
resulting from the formation of Pt-S bonds.
60
 The preference for Pt-N bond formation in 
the presence of S-donor ligands in cells has also been reviewed.
61
 Thus although there is 
some evidence to suggest that other biological targets may be important in the cisplatin 
mechanism, it is generally accepted that DNA is the primary target, and research in this 
area has predominated. The theory that DNA is the target was corroborated by 
experiments measuring the rates of synthesis of DNA, RNA and proteins in cells treated 
with cisplatin by monitoring the incorporation of radiolabeled precursors. At therapeutic 
doses of cisplatin, DNA synthesis was preferentially inhibited over RNA and protein 
synthesis in both human AV3 cells in culture and in Ehrlich ascites cells in vivo.
41, 62
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The inactive trans isomer inhibited DNA synthesis to only a minor extent at similar 
doses.
62
 
1.6.5. DNA Structure and Metal Binding Sites 
 
The surface of the DNA double helix is characterised by major and minor groves 
(Figure 4). The backbone of each DNA strand is composed of deoxyribose 
phosphodiester units. In Figure 5, is displayed a schematic of the backbone containing 
the numbering of the deoxyribose rings. The DNA backbone has polarity; the 5’-end of 
the molecule is at the top and the 3’-end is at the bottom. 
 
Figure 4. Wireframe representation of the side view of B-DNA, arrows near the top and 
bottom of the helix point to major and minor grooves respectively, red dots represent 
waters of crystalisation.
63
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Figure 5. Schematic of the DNA backbone, showing deoxyribose ring numbering 
schemes. 
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The N9 atoms of the purine bases, adenine and guanine (Figure 5), are attached via the 
glycosyl bond to the 1’-carbon atoms of the DNA backbone. The pyrimidine bases, 
cytosine and thymine, bond to C1’ through their N1 atoms. 
 
The double helix is stabilised by hydrogen bonds between guanine and cytosine and 
between thymine and adenine of opposite strands and by stacking interactions between 
parallel bases perpendicular to the helix axis. Figure 6 depicts the most common 
hydrogen bonding interactions between paired bases and their numbering schemes.  
Looking down the helix axes in Figure 4, the major groove of DNA is at the top of each 
base pair and the minor groove is at the bottom. 
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Figure 6. Schematic of Watson-Crick A-T and G-C base pairs, showing the atom 
numbering schemes. In these views down the helix axes, the major grooves of DNA are 
pointed toward the top of the figure and the minor grooves are pointing toward the 
bottom of the figure. 
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There are a variety of binding sites available to heavy metals on DNA.
64
 Metals may 
covalently bind to the negatively charged phosphate oxygen atoms and to the nitrogen 
and oxygen atoms of the purine and pyrimidine bases. Planar molecules can intercalate 
between DNA base pairs.
65
 
 
Early experiments revealed a shift of the absorbance maximum of DNA from 259 to 
264 nm upon reaction with platinum compounds, indicating platinum association with 
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the bases.
66
 Moreover, cisplatin noncompetitively inhibits the binding of the 
intercalator, ethidium bromide, to DNA. The platinum complex therefore binds 
covalently and not by intercalation.
67, 68
 Although the platinum can bind to the 
phosphates of mononucleotides,
69, 70
 the pyridine-like and imidazole-like nitrogen atoms 
have a greater affinity for the polarisable Pt
II
 atom,
71
 and it is therefore less likely that 
phosphate coordination will occur in a competitive binding situation.
72
  
 
X-ray diffraction and NMR studies of complexes formed between platinum and N9-
alkylated purines, N1-alkylated pyrimidines, nucleosides and nucleotides have been 
used to elucidate platinum binding sites.
73
 Under neutral conditions, platinum binds to 
the N7 atom of guanine, the N7 and N1 atoms of adenine and the N3 atom of cytosine. 
In DNA, atoms involved in base pairing, i.e. N1 of adenine and N3 of cytosine, are less 
available for metal binding than the more exposed sites in the grooves.  By Raman 
difference spectrophotometry, the order of reactivity in competitive reactions of four 
nucleoside monophosphates with cis- and trans-platin was established as GMP > AMP 
>> CMP > UMP, confirming that N7 of GMP is the preferred binding site.
74
 
Electrostatic potential calculations indicate that the guanine carbonyl group enhances 
the basicity of N7, while the amino group in adenine reduces the relative basicity of 
N7.
75
 In DNA, N7 of guanine is exposed on the surface of the major groove (Figure 6), 
making it very accessible to metal binding.  
 
1.6.6. Binding Modes of Cisplatin with DNA 
 
Various possible bifunctional binding modes of cisplatin with DNA are represented in 
Figure 7. Since cis- and trans-platin are expected to form similar monofunctional 
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adducts, and because platinum complexes such as [Pt(dien)Cl]+ are inactive as 
antitumour drugs and ineffective at blocking DNA replication in vitro,
76
 monofunctional 
adducts are unlikely to be responsible for the biological activity of cisplatin. Instead, 
cross-links between two bases on opposite strands of the DNA helix, DNA-protein 
cross-links and intrastrand cross-links between two bases on the same DNA strand have 
all been proposed as being responsible for the antitumour activity of cisplatin. 
 
Figure 7. Four DNA adducts a) Interstrand, b) Intrastrand, c)DNA-Protein crosslink, d) 
N7-O6 chelate with guanine. 
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Some of the earliest proposed binding modes involved platinum coordination to two 
sites on a single base.
77
 Among these, the most popular was an N7-O6 chelate on 
guanine, which would alter the normal Watson-Crick hydrogen bonding of the G-C base 
pair in duplex DNA.
78, 79
 To date there is no X-ray crystallographic or NMR support for 
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such a structure,
80
 and the N7-O6 chelate has been generally rejected on geometric 
grounds.
64
 It is also unlikely that such a binding mode would compete with other, more 
favourable binding interactions under normal conditions.
81
 
 
Interstrand cross-linking of DNA in vivo and in vitro 
82
 has been measured by both 
denaturing gradient centrifugation and alkaline elution techniques. By analogy to 
bifunctional DNA alkylating agents,
83
 which display many of the same biological 
properties of cisplatin, such crosslinks have been postulated to be responsible for the 
activity of platinum anticancer drugs. Later estimates indicate that DNA interstrand 
cross-links formed in mammalian cells constitute less than 1% of total Pt-DNA adducts 
shortly after treatment.
84
 Statistically this percentage is too low to account for the 
cytotoxicity of cisplatin.
85
 
 
From experiments carried out to identify the adducts produced by binding cisplatin to 
DNA, it has been demonstrated that interstrand cross-linking occurs predominantly 
between two guanine N7 atoms on opposite strands.
86
 
 
Cross-links between DNA and proteins also comprise only a small fraction (0.15%) of 
the total Pt-DNA adducts formed in mammalian cells.
84
 Both cis- and trans-platin cross-
link nuclear DNA and non histone chromosomal proteins
87
 transplatin forms more such 
cross-links than cisplatin at equivalent D / N ratios. There is no correlation between 
inhibition of DNA synthesis and DNA-protein cross-linking,
87
 which along with their 
low frequency, indicates that DNA-protein cross-links are unlikely to be responsible for 
the antitumour avtivity of cisplatin. As yet, nothing is known about the identities of 
donor atoms on proteins involved in DNA-protein cross-links. Intrastrand binding of 
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cisplatin to the N7 atoms of two adjacent guanosine nucleosides occurs more frequently 
in vitro and in vivo than any other binding mode. The notion that cisplatin preferentially 
binds to guanosine was supported by experiments using both spectrophotometry and 
195
Pt-labeled cisplatin to monitor its reaction with DNA.
88, 89
 Conclusions were drawn 
from buoyant density measurements that both cis- and trans-platin bind equally well to 
individual guanine bases but that only cisplatin is selective for adjacent guanosines.
90
  
 
Not only are the site and mode of bidentate platinum binding to DNA dictated by local 
helix structure, but the resulting platinum adducts, in turn distort the structure of the 
double helix. There has been much conflicting information, however, concerning the 
extent of the distortions caused by cisplatin, transplatin and even [Pt(dien)Cl]
+
 on DNA 
structure.  
 
Changes in both the UV and circular dichroism spectra upon binding of cis- and 
transplatin to DNA reflect a loss in normal base stacking within the helix. [Pt(dien)Cl]
+
 
does not seem to affect base stacking as measured by these techniques.
88, 91
 Increasing 
amounts of bound cis-[Pt(NH3)2]
2+
 destabilise the DNA double helix resulting in a 
decrease in melting temperature. 
 
High resolution X-ray and NMR structure studies of various cisplatin-DNA adducts 
have been carried out previously and revealed their propensity to distort DNA in very 
different ways. The major 1,2-intrastrand cross-links afford a bent, unwound duplex 
with a widened, shallow minor groove unlike that displayed by the minor cisplatin 
adducts. Their contrasting structural features suggest different roles for these various 
adducts in mediating the antitumour properties of cisplatin. This is also a suggestion for 
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other anticancer metallodrugs, that they interact with DNA to form different adducts, to 
those of cisplatin and their antitumour mechanism is therefore slightly different. 
 
Figure 8 shows the NMR solution of a cis-GG cross-link on a platinated DNA 
dodecamer and here the overall helix bend is 78
o
, and the dihedral angle between 
adjacent guanine bases is 47
o
. These values are larger than observed for the X-ray 
crystal structure, reflecting the influence of crystal packing in the latter study. The base 
pairing at the site of platination is also more distorted in the NMR solution structure.
84
 
 
Figure 8. The NMR solution of a DNA dodecamer with a cisplatin adduct at d(GpG).
84
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1.7. Effects of Metallodrugs on DNA Functions 
 
The ability of anticancer metallodrugs to bind to DNA and distort its structure suggest 
that they could interfere with the normal functioning of this important cellular 
component. DNA replication and transcription are essential for cell division and protein 
production; any disruption in these processes would be cytotoxic. 
 
1.7.1. DNA Replication 
 
When a cell is going to divide, each DNA molecule replicates itself; this is an essential 
molecular process that involves unravelling of double stranded DNA from chromatin, 
separation of the duplex strands, and the synthesis of a new DNA using the original 
strands as templates. DNA polymerases are integrally involved in this process. It has 
been proposed that metallodrugs can inhibit the process of DNA replication by blocking 
the enzymes needed for this process. The metal-DNA lesions alter the conformation of 
the DNA helix by distorting the DNA base pairs at the site of metallation, which was 
suggested to alter the alignment of DNA in the binding site of the DNA polymerases, 
slowing the protein conformational change necessary for polymerisation. The binding of 
the next correct nucleotide would then also be affected by the presence of the metal 
adduct. The inhibition of replication by the metallodrugs suggests that they might kill 
cancer cells by blocking their ability to synthesise new DNA required for division. 
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1.7.2. DNA Transcription 
 
Transcription is the essential cellular process whereby mRNA is produced from a DNA 
template, a critical step in protein synthesis. Again it has been proposed that anticancer 
metallodrugs may inhibit this essential process by blocking RNA polymerase enzymes 
due to metal-DNA lesions and therefore inhibiting gene expression, which means the 
inability to synthesise some of the essential proteins required for cell function. This 
would lead to the cell cycle being arrested and ultimately cell death. 
 
1.7.3. Telomeres and Telomerase 
 
The telomeric regions of DNA represent a very appealing target for cisplatin and may 
interfere with normal DNA function. Telomeres occur at the ends of eukaryotic 
chromosomes and consist of a tandem, G-rich repeat sequence. In humans, the sequence 
is 5’-TTAGGG-3’.92 Part of their function is to protect the ends of the chromosomes 
from degradation and to ensure that the genetic information is properly inherited at each 
cell division.
93
 During one cell division, telomeres are shortened by 50-200 bp.
94
 When 
they become critically shortened, cells become senescent and die. One way cells can 
become immortalised is to counteract the shortening of the telomeres with the 
ribonucleoprotein telomerase. Telomerase synthesises these repeat sequences at the ends 
of chromosomes and is postulated to play a role in the growth of malignant tumours.
95
 
Since the telomere-repeat sequences contain many guanosine residues, they represent a 
promising potential target for cisplatin.   
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1.7.4. DNA Damage and Apoptosis 
 
Another mechanism by which cell death may occur and is the mechanism that has been 
widely accepted as the most probable (for ciaplatin at least), is by recognition of the 
distortion of DNA by a variety of proteins which leads to cell apoptosis (programmed 
cell death). This mechanism is thought to be the most probable mechanism of cisplatin 
induced cell death. An important aspect of this process is believed to be high-mobility 
group (HMG), domain protein recognition of and binding to DNA bent by the metal 
adduct (Figure 9). HMG domain protein binding is believed to interfere with the repair 
and removal of the metallated site by the normal repair mechanisms and this 
interference probably initiates the apoptosis process.  
 
Figure 9. The Crystal structure of HMG1 domain A bound to a cisplatin modified DNA 
duplex.
96
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1.8. Likely Mechanism of Action of Cisplatin After Entering the Cell 
 
Experiments have shown that cisplatin binding to DNA is kinetically rather than 
thermodynamically controlled. As mentioned previously, once inside the cell cisplatin 
experiences a diminished chloride concentration compared to the blood stream, which 
facilitates hydrolysis. This results in an activated, monoaquated form, 
cis[Pt(NH3)2Cl(H2O)]
+
, which can react more readily with cellular targets. This 
hydrolysis reaction is the rate limiting step for DNA binding, the half life being ~2 h. 
Aquated cisplatin subsequently binds to an N7 atom of a guanine base in DNA, which 
displaces the water molecule in a relatively fast reaction step (t1/2 ~ 0.1 h), forming a 
monofunctional adduct. Closure of the monofunctional adduct to form the bifunctional 
adduct involves hydrolysis of the second chloride ligand, with a half life of ~2 h. The 
distortion of the DNA is recognised by the HMG-domain A protein which ultimately 
signals apoptosis and cell death results (Figure 10).
97
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Figure 10. The sequence of events in cisplatin binding to DNA involves at least, (b) 
aquation, (c) preassociation, (d) monofunctional adduct formation, (e) closure to a 
bifunctional adduct (perhaps preceded by aquation), (f) distortion of DNA and 
recognition of this distortion by a variety of proteins.
97
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1.9. Design of Schiff Base Metallodrugs 
 
N
N N
R RM
X X  
      17 
The use of metals in drug design provides new opportunities in the development of next 
generation anti-tumour drugs. Recently several classes of organometallic complexes 
(species that contain metal-carbon bonds) have been found to show anti-tumour 
properties. Of these, the metallocene dihalides and diacido complexes, 12 [Cp2MX2 (Cp 
= 5 – C5H5; M = Ti, V, Nb, Mo, Re; X = halide or acido ligand), have been most 
widely studied and show activity against a range of tumour models in mice and several 
xenografted human tumours transplanted into athymic mice.
98
 Titanocene dichloride 
(Cp2TiCl2) made phase-II clinical trials
99
 and more recently functionalised titanium 
metallocene compounds have been discovered to show promise as new antitumour 
drugs.
100-102
 The metallocene type complexes have also found important applications in 
polymerisation catalysis.
103-105
 The schiff base metal complexes of diformylpyridine, (X 
= halide, R = aryl group), developed by the Brookhart group in 1995, have shown high 
potential as effective polymerisation pre-catalysts.
25, 104, 105
 The Schiff base complexes 
17, show very similar chemistry in many respects to the metallocenes 12, but have yet 
to be investigated in anti-cancer drug applications. 
 
 
Previously new generations of catalyst with similar ligand and co-ordination chemistry 
have been desired and are the next step in producing new and possibly improved 
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catalyst complexes. This would also be an interesting step to be taken in terms of drug 
design. 
 
When systematically changing the ligand design of the complexes, obvious ligands with 
similar chemistry are the bidentate 1,10-phenanthroline 18 and 2,2’-bipyridine 19 
ligands with diformyl groups to form the schiff base ligands, by condensation with 
primary amines ( R = alkyl, aryl). 
 
N N
N N
R R
N N
N N
R R  
    18    19 
In order to generate a matrix of ligands that could be easily compared against activity 
results to present structure activity relationships, subtle variations in the ligand head and 
tail groups had to be devised along with variation in the central metal atom and labile 
ligands. The ligand ‘head groups’ used were three dicarbaldehydes, their structures 
shown in Table 5. As previously mentioned pyridine-2,6-dicarbaldehyde and 2,9-
dicarbaldehyde-1,10-phenanthroline compounds have been used previously as 
precursors for polymerisation precatalysts and the 6,6’-dicarbaldehyde-2,2’-bipyridine 
being very much a novel precursor, again its application as a polymerisation precatalyst. 
These three ‘head groups’ provide subtle variations which can give varying metal cavity 
dimensions, denticity, electronic effects on the metal centre and also as we go from 
pyridine, bipyridine to phenanthroline, provide an extra domain that may afford 
intercalating abilities into the DNA structure, to supply a foothold for covalent binding 
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of the metal centre to donor atoms of nucleobases and also a possibility of inducing 
local modifications in DNA structure that may influence the sequence specificity of 
metallation.  The ligand ‘tail groups’ can then be added to these precursors by 
condensation of 2 equivalents of primary amine with the dicarbaldehyde to form open 
macrocycles. Such variation of the ‘tail groups’ include degree of unsaturation, 
aromaticity, flexibility and functional groups. These variations in ‘tail groups’ can 
provide the ability to tune ligand affinities, electron transfer and substitution rates, and 
in the case of redox active metals reduction potentials and also the opportunity to 
provide secondary binding. The metal salts used in this program are the chlorides of 
Co
II
, Ni
II
, Cu
II
, Zn
II
, and Ru
III
. The reasons why these metals have been chosen is the 
fact that they are cheap, readily available, relatively air stable and have been used 
previously with these ligand systems as polymerisation precatalysts and have yet to be 
deeply studied in drug applications, with the exception of Ru which has shown great 
promise as a metal centre in anticancer drug applications with imine ligands.
106
 
However Co, Ni, Cu and Zn have shown activity against cancer cell lines with various 
other ligands previously,
107-110
 notably Co
III
 compounds have shown considerable 
promise as bioreductive drugs offering a selective strategy.
111-117
 The chloride anion was 
chosen initially as these metal salts are readily available and cisplatin and titanocene 
dichloride both contain cis- chloride ligands along with many of the afore mentioned 
metallodrugs. The chloride ligands could also provide stability for transport in vivo 
where a chloride ion concentration gradient exists between the systemic system and the 
cell, facilitating hydrolysis and consequently activation at the desired site. Other labile 
ligands that were of interest and subsequently used in this study were the acetate, 
nitrate, isothiocyanate and other halide ligands. Varying the anionic coordintating 
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ligand potentially provided variation and tuning of metal-ligand substitution rates 
(particularly hydrolysis), to values that can improve potency.  
 
The rationale behind changing the ligand ‘tail’ group was to create subtle variations in 
chemical and physical properties of the complexes to affect the way these complexes 
could effectively carry out their role as cytotoxic agents in vivo.  
 
The subtle variation consisted of several parts. The first was by starting with a short 
chain aliphatic tail group and increasing the length and degree of branching of these 
groups (Table 5). These changes can impose several variations in electronic properties 
of the ligand on the metal centre through the inductive effect, this could effectively tune 
several properties of the metal centre, namely the solvolysis rates (in particular 
hydrolysis), of any labile coordinating ligands thereby effectively altering the activation 
process for metallation of DNA, that is if the complexes work analogously to cisplatin. 
The second effect would be that on the metal centred redox poperties. The +I variation 
could tune the redox profiles to biologically accessible values whereby altering the 
complex’s cytotoxic effect if they are at all working via a redox mechanism or 
potentially both redox and DNA binding. 
 
The degree of branching could also affect steric properties of the complexes. The 
bulkiness of the tail groups could aid or hinder the complexes binding to donor sites on 
biomolecular targets, thereby affecting the mode of action of these complexes and 
therefore their cytotoxic effect. Also the increase in carbon chain length and degree of 
branching can effect the lipophilicities of the ligands and therefore potentially the 
complexes. These physical chemical differences can be expressed numerically in terms 
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of their LogP values. In the case of the complexes of this study, the experimental LogP 
values of the complexes were not determined, but the calculated LogP (cLogP), valus 
have been calculated of the free ligands using Chem Draw software. Generally the 
larger the LogP value the greater the lipophilicity of the compound. A list of cLogP 
values for the free ligands can be seen in Table 6. 
 
The second part of the subtle structural changes was by making the tail groups aromatic 
and changing different substituents on the aromatic ring to alter both steric and 
electronic properties of the ligands and again to impose the same effects as those 
designed for the aliphatic tail groups. The steric, electronic and solubility properties of 
the ligands could be altered by simply placing various groups in different positions of 
the rings and also perhaps adding multiple groups to the rings. In this study only p-
monofunctionalised anilines were utilised and therefore a systematic series was 
obtained. All these structural changes are also depicted in Figure 11.  
  
Figure 11. Influence of Structural Changes on Complex Chemistry 
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Table 5. Matrix of ‘Head’ and ‘Tail’ groups with ligand abbreviations. 
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Table 6. List of cLogP values for the designed ligands obtained using an algorithm in 
ChemDraw Ultra 9.0. 
118
 
 
N
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NH
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NH
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2. Experimental 
2.1. Chemical Methods 
2.1.1. Reagents 
 
Reagents employed were used as supplied, unless otherwise stated and were of general 
purpose reagent (GPR) grade. Aniline and cyclohexylamine were distilled prior to use. 
 
2.1.2. Starting Materials 
 
Origins and purities of reagents used in the synthesis of organic precursor compounds 
are summarised in Table 7. 
 
Table 7. Origin and estimated purity of reagents used in synthesis of compounds. 
Compound    Source  Purity/Concentration 
Ni : Al alloy    Avocado   50:50 
2-amino-6-methylpyridine  Aldrich   98 % 
Neocuproine hemihydrate  Avocado   98 % 
Pyridine-2,6-dimethanol  Avocado   98 % 
Ethylamine    Aldrich   98 % 
n-propylamine    Aldrich   98 % 
i-propylamine    Aldrich   98 % 
n-butylamine    Aldrich   98 % 
i-butylamine    Aldrich   98 % 
R/S sec-butylamine   Aldrich   98 % 
t-butylamine    Aldrich   98 % 
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Cyclohexylamine   Aldrich   98 % 
cis/trans-p-methylcyclohexylamine Aldrich   98 % 
aniline     Aldrich   98 % 
p-methylaniline   Aldrich   98 % 
p-chloroaniline   Aldrich   98 % 
p-nitroaniline    Aldrich   98 % 
2-aminobenzimidazole  Aldrich   98% 
RuCl3.x H2O    Aldrich   97% 
CoCl2.6H2O    Aldrich   98 % 
CoBr2     Aldrich   98% 
Co(NCS)2.xH2O   Aldrich   96% 
Co(NO3)2.6H2O   Aldrich   98% 
Co(AcO)2.4H2O   Aldrich   98% 
Co(BF4)2.6H2O   Aldrich   99% 
NiCl2.6H2O    Aldrich   98 % 
Ni(AcO)2.4H2O   Aldrich   98% 
CuCl2.2H2O    Aldrich   98 % 
Cu(NO3)2.3H2O   Aldrich   98% 
CuBr2.2H2O    Aldrich   98 % 
Cu(BF4)2    Aldrich   98 % 
ZnCl2     Aldrich   98 % 
Zn(NO3)2.6H2O   Aldrich   98% 
Zn(AcO)2.2H2O   Aldrich   98% 
AgBF4     Aldrich   98% 
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2.1.3. Preparation of Raney Nickel 
 
Raney-nickel was prepared by dissolution of aluminium in a nickel-aluminium alloy 
(50:50), with aqueous sodium hydroxide. The method was carried out by a developed 
procedure as written in Vogle’s, ‘Textbook of Practical Organic Chemistry’.119 
2.1.4. Solvents 
 
General purpose grade solvents were used as supplied in most cases unless otherwise 
stated. Toluene was dried by standing over activated 5 Å molecular sieves.
120
 1,4-
dioxane was predried over CaH2 and then distilled from sodium/benzophenone under 
dry nitrogen and used within one week.
121
 Ethanol was dried by distilling over 
magnesium and iodine under nitrogen, used immediately or stored over 3 Å molecular 
sieves under nitrogen.
121
 Acetonitrile was dried by distilling over P2O5 under nitrogen 
used immediately or stored under nitrogen.
122
 In all cases the initial forerun (ca. 5 %) 
was rejected. 
2.1.5. Instrumental Methods 
2.1.5.1. Infrared Spectroscopy (IR) 
 
IR spectra of solid samples were recorded as KBr plates and spectra of liquids were 
obtained as capillary films using NaCl plates. Spectra were recorded with a Nicolet 140 
FTIR spectrophotometer in the range 4000 - 400 cm
-1
. 
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2.1.5.2. Nuclear Magnetic Resonance Spectroscopy (NMR) 
 
1
H and 
13
C[
1
H] NMR spectra were recorded at 270 and 68 MHz, respectively, on a 
JEOL GX270 spectometer, or at 600 and 170 MHz, respectively, on a JEOL ECA600 
spectrometer. Chemical shifts were referenced to tetramethylsilane (TMS), as an 
internal standard (0 ppm), or via the residual proton impurity of the deuterated solvent. 
Deuterated solvents were obtained from Goss Scientific Instruments. For all spectra 
1
H 
and 
13
C typically 10-20 mg of sample was dissolved in 0.7 ml of the appropriate 
deuterated solvent, the solution was filtered if dissolution was incomplete. The spectra 
were recorded at ambient probe temperature (293 K) unless otherwise stated.  
 
For diamagnetic compounds standard JEOL Delta 
1
H and 
13
C experiments and 
processing was employed. For paramagnetic compounds, 
1
H spectra were obtained with 
a scan range between -50 – 250 ppm, 64 K datapoints, 16 scans, and a relaxation delay 
of 100 ms.  
 
The following notation is used for the 
1
H NMR spectral splitting patterns: singlet (s), 
doublet (d), triplet (t), multiplet (m), broad (b). 
2.1.5.3. Magnetic Susceptibility 
 
Magnetic susceptibilities were obtained ccording to the NMR method described by 
Evans.
123
 A solution of the compound (ca. 3 mg), in a mixture of a suitable deuterated 
solvent (in our case methanol-d4 or D2O was used), and t-butylalcohol (95/5 v/v) as 
reference was prepared in a 1.0 ml volumetric flask. A portion of this solution was 
transferred into a Wilmad 517-insert co-axial NMR tube and was placed into a Wilmad 
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517 (5 mm) NMR tube containing the deuterated solvent / t-butylalcohol (95/5) mixture. 
The chemical shift difference of the t-butylalcohol signal between the inner and the 
outer tubes was measured at ambient probe temperature. From this difference in the 
chemical shift the molar susceptibility (χM) and the magnetic moment (μeff) can be 
calculated with Equation 1 and Equation 2 (given in S.I. units). 
 
Equation 1 
fc
f
M 1000
3

 
 
Equation 2 
 



MM
B
eff
TT
k
N
798
3
2
00
  
 
Where χM: is the molar susceptibility of the sample in m3 mol, Δf: is the difference in the 
chemical shift of the reference protons in Hz, c: is the concentration of the sample in 
mol dm
-3
, f: is the magnetic frequency of the spectrometer in Hz, T: is the temperature 
in K, k: is the Boltzman constant, N0: is Avagadros number, μ0: is the magnetic constant 
and μB: is the Bohr magneton.  
 
As an example the magnetic susceptibility determination of [CoCl2(L
1
Ph)] is described 
below:  
 
A solution of [CoCl2(L
1
Ph)] (3.53mg, 8.5mM), in D2O/tBuOH (95:5), was placed into 
the co-oxial insert which was then placed inside the NMR tube containing D2O/tBuOH 
  
59 
(95:5). The 
1
H NMR spectrum was obtained at a frequency, f of 270 MHz, and a probe 
temperature, T of 15.9 °C (288.9 K) and afforded a shift, Δf  between methyl signals of 
tBuOH of 75.645 Hz (See Figure 12). After inputting the data into equation 1 to give 
the molar susceptibility, χM (9.89x10-8 m3mol-1). After applying χM to equation 2, the 
magnetic susceptibility, μeff  is thus obtained (4.27 μB).  
 
Figure 12. 1H NMR spectrum (270 MHz) of tBuOH observed when running the magnetic 
susceptibility determination of [CoCl2(L
1
Ph)].   
 
2.1.5.4. Mass Spectrometry (MS) 
 
Electron impact mass spectra (EI-MS), were obtained for organic compounds using a 
AEI MS902 operated by Andrew Healey at the University of Bradford. Electrospray 
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ionisation mass spectra (ESI-MS), obtained for inorganic compounds, were recorded on 
a Waters, Quadrupole LC/MS-MS by Andrew Healey at the University of Bradford. 
2.1.5.5. Single Crystal X-Ray Diffraction 
 
Single crystals of compounds were generally grown by slow vapour diffusion of diethyl 
ether into a saturated acetonitrile solution of the complex, unless otherwise stated. The 
crystals were mounted and reflection data was recorded on a STOE STADI-4 
diffractometer or Bruker Apex X8 diffractometer. X-ray data collection, structure 
solution  and refinement is described  in section 6.2. 
2.1.5.6. CHN Microanalysis 
 
Analysis for carbon, hydrogen and nitrogen content of samples was carried out in 
duplicate at the School of Pharmacy, University of London. 
2.1.5.7. Melting Points  
 
Melting points of solid products were recorded on a Kopfler hotstage microscope 
between glass slides and are uncorrected.
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2.1.5.8. Numbering Scheme for Precursor Compounds and Ligand 
Head and Tail Groups. 
5
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2.1.6. Preparation of Precursor Compounds 
2.1.6.1. Preparation of pyridine-2,6-dicarbaldehyde, P1 
 
Pyridine-2,6-dicarbaldehyde was prepared through an adaptation of a method developed 
by Jerchel et al,
124
 utilising selenium dioxide to controllably oxidise pyridine-2,6-
dimethanol to the desired dicarbaldehyde. 
 
 
 
Pyridine-2,6-dimethanol (5.3 g, 38.0 mmol), and dry 1,4-dioxane (80ml), were placed in 
a 250 ml round bottomed flask along with selenium dioxide (5.7 g, 50.6 mmol), and the 
mixture was refluxed for 4 hours, during which time the colour of the mixture changed 
to a brick red solution and finally to a green/yellow solution, with a solid black 
selenium precipitate. The hot solution was filtered under gravity to remove the 
precipitated selenium and solvent was removed from the filtrate with a rotary evaporator 
to leave a green solid residue. The solid was recrystallised from chloroform / petroleum 
ether (bp 40-60). The product was isolated at the pump and dried in vacuo to give off 
white crystals of P
1
 (3.74 g, 72 %), mp 132-134 
o
C (lit.,
124
 132-134 °C), m/z  135 (M)
+
, 
107 (M-CO)
+
, 78 (M-(CO)(CHO))
+
, max cm
-1
 3150, 3100, 3025 (aromatic C-H), 2875 
(aldehyde C-H), 1720 (C=O), 1695 (C=N); H (270 MHz, CDCl3) 10.19 (HC=O, 2H, s 
); 8.17 (H
3/5
, 2H, d, J = 8.1 Hz); 8.07 (H
4
, 1H, t, J = 8.1 Hz).  
 
N
OH OH
N
O O
SeO2
1,4-dioxane, heat
P1
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2.1.6.2. Preparation of 2-bromo-6-methyl pyridine 
 
2-bromo-6-methyl pyridine was prepared from 2-amino-6-methyl pyridine by a 
Sandmeyer reaction adapted from the method given by Vogtle et al. 
125
 
 
N NH
2 N Br
HBr, Br2
NaNO2
 
 
To a three necked flask fitted with mechanical stirrer and dropping funnel was added 
hydrobromic acid (80 ml), and then crushed 2-amino-6-methyl pyridine (15.1 g, 0.14 
mmol), was added with care. The solution was stirred and cooled to below -15 
o
C with 
an IMS / dry ice bath. Bromine (24 ml, 0.15 mol) was added dropwise over Ca. 45 
mins, during which time the reaction mixture became increasingly viscous and deep 
orange in colour. After the addition of bromine was complete, sodium nitrite (27 g, 0.47 
mmol), in water (40 ml), was added dropwise whilst the temperature was maintained 
below -10
o
C. During the addition, bromine gas was evolved, and the reaction mixture 
became a dark brown colour. Once the evolution of bromine gas had ceased (Ca. 30 
mins), sodium hyrdoxide (60 g, 1.5 mol), in water (100 ml) was added over 1 h, whilst 
maintaining the temperature of the mixture below 0
o
C. At this stage the mixture became 
a darker orange colour. The orange solution was allowed to warm to room temperature 
and the product was then extracted from the mixture with diethyl ether (3 x 200 ml), the 
organic extracts were combined and washed with water (2 x 100 ml), then dried over 
magnesium sulphate  and the solvent was removed using a rotary evaporator at 40
o
C, to 
yield an orange / brown liquid. The resulting liquid was vacuum distilled to leave a 
colourless free flowing liquid (16.46 g, 68 %), bp (1.6-1.7 mmHg) 50-54
o
C (lit,.
125
 91 
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mmHg 46-49 °C), m/z  171 (M)
+
, 173 (M+2)
+
, 92 (M-Br)
+
, max cm
-1
 3150, 3100 
(aromatic C-H),  2990, 2950, 2900 (methyl C-H), 1650 (Ring breathing), 1595, 1560 
(C=C), H (270 MHz, CDCl3) 7.41 (H
4
, 1H, t, J = 8.1 Hz); 7.27 (H
3
, 1H, d, J = 8.1 Hz); 
7.08 (H
5
, 1H, d, J = 8.1 Hz); 2.52 (CH3, 3H, s).  
 
  
65 
2.1.6.3. Preparation of 6,6’-dimethyl-2,2’-bipyridine 
 
This preparation was developed by Breitmer and Rode.
126
 and utilises finely divided 
nickel to complex to and displace bromine from 2-bromo-6-methyl pyridine, to form the 
6,6’-dimethyl-2,2’-bipyridine nickel(II)bromide complex. The resulting nickel bromide 
complex is then hydrolysed to give the free bipyridine.  
 
 
 
2-bromo-6-methyl pyridine (16.46 g, 95.7 mmol) was added dropwise over half an hour 
to a refluxing suspension of rayney-nickel (Ca. 8g), in dry toluene (100 ml). The 
mixture was refluxed for 22 hours whereupon a dark purple solid precipitated in a bright 
blue sloution. The mixture was allowed to cool to room temperature and was then 
filtered under suction and washed with dry toluene (2 x 10 ml). The purple solid (6.7 g), 
was then added to water (200 ml), and was stirred and maintained at ca. 60 
o
C for 24 
hours, after 2 hours of that time, the purple suspension turned to a dark green/ turquoise 
colour. The green suspension was then filtered at the pump to afford a very pale green 
filtrate. The solid was washed with DCM (3 x 30 ml), and the filtrate was extracted into 
DCM (3 x 75 ml) to give a beige coloured organic layer. The organic layer was dried 
over magnesium sulphate and the solvent removed on the rotary evaporator to leave a 
pale beige solid. The solid was recrystallised from petroleum spirit (bp 40-60 °C). The 
desired product was isolated at the pump as off white crystals (1.70 g, 19 %) mp 92-94 
o
C (lit,.
125, 126
 88-89 °C), m/z  184 (M)
+
, 169 (M-CH3)
+
, max cm
-1
 3067 (aromatic C-H), 
N Br N N
Ni
Br Br
N N
2
Rayney Ni Water
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2975, 2969, 2932 (methyl C-H), 1573 (C=C), 1437, 1375 (methyl C-H bend), H (270 
MHz, CDCl3) 8.17 (H
3/3’
, 2H, d, J = 8.1 Hz ) 7.64 (H
4/4’
, 2H, t, J = 8.1 Hz) 7.11 (H
5/5’
, 
2H, d, J = 8.1 Hz) 2.61 (CH3, 6H, s).  
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2.1.6.4. Attempted Preparation of 2,2’-bipyridine-6,6’-
dicarbaldehyde, P
2
 with Selenium Dioxide. 
 
This procedure was carried out by a method previously developed by Newkome et al,
127
 
via a controlled oxidation with selenium dioxide, to the dicarbaldehyde. 
 
 
 
Selenium dioxide (2.6 g, 23.5 mmol), was placed in a 250 ml round bottomed flask with 
glacial acetic acid (100 ml). To the suspension was added 6,6’-dimethyl-2,2’-bipyridine 
(1.1 g, 5.7 mmol), and the mixture was refluxed for 24 hours, during which time the 
clear solution formed a green solution, with precipitated selenium in suspension. The 
hot mixture was filtered and the solvent was removed from the filtrate with a rotary 
evaporator, to leave an off-white powder. The powder was washed with cold methanol 
and treated by Soxhlet extraction with xylene to give a yellow solution. The solution 
was left to cool in the fridge overnight and crystals formed. The product was isolated at 
the pump as off white crystals (0.20 g, 20%), mp >230 
o
C (lit,.
127
 233-237 °C) m/z  212 
(M)
+
, 184 (M-CO)
+
, 155 (M-(CO)(CHO))
+
, max cm
-1
 3073 (aromatic C-H), 2855 
(aldehyde C-H), 1703 (C=O); 1634 (C=N), H (600 MHz, CDCl3) 10.18 (2H, s, HC=O);  
8.81 (H
3/5
, 2H, d, J = 6.2 Hz); 8.05 (H
4
, 2H, t, J = 6.2 Hz); 8.03 (H, 2H, d, J = 6.2 Hz).  
 
N N N N
O O
SeO2
(AcOH), heat
P2
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2.1.6.5. Preparation of 2,2’-bipyridine-6,6’-dicarbaldehyde, P2 with 
DMSO and Iodine. 
 
This method was adapted from a general method for oxidation of methyl pyridines and 
picolines to the corresponding aldehydes.
128
  
 
 
 
6,6’-dimethyl-2,2’-bipyridine (0.5 g, 2.8 mmol); was dissolved in DMSO ( 5 ml), in a 
25 ml beaker. Iodine (1.42 g, 5.6 mmol) was added to the solution. The solution was 
then dropped into DMSO (50 ml), preheated to 130 
o
C. The mixture was then refluxed 
and stirred, where a vigorous exothermic reaction occurred with evolution of dimethyl 
sulphide. The mixture was held at reflux for 24 hours and left to cool to room 
temperature. Excess iodine was then destroyed by addition of a saturated aqueous 
sodium thiosulphate solution, until a pale yellow solution was obtained. Water was 
added to the solution to give a total volume of 250 ml and the solution was then 
extracted with dichloromethane (3 x 200 ml), washed with water (2 x 100 ml), dried 
over magnesium sulphate, filtered and finally the solvent removed on the rotary 
evaporator to yield a beige solid. The crude product was then crystallised by 
dichloromethane / petroleum ether bp 40-60
o
C to afford beige plates of P
2
 ( 0.42 g, 71 
%). mp >230 
o
C (lit,.
127
 233-237 °), m/z  212 (M)
+
; 184 (M-CO)
+
; 155 (M-
(CO)(CHO))
+
, max cm
-1
 3073 (aromatic C-H), 2855 (aldehyde C-H), 1703 (C=O), 1634 
N N N N
O O
I2
(DMSO), heat
P2
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(C=N), H (600 MHz, CDCl3) 10.18 (2H, s, HC=O);  8.81 (H
3/5
, 2H, d, J = 6.2 Hz); 8.05 
(H
4
, 2H, t, J = 6.2 Hz); 8.03 (H, 2H, d, J = 6.2 Hz).  
Figure 13. Crystal sturcture of 2,2’-bipyridine-6,6’-dicarbaldehyde, P2. 
 
Table 8. X-ray structure and refinement parameters for P
2
. 
Compound 
2,2’-bipyridine-6,6’-
dicarbaldehyde 
Chemical Formula C12H8N2O2 
Formula Weight 212.20 
Crystal System Monoclinic 
Space Group P21/c1 
a / Å 8.2199 (4) 
b / Å 11.4334 (7) 
c / Å 5.5947 (3) 
α / ° 90 
β / ° 109.896 (0) 
γ / ° 90 
V / Å
3
 494.41 (0) 
T / K 273 (2) 
Z 2 
S 0.760 
No. unique data (Rint) 1476 
No. measured reflections 17704 
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2.1.6.6. Preparation of 1,10-phenanthroline-2,9-dicarbaldehyde, P3 
 
This method is an adaptation of a method described by Masood et al.
129
  
 
 
 
Selenium dioxide (5.0 g, 45 mmol), was placed in a 500 ml round bottomed flask with 
2,9-dimethyl-1,10-phenanthroline (2.50 g, 11.5 mmol), and 1,4-dioxane (200 ml). The 
mixture was stirred and refluxed for 4 hours, during which time the solution went 
through a series of colour changes, from a white precipitate to orangey pink and finally 
to a yellow solution with a suspended black precipitate of selenium. The mixture was 
filtered whilst hot to remove any selenium and the solvent was removed from the filtrate 
on the rotary evaporator to leave a green residue. The residue was dissolved in a 
minimum amount of DMF and left in the fridge for ~ 16 hours to precipitate any 
residual selenium. The cold solution was filtered and then crystallised from the DMF 
solution and water. The product was isolated at the pump as very fine needle-like, pale 
yellow crystals (1.90 g, 70 %). mp decomposes >230 
o
C (lit,.253 °C), m/z  236 (M)
+
; 
208 (M-CO)
+
; 180 (M-2(CO))
+
. max cm
-1
 3100, 3050, 3042 (aromatic C-H),  2852 
(aldehyde C-H), 1702 (C=O), H (600 MHz, CDCl3) 10.55 (HC=O, 2H, s); 8.49 (H
3/8
, 
2H, d, J = 8.1 Hz); 8.39 (H
4/7
, 2H, d, J = 8.1 Hz); 8.04 (H
5/6
, 2H, s).  
 
N N N
O O
N
SeO2
1,4-dioxane, heat
P3
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2.1.6.7. Preparation of 1,10-phenanthroline-2,9-dicarbaldehyde, P3 
with DMSO and Iodine. 
 
The method used in the formation of P
3
 using DMSO and iodine was a method adapted 
from the previous method used for both P
1
 and P
2
. This method was first carried out by 
Daran et al,
130
 and utilizes t-butyliodide as a reaction initiator. 
 
 
 
Iodine (7.02 g, 27.65 mmol, 2 equiv.), was added to a solution of neocuproine 
hemihydrate (2,9-dimethyl-1,10-phenanathroline, 3.0 g, 13.8 mmol, 1 equiv.), dissolved 
in DMSO (200 ml). The brown solution was stirred for 5 min at room temperature 
before 2-iodo-2-methylpropane (t-BuI, 3.42 ml, 28.7 mmol, 2.7 equiv.) was added. 
Finally TFA (3 ml, 38.94 mmol, 2.8 equiv.), was slowly added to the dark brown 
solution by syringe and the mixture was stirred under reflux for 2 h (148 
o
C). After this, 
the solution was allowed to cool to room temperature. The excess of iodine was 
neutralized by slow addition of a solution of Na2S2O3 (16 g, 120 ml), and the dark 
precipitate formed was removed by filtration. The pH of the solution was then adjusted 
to pH = 4-5 by addition of aqueous NaHCO3 (10%), extracted with dichloromethane (3 
x 250 ml), and washed with water (1 x 250 ml). The organic phases were combined and 
dried over MgSO4, concentrated on the rotary evaporator and the resulting pale residue 
was washed with diethyl ether to remove traces of DMSO. The crude product was 
recrystallised from DMF / water, filtered at the pump and dried under vacuum to give 
N N N
O O
N
t-BuI / I2 / TFA
(DMSO), heat
P3
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the pure compound (1.62 g, 50 %), mp decomposes >230 
o
C, (lit,.
130
 253 °C), m/z  236 
(M)
+
; 208 (M-CO)
+
; 180 (M-2(CO))
+
, max cm
-1
 3100, 3050, 3042 (aromatic C-H),  
2852 (aldehyde C-H), 1702 (C=O), H (600 MHz, CDCl3) 10.55 (HC=O, 2H, s); 8.49 
(H
3/8
, 2H, d, J = 8.1 Hz); 8.39 (H
4/7
, 2H, d, J = 8.1 Hz); 8.04 (H
5/6
, 2H, s). 
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2.1.7. Preparation of Ligands 
2.1.7.1. General Procedure for the Preparation of Schiff base Ligands 
L
1
R and L
3
R 
 
 
 
The preparation of the free Schiff base ligands, was carried out by two methods 
depending on the primary amine used. All methods with volatile primary amines (i.e. 
alkyl amines) were carried out by refluxing the dicarbaldehyde P
1
 or P
3
 (1.85 mmol), 
with 2.2 equivalents of the appropriate primary amine (4.1 mmol), in anhydrous ethanol 
(Ca. 25 ml), over powdered 3Å molecular sieves (~1g). For aromatic amines (i.e. non 
volatile amines) LR was prepared by refluxing the dicarbaldehyde P
1
 or P
3
 (1.85 mmol), 
with 2 equivalents of the appropriate primary amine (3.7 mmol), in anhydrous ethanol 
(Ca. 25 ml), over powdered 3Å molecular seives. These methods were taken from a 
procedure by Lions et al.
131
 and modified to give better yields and cleaner products. The 
loss of P
1
 was monitored by TLC under 254nm UV light, (Rf 0.45, DCM:MeOH, 95:5), 
every 15 minutes (spots for intermediate and product stuck to the baseline). When the 
spot for P
1
 was no longer observed the reaction time was noted, and the mass was 
allowed to reflux for the same time again to ensure full conversion for this consecutive 
N
O O
N
O O
N
N
N N
R R
N
N N
N
R R
2 RNH2
2 RNH2
L1R
L3R
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reaction. For P
3
 compounds, P
3
 did not elute on the TLC plate under various conditions, 
and so the reactions were allowed to proceed at reflux for 8 hours. Schiff base ligands 
with aryl tail groups tended to form crystalline solids, whereas ones with alkyl tail 
groups tended to form viscous, yellow to tan oils. The desired pure compounds were 
isolated by either:- 
 
Where the Schiff base formed an oil, the product was isolated by filtering the warm 
suspension into a 50ml round bottomed flask, any residual product on the powdered 
sieves was washed into the flask with fresh dry ethanol (2 x 10ml). The solvent and any 
residual amine was removed by rotary evaporation at 40 
o
C to constant mass. 
 
Where the Schiff base formed a crystalline solid, the product was isolated by filtering 
the hot suspension into a 50ml round bottomed flask, any residual product on the 
powdered sieves was washed into the flask with hot fresh dry ethanol (2 x 10ml). The 
mass was concentrated to saturation point by solvent removal on the rotary evaporator 
at 40 
o
C. After cooling, the crystalline product was isolated by filtration and dried in 
vacuo over P2O5 for 24 hours.  
 
The Schiff base compounds synthesized along with their analyses are given in Table 9 
and Table 10 for L
1
R ligands and Table 11 for L
3
R ligands.  
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Table 9. Characterisation data for Schiff bases L
1
R. 
 
Compound Colour
Yield 
(solvent)
m.p. Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum 1H NMR
(L
1
Et) Tan 98% Oil
3063w (aromatic C-H), 2968s, 2931s, 2925s (sp3 C-H), 2870s 
(aldimine C-H), 1644s (aldimine C=N); 1591s, 1567s, 1458s 
(ring stretching)
ESI+ (MeOH);  m/z  222 (M+ MeOH)
+ H (270 MHz, CDCl3)  8.42 (2H, s, HC=N), 7.98 (H
3/5
, 2H, d, J = 8.1 Hz), 7.79 
(H
4
, 1H, t, J = 8.1 Hz), 3.71 (H
a
,4H, q, J = 7.2 Hz), 1.32 (H
b
, t, 6H, J = 7.2 Hz) 
(L
1
Pr
n
) Tan 97% Oil
3059w (aromatic C-H), 2974s, 2931s, 2925s (sp3 C-H), 2867s 
(aldimine C-H), 1644s (aldimine C=N) 1590s, 1570s, 1452s 
(ring stretching)
EI; m/z 217 (M)
+
, 188 (M-C2H5)
+
, 174 
(M-C3H7)
+ 
H (270 MHz, CDCl3) 8.40 (2H, s, HC=N), 7.99 (H
3/5
, 2H, d, J = 7.7 Hz), 7.78 
(H
4
, 1H, t, J = 7.9 Hz), 3.64 (H
a
,4H,t, J = 6.9 Hz), 1.76 (H
b
, m, 4H, J = 7.2 Hz), 
0.95 (H
c
, t, 6H, J = 7.4 Hz) 
(L
1
Pr
i
) Tan 99% Oil
3058m (aromatic C-H), 2968s, 2931s, 2925s (sp3 C-H), 2868s 
(aldimine C-H), 1644s (aldimine C=N), 1590s, 1564s, 1458s 
(ring stretching)
ESI+ (MeOH); m/z  218 (M)
+
H (270 MHz, CDCl3) 8.46 (2H, s, HC=N), 8.00 (H
3/5
, 2H, d, J = 7.7 Hz), 7.76 
(H
4
, 1H, t, J = 8.0 Hz), 3.64 (H
a
,2H, m, J = 6.3 Hz), 1.27 (H
b
, d, 12H, J = 6.3 
Hz)
(L
1
Bu
n
) Tan 96% Oil
3061m (aromatic C-H), 2962s, 2925s  (sp3 C-H), 2870s 
(aldimine C-H), 1653s (aldimine C=N), 1586s, 1573s, 1462s 
(ring stretching)
EI; m/z  245 (M)
+
,  202 (M-C3H7)
+
H
 
(270 MHz, CDCl3) 8.40 (2H, s, HC=N), 7.98 (H
3/5
, 2H, d, J = 7.8 Hz), 7.78 
(H
4
, 1H, t, J = 7.8 Hz), 3.67 (H
a
,4H,t, J = 7.2 Hz), 1.69 (H
b
, m, 4H, J = 7.2 Hz), 
1.38 (H
c
, m, 4H, J = 7.2 Hz), 0.93 (H
d
, t, 6H, J = 7.2 Hz) 
(L
1
Bu
2
) Tan 99% Oil
3061m (aromatic C-H), 2968s, 2931s (sp3 C-H), 2870s 
(aldimine C-H), 1647s (aldimine C=N), 1586s, 1573s, 1462s 
(ring stretching)
ESI+ (MeOH); m/z  246 (M)
+
H (270 MHz, CDCl3) 8.40 (2H, s, HC=N), 8.03 (H
3/5
, 2H, d, J = 7.7 Hz), 7.76 
(H
4
, 1H, t, J = 8.0 Hz), 3.30 (H
a
,2H, m, J = 6.4 Hz), 1.62 (H
b
, m, 4H, J = 7.1 
Hz), 1.25 (H
d
, d, 6H, J = 6.3 Hz), 0.84 (H
c
, t, 6H, J = 7.4 Hz)
(L
1
Bu
i
) Tan 98% Oil
3055m (aromatic C-H), 2956s, 2925s, 2900s (sp3 C-H), 2869 
(aldimine C-H), 1654s (aldimine C=N), 1586s, 1567s, 1468s 
(ring stretching)
ESI+ (MeOH); m/z  246 (M)
+
. 
H (270 MHz, CDCl3) 8.36 (2H, s, HC=N), 8.00 (H
3/5
, 2H, d, J = 7.9 Hz), 7.78 
(H
4
, 1H, t, J = 7.5 Hz), 3.48 (H
a
,4H, d, J = 6.6 Hz), 2.03 (H
b
, m, 2H, J = 6.7 Hz), 
0.95 (H
c
, d, 12H, J = 6.7 Hz)
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 Table 10. Characterisation data for Schiff bases L
1
R 
 
Compound Colour
Yield 
(solvent)
m.p. Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum 1H NMR
(L
1
Bu
t
) Tan 97% Oil
3060m (aromatic C-H), 2960s, 2925s (sp3 C-H), 2866 
(aldimine C-H),1655s (aldimine C=N), 1587s, 1567s, 1466s 
(ring stretching)
ESI+ (MeOH); m/z  246 (M)
+ H (270 MHz, CDCl3) 8.39 (2H, s, HC=N), 8.04 (H
3/5
, 2H, d, J = 7.67 Hz), 7.76 
(H
4
, 1H, t, J = 7.36 Hz), 1.31 (H
a
,18H, s)
(L
1
Cy) Tan 98% Oil
3051w (aromatic C-H), 2950s, 2925s (sp3 C-H), 2864s 
(aldimine C-H),1647s (aldimine C=N), 1590s, 1566s, 1455s 
(ring stretching)
ESI+ (MeOH); m/z  298 (M)
+ H (270 MHz, CDCl3) 8.42 (2H, s, HC=N), 8.02 (H
3/5
, 2H, dd, J = 8.1 Hz), 7.75 
(H
4
, 1H, t, J = 8.1 Hz), 3.29 (H
a
, 2H, m), 1.35-1.85 (H
b
, mm, 20H)
(L
1
CyMe) Tan 97% Oil
3049w (aromatic C-H), 2950s, 2926s (sp3 C-H),  2861s 
(aldimine C-H), 1647s (aldimine C=N), 1591s, 1567s, 1456s 
(ring stretching)
ESI+ (MeOH); m/z  326 (M)
+
H (270 MHz, CDCl3) 8.42 (2H, s, HC=N), 8.04 (H
3/5
, 1H, d, J = 7.8 Hz), 7.79 
(H
3/5 iso
, 1H, d, J = 7.8 Hz), 7.75 (H
4
, 1H, t, J = 7.4 Hz), 3.46 (H
a
, 1H, m), 3.25 
(H
a iso
, 1H, m), 1.85-1.50 (H
b/c
, mm, 16H), 1.15-1.00 (H
d
, 2H, m), 0.98 (H
e
, 3H, 
d, J = 6.6 Hz), 0.91 (H
e iso
, 3H, d, J = 6.6 Hz)
(L
1
Ph) Yellow
80 % 
(EtOH)
108-110 
o
C
3070m, 3050m, 3030m, 2993m (aromatic C-H), 2870m 
(aldimine C-H), 1625m (aldimine C=N), 1597m, 1585m, 1480m  
(ring stretching)
EI; m/z 285 (M)
+
, 192 (M-C6H7N)
+ H (270 MHz, CDCl3) 8.68 (HC=N, 2H, s), 8.29 (H
3/5
, 2H, d, J = 7.6 Hz), 7.93 
(H
4
, 1H, t, J = 8.1 Hz), 7.42 (H
b
, 4H, tt, 7.6 Hz) 7.29 (H
a/c
, 6H, m)  
(L
1
PhMe) Pale Yellow
95 % 
(EtOH)
181-183 
o
C
3080m, 3050m, 3030m, 2999m (aromatic C-H) 2907m, 2882m 
(methyl C-H), 2863m (aldimine C-H), 1628m (aldimine C=N), 
1575m, 1505s, 1468m (ring stretching) 
EI; m/z 313 (M)
+
, 298 (M-CH3)
+
, 222 
(M-C7H7)
+ 
H (600 MHz, CDCl3) 8.69 (HC=N, 2H, s), 8.26 (H
3/5
, 2H, d, J = 7.2 Hz), 7.91 
(H
4
, 1H, t, J = 7.8 Hz), 7.25 (H
a
, 4H, d, 7.8 Hz), 7.22 (H
b
, 4H, d, 8.4 Hz),  2.38 
(H
c
, 6H, s)
(L
1
PhCl) Pale Green
97 % 
(EtOH)
198-200 
o
C
3086m, 3050m, 3005m, 2969m, 2919m (aromatic C-H); 2869m 
(aldimine C-H); 1628m (aldimine C=N); 1586, 1567, 1486 (ring 
stretching)
EI; m/z 355 (M+ 2)
+
, 353 (M)+, 318 
(M-Cl)
+
, 242 (M-C6H4Cl)
+
H (600 MHz, CDCl3) 8.64 (HC=N, 2H, s), 8.27 (H
3/5
, 2H, d, J = 7.6 Hz), 7.95 
(H
4
, 1H, t, J = 9.6 Hz), 7.39 (H
b
, 4H, d, 7.9 Hz), 7.25 (H
a
, 4H, d, 7.9 Hz)
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Table 11. Characterisation data for Schiff bases L
3
R. 
 
Compound Colour
Yield 
(solvent)
m.p. Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum 1H NMR
(L
3
Bu
n
) Colourless 90% Oil
3057w, 3010w (aromatic C-H), 2953s, 2925s (sp3 C-H), 2865s 
(aldimine C-H), 1646s (aldimine C=N), 1622m, 1578m, 1567m, 
1515m, 1405m (ring stretching) 
EI; m/z  346 (M)
+
, 303 (M-C3H7)
+ 
H (270 MHz, CDCl3) 8.85 (2H, s, HC=N), 8.42 (H
3/8
, 2H, d, J = 8.4 Hz), 8.31 
(H
4/7
, 2H, d, J = 8.4 Hz), 7.86 (H
5/6
, 2H, s), 3.77 (H
a
, 4H, t, J
 
= 7.2 Hz), 1.75 (H
b
, 
4H, m, J = 7.2 Hz), 1.44 (H
c
, 4H, m, 7.7 Hz), 0.96 (H
d
, 6H, t, J = 7.4 Hz)
(L
3
Bu
2
) Colourless 90% Oil
3055w, 3012w (aromatic C-H), 2961s, 2925s (sp3 C-H), 2868s 
(aldimine C-H), 1647s (aldimine C=N), 1620m, 1580m, 1566m, 
1514m, 1402m (ring stretching) 
ESI+ (MeOH);  m/z  447 (M)
+
H (600 MHz, CD3OD) 8.80 (2H, s, HC=N), 8.52 (H
3/8
, 2H, d, J = 8.2 Hz), 8.40 
(H
4/7
, 2H, d, J = 8.2 Hz), 8.03 (H
5/6
, 2H, s), 3.45 (H
a
, 2H, m, J
 
= 7.2 Hz), 1.68 
(H
b
, 4H, m, J = 7.2 Hz), 1.31 (Hd, 6H, d, J = 6.2 Hz), 0.89 (H
c
, 6H, t, J = 7.4 Hz)
(L
3
Bu
i
) Colourless 95% Oil
3050w, 3010w (aromatic C-H), 2959s, 2926s (sp3 C-H), 2865s 
(aldimine C-H), 1647s (aldimine C=N), 1621m, 1580m, 1566m, 
1514m, 1403m (ring stretching) 
ESI+ (MeOH);  m/z  447 (M)
+
H (600 MHz, CD3OD) 8.77 (2H, s, HC=N), 8.51 (H
3/8
, 2H, d, J = 8.4 Hz), 8.39 
(H
4/7
, 2H, d, J = 8.4 Hz), 8.02 (H
5/6
, 2H, s),  3.61 (H
a
, 4H, d, J
 
= 6.7 Hz), 2.08 
(H
b
, 2H, m, J = 6.7 Hz), 1.01 (H
c
, 12H, d, J = 6.5 Hz)
(L
3
Bu
t
) Colourless 94% Oil
3058w, 3014w (aromatic C-H), 2970s, 2915s (sp3 C-H), 2865s 
(aldimine C-H), 1647s (aldimine C=N), 1622m, 1579m, 1569m, 
1515m, 1403m (ring stretching) 
ESI+ (MeOH);  m/z  447 (M)
+ H (270 MHz, CDCl3) 8.84 (2H, s, HC=N), 8.46 (H
3/8
, 2H, d, J = 8.1 Hz), 8.29 
(H
4/7
, 2H, d, J = 8.1 Hz), 7.85 (H
5/6
, 2H, s), 1.35 (Ha, 18H, s)
(L
3
Cy) Colourless 70%
Oil 
Solidifies on 
standing
3060w, 3010w (aromatic C-H), 2950s (sp3 C-H), 2870s 
(aldimine C-H), 1647m (aldimine C=N), 1623m, 1580m, 
1567m, 1510m, 1402m (ring stretching) 
EI; m/z  398 (M)
+
, 314 (M-C6H12)
+ 
H (270 MHz, CDCl3) 8.88 (2H, s, HC=N), 8.42 (H
3/8
, 2H, d, J = 8.4 Hz), 8.27 
(H
4/7
, 2H, d, J = 8.4 Hz), (H
5/6
, 2H, s), 3.42 (H
a
, 2H, tt, J
ab 
= 3.5 Hz, J
ab'
 = 10.5 
Hz), 1.88-1.23 (H
b/c/d
, 20H, mm)
(L
3
Ph) Yellow
75 % 
(Toluene)
>230 °C
3100w, 3050w, 3015w, 2931w (aromatic C-H), 1604s 
(aldimine C=N); 1563w, 1550w, 1499s (ring stretching)
EI; m/z  386 (M)
+ 
H (270 MHz, CDCl3) 9.15 (2H, s, HC=N), 8.67 (H
3/8
, 2H, d, J = 8.4 Hz), 8.38 
(H
4/7
, 2H, d, J = 8.4 Hz), 7.91 (H
5/6
, 2H, s), 7.50-7.40 (H
a/b
, 8H, m), 7.31 (H
c
, 
2H, m) 
(L
3
PhMe) Yellow
65% 
(MeOH)
210-214 °C
3086m, 3061m, 3018m, 2919m (aromatic C-H), 1623m 
(aldimine C=N), 1580m, 1554m, 1511s (ring stretching) 
EI; m/z  414 (M)
+
, 399 (M-CH3)
+
, 323 
(M-C7H7)
+
H (600 MHz, CDCl3) 9.16 (2H, s, HC=N) 8.66 (H
3/8
, 2H, d, J = 8.3 Hz), 8.38 
(H
4/7
, 2H, d, J = 8.3 Hz), 7.91 (H
5/6
, 2H, s), 7.35 (H
a
, 4H, d, J = 8.1 Hz), 7.25 
(H
b
, 4H, d, 8.1 Hz), 2.39 (H
c
, 6H, s) 
(L
3
PhCl) Yellow
80% 
(MeOH)
>230 °C
3080m, 3059m, 3018m, 2920m (aromatic C-H), 1628m 
(aldimine C=N), 1580m,1567w, 1499m (ring stretching) 
EI; m/z  456 (M+ 2)
+
, 454 (M)
+
,419 (M-
Cl)
+
, 111(C6H4Cl)
+
H (600 MHz, CDCl3) 9.09 (2H, s, HC=N), 8.64 (H
3/8
, 2H, d, J = 8.3 Hz), 8.40 
(H
4/7
, 2H, d, J = 8.3), 7.93 (H
5/6
, 2H, s), 7.41 (H
b
, 4H, d, J = 8.6 Hz), 7.34 (H
a
, 
4H, d, J = 8.6 Hz)
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2.1.8. Preparation of Metal Complexes of L1R, L2R and L3R 
2.1.8.1. Preparation of [MX2L] complexes. 
 
 
 
The preparation of the 1:1 ligand to metal complexes, were carried out by two methods 
which both involved stirring at room temperature for 0.5 hrs. The first was simply by 
stoichiometric mixing of 0.5 millimolar equivalents of the Schiff base ligand, with the 
appropriate metal salt, in an appropriate solvent (typically CH3CN or MeOH (15 ml) 
depending on the salt solubilities). The second method which was the foremost method 
used was a template synthesis
132, 133
 whereby the dicarbaldehyde P
1
, P
2
 or P
3
 (0.75 
mmol) was mixed with 1 equivalent of the metal salt (0.75 mmol), in an appropriate 
solvent (typically solvents as above), and then two equivalents of primary amine (1.5 
mmol), were added to form the 1:1 Schiff base metal complex. The complexes either 
spontaneously precipitated upon mixing or shortly thereafter to give microcrystalline 
powders. Complexes that did not precipitate, were crystallised or precipitated by 
reducing the volume of the reaction mixture to ca. 5 ml on the rotary evaporator and 
then vapour diffusion of diethyl ether. The products were isolated at the pump and 
washed with diethyl ether, typically (3 x 10 ml).  The metal complexes synthesized 
along with their analyses are given in Table 12 to Table 21. 
 
 
N
O O
N
N N
R RM
N
N N
R R
X X
MX2
MX2
2 RNH2
[MX2(L
1R)]
P1 L1R
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2.1.8.2. Preparation of [ML2]X2 Complexes of L
1
R 
 
 
 
The preparation of the 2:1 ligand to metal complexes, was carried out using the template 
effect only. The template synthesis was performed by stirring P
1 
(1.5 mmol) with 0.5 
equivalent of the appropriate metal salt (0.75 mmol) in an appropriate solvent (typically 
CH3CN [15 ml]), and then two equivalents of primary amine (3 mmol) were added to 
form the 2:1 Schiff base metal complex. The metal salts used to prepare the 2:1 
complexes were Cu(BF4)2.6H2O, Co(NCS)2.xH2O or Co(NO3)2.6H2O. The complexes 
either spontaneously precipitated upon mixing or shortly thereafter to give 
microcrystalline powders. Complexes that did not precipitate were crystallised or 
precipitated by reducing the volume of the reaction mixture to Ca. 5 ml on the rotary 
evaporator and then vapour diffusion of diethyl ether. The products were isolated at the 
pump and washed with diethyl ether, typically (3 x 10 ml).  The metal complexes 
synthesized along with their analyses are given in tables 2.1.9.1a-g. Note: A few bis 
complexes were prepared by serendipity, when actually trying to obtain the 1:1 
complex. For example [Co(L
1
Cy)2][NO3]2, [Co(L
1
Cy)2][Co(NCS)4] and 
[Co(L
1
Cy)2][BF4]2, the latter was prepared during an attempted ligand exchange 
reaction detailed below. Characterisation data is provided in Table 12 to Table 21. 
 
 
 
 
 
2 P1 + MX2 + 4 R-NH2 [M(L
1R)2]X2
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2.1.8.3. Formation of [Co(H2O)2(L
1
Cy)][BF4]2. 
 
 
 
[CoCl2(L
1
Cy)] (200 mg, 0.47 mmol) was dissolved in deionised water (10 ml) in a 25 
ml round bottomed flask and was stirred. To the deep red solution was added two 
equivalents of AgBF4 (183 mg, 0.94 mmol) whereupon an off white precipitate started 
to form. The solution was left to stir for 1h, after which time the pinky precipitate was 
filtered through a Pasteur pipette plugged with a small ball of cotton wool. Water was 
then removed from the filtrate on the rotary evaporator to leave a dark red residue. The 
product was also extracted from the precipitate as well by washing with acetone (20 
ml), to give a deep red solution. This was combined with the residue obtained from the 
filtrate and the solvent was reduced to ca. 5 ml on the rotary evaporator. The product 
was crystallized by slow vapour diffusion of diethyl ether into the acetone solution to 
give deep red block crystals (136 mg, 64 %). The product was identified through CHN 
microanalysis and later single crystal X-ray diffraction to be the 2:1 ligand to metal 
complex and was not the diaqua complex as anticipated. Characterisation data can be 
found in Table 17. 
[CoCl2(L
1Cy)]  +  2 AgBF4 [Co(L
1Cy)2][BF4]2
H2O
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Table 12. Characterisation data for Cu
II
 complexes of L
1
R; a) Peaks too broad to be observed. 
 
Compound Colour
Yield 
(solvent)
Microanalysis Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum ESI+
[CuCl2(L
1
Et)] Green 80% (EtOH)
Calc. C, 40.8%; H, 4.7%; N, 13.0%. 
Found. C, 41.1%; H, 4.7%; N, 12.7%.
3092m, 3061m, 3012m, (aromatic C-H); 2981m, 2937m, 2913m (sp3 C-
H); 2876m, (aldiminine C-H); 1637w, (aldimine C=N); 1591s, 1480m, 
(ring stretching)
m/z , 441 (
63
Cu+2L-H)
+
, 287 
(
63
Cu+L+Cl-H)
+ 
[CuCl2(L
1
Pr
n
)] Green
76 % 
(CH3CN)
Calc. C, 44.4%; H, 5.4%; N,12.0%. 
Found. C, 44.6%; H, 5.1%; N, 11.9%.
3092m, 3055m, 3025m, (aromatic C-H); 2968s, 2931s, (sp3 C-H); 
2870m, (aldiminine C-H); 1634w, (aldimine C=N); 1585s, 1474s, (ring 
stretching) 
m/z 497, (
63
Cu+2L-H)
+
, 315 
(
63
Cu+L+Cl-H)
+
, 249 (
63
Cu+2L)
2+ 
[Cu(NO3)2(L
1
Pr
n
)] Green
85% 
(CH3CN : 
Et2O)
Calc. C, 38.6%; H, 4.7%; N, 17.3%. 
Found. C, 38.6%; H, 4.6%; N, 17.5%.
3086w, 3025w, (aromatic C-H); 2974m, 2937m, (sp3 C-H); 2876m, 
(aldiminine C-H); 1636w, (aldimine C=N); 1585s, 1486s, (ring 
stretching); 1412s, 1313s, 1011m (nitrato N-O)
m/z 341 (
63
Cu+L+NO3-2H)
+
, 248.5 
(
63
Cu+2L)
2+
[CuBr2(L
1
Pr
n
)] Green 90% (EtOH)
Calc. C, 35.4%; H, 4.4%; N, 9.5%. 
Found. C, 35.5%; H, 4.5%; N, 9.6%.
3086w, 3055w, 3025w, (aromatic C-H); 2968s, 2931s, (sp3 C-H); 
2876m, (aldiminine C-H); 1634w, (aldimine C=N); 1585s, 1474s, (ring 
stretching) 
m/z 359 (
63
Cu+L+Br-H)
+ 
[Cu(L
1
Pr
n
)2][BF4]2 Green
50% (EtOH 
: CH3CN)
Calc. C, 46.5%; H, 5.7%; N, 12.5%. 
Found. C, 46.4%; H, 5.4%; N, 12.2%.
3093w, 3056w, 3040w, (aromatic C-H); 2954m, 2935m, (sp3 C-H); 
2873m, (aldiminine C-H); 1634wbr, (aldimine C=N); 1590m, 1470m, 
(ring stretching) 1057s, 1039s (BF4)
m/z 497 (
63
Cu+2L-H)
+
, 248.5 
(
63
Cu+2L)
2+ 
[CuCl2(L
1
Pr
i
)] Green
88% 
(CH3CN)
Calc. C, 44.4%; H, 5.4%; N,12.0%. 
Found. C, 44.2%; H,5.4%; N, 12.0%.
3086m, 3055m, (aromatic C-H); 2980s, 2937m, (sp3 C-H); 2869m, 
(aldiminine C-H); 1634w, (aldimine C=N); 1591s, 1477s, (ring 
stretching)
m/z 315 (
63
Cu+L+Cl-H)
+
[CuCl2(L
1
Bu
n
)] Green
55 % 
(CH3CN : 
Et2O)
Calc. C, 47.4%; H, 6.1%; N, 11.1%. 
Found. C, 47.3%; H, 6.0%; N, 11.1%.
3065s, 3033s, 3005s, (aromatic C-H); 2955s, 2932s, (sp3 C-H); 2871s, 
(aldiminine C-H); 1627w, (aldimine C=N); 1583s, 1472s, (ring 
stretching) 
m/z 343 (
63
Cu+L+Cl)
+
[CuCl2(L
1
Bu
2
)] Green
62 % 
(CH3CN : 
Et2O)
Calc. C, 47.4%; H, 6.1%; N, 11.1%. 
Found. C, 47.3%; H, 6.3%; N, 10.9%.
 3063m, 3035m, 3003m (aromatic C-H); 2962s, 2931s, (sp3 C-H); 
2872m, (aldiminine C-H); 1628wbr, (aldimine C=N); 1585s, 1474s, 
(ring stretching) 
m/z 553 (
63
Cu+2L-H)
+
, 308 (
63
Cu+L-
H)
+
, 276.5 (
63
Cu+2L)
2+ 
1H NMR
H (600 MHz, D2O) 3.35 (H
a
, 4H, bt), 1.18 (H
b
, 6H, bd) 
H (600 MHz, D2O) 2.75 (H
a
, 4H, bt), 1.47 (H
b
, 4H, bm), 0.77 (H
c
, 
6H, bt) 
H (600 MHz, D2O) 2.77 (H
a
, 4H, bs), 1.65 (H
b
, 4H, bs), 0.78 (H
c
, 
6H, bs) 
H (600 MHz, D2O) 2.80 (H
a
, 4H, bt), 1.52 (H
b
, 4H, bm), 0.81 (H
c
, 
6H, bt) 
a
H (270 MHz, D2O) 3.33 (H
a
, 2H, bm), 1.15 (H
b
, 12H, bd) 
H (270 MHz, D2O) 2.85 (H
a
, 4H, bt), 1.48 (H
b
, 4H, bm), 1.23 (H
c
, 
4H, bm), 0.75 (H
d
, 6H, bt) 
H (600 MHz, D2O) 3.11 (H
b
, 2H, bm), 1.49 (H
c/c’
, 2H, bm), 1.42 
(H
c/c’
, 2H, bm), 1.10 (H
a
, 6H, bd), 0.79 (H
d
, 6H, bt)
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Table 13. Characterisation data for Cu
II
 complexes of L
1
R continued; a) Peaks too broad to be observed; b) Insoluble. 
 
Compound Colour
Yield 
(solvent)
Microanalysis Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum ESI+
[CuCl2(L
1
Bu
i
)] Green
86% 
(CH3CN : 
Et2O)
Calc. C, 47.4%; H, 6.1%; N, 11.1%. 
Found. C, 47.2%; H, 6.2%; N, 11.0%.
3056m, 3002m, (aromatic C-H); 2951s, 2940s, (sp3 C-H); 2865s, 
(aldiminine C-H); 1628w, (aldimine C=N); 1585m, 1475m, (ring 
stretching) 
m/z 343 (
63
Cu+L+Cl)
+
[CuCl2(L
1
Bu
t
)] Green
[CuCl2(L
1
Cy)]. (CH3CN) Green
98% 
(CH3CN)
Calc. C, 53.3%; H, 6.4%; N, 11.9%. 
Found. C, 53.2%; H, 6.3%; N, 11.5%.
3072m, 3035m, 3005m, (aromatic C-H); 2925s, (sp3 C-H); 2875s, 
(aldiminine C-H); 1638wbr, (aldimine C=N); 1585m, 1475m, (ring 
stretching)
m/z 395 (
63
Cu+L+Cl-H)
+
, 359 
(
63
Cu+L)
+
[Cu(L
1
Cy)2][BF4]2. 
2.5(H2O)
Green
90% 
(CH3CN)
Calc. C, 52.0%; H, 6.5%; N, 10.0%. 
Found. C, 52.0%; H, 6.3% N, 9.4%.
3084w, (aromatic C-H); 2930s, (sp3 C-H); 2855s, (aldiminine C-H); 
1645wbr, (aldimine C=N); 1591m, 1467w, (ring stretching), 1080s, 
1039s (BF4)
m/z 744 (
63
Cu+2L+BF4)
+
, 329 
(
63
Cu+2L)
2+
racemic -[CuCl2(L
1
CyMe)] Green
73 % 
(CH3CN)
Calc. C, 54.8%; H, 6.8%; N, 9.1%.  
Found. C, 54.8%; H, 6.6%; N, 9.1%.
3066m, 3030m, (aromatic C-H); 2925s, 2870m, (sp3 C-H); 2850m, 
(aldiminine C-H); 1628wbr, (aldimine C=N); 1580m, 1474m, (ring 
stretching)
m/z 423 (
63
Cu+L+Cl+H)
+
, 387 
(
63
Cu+L)
+
[CuCl2(L
1
Ph)] Orange
100 % 
(CH3CN)
Calc. C, 54.4%; H, 3.6%; N, 10.0%. 
Found. C, 51.3%; H, 3.8%; N, 11.8%.
3053, 3016, (aromatic C-H); 2851 (aldimine C-H); 1550, 1495s, (ring 
stretching) 
m/z 633 (
63
Cu+2L)
+ 
[CuCl2(L
1
PhMe)] Orange
99 % 
(CH3CN)
Calc. C, 56.3%; H, 4.2%; N, 9.4%. 
Found. C, 56.0%; H, 4.0%; N, 9.2%.
3071m, 3040m, 3004m, (aromatic C-H); 2952m, 2930m, (sp3 C-H); 
2872 (aldiminine C-H); 1595m, 1549m, 1510m, 1470m, (ring 
stretching)
m/z 689 (
63
Cu+2L-H)
+
, 411 
(
63
Cu+L+Cl-H)
+
, 376 (
63
Cu+L-H)
+
[CuCl2(L
1
PhCl)] Orange
88 % 
(CH3CN)
Calc. C, 46.7%; H, 2.7%; N, 8.6%. 
Found. C, 46.6%; H, 2.6%; N, 8.5%.
3073m, 3036m, 3018m (aromatic C-H); 1620w (aldimine C=N) 1589m, 
1560m, 1486s (ring stretching)
m/z 771 (
63
Cu+2L)
+ 
[CuCl2(L
1
PhNO2)] Orange
96 % 
(CH3CN)
Calc. C, 44.8%; H, 2.6%; N, 13.7%. 
Found. C, 44.9%; H, 2.3%; N, 13.6%.
3100m, 3082m, 3054m, 3040m, (aromatic C-H); 2857m, (aldiminine C-
H); 1605w, (aldimine C=N); 1580w, 1495m, (ring stretching); 1519s, 
1345s, (N=O) 
FAB-MS m/z (
63
Cu+L+2Cl)
+ 
H (600 MHz, D2O) 3.01 (H
a
, 2H, bm), 1.83 (H
b/b’
, 4H, bm), 1.67 
(H
c/c’
, 4H, bm), 1.50 (H
d/d’
, 2H, bd), 1.19 (H
b/b’/c/c’
, 8H, bm), 1.02 
(H
d/d’
, 2H, bm)
a
H (600 MHz, D2O) 3.20 (H
a
, 2H, bm), 2.95 (H
a
 
iso
, 2H, bm), 1.84 
(H
b/b' iso
, 4H, bm), 1.63 (H
b/b’iso
, 4H, bm), 1.60-1.52 (H
b/b'
, 8H, 
bmm), 1.49-1.43 (H
c/c'
, 4H, bm), 1.22 (H
c/c' iso
,4H, bm),1.22-1.15 
(H
c/c'
 H
d/d iso
, 8H, bm), 0.88 (H
c/c' iso
, 4H, bm), 0.78 (H
e
, 6H, d), 0.73 
(H
e iso
, 6H, d)
b
1H NMR
b
b
H (270 MHz, D2O) 2.69 (H
a
, 4H, bd), 1.78 (H
b
, 2H, bm), 0.83 (H
c
, 
12H, bd)
b
No Solid Products Could be isolated.
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Table 14. Characterisation data for Zn
II
 complexes of L
1
R; a) Insoluble. 
 
Compound Colour
Yield 
(solvent)
Microanalysis Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum ESI+
[ZnCl2(L
1
Et)] Colourless
62 % 
(CH3CN)
Calc. C, 40.6%; H, 4.6%; N, 12.9%. 
Found. C, 40.7%; H, 4.7%; N, 12.8%.
3092m, 3061m, 3044m, (aromatic C-H); 2970m, 2950m, 2922m (sp3 C-
H); 2867m, (aldiminine C-H); 1650m, (aldimine C=N); 1591s, 1475m, 
(ring stretching)
m/z  288 (
65
Zn+L+H2O+OH-H)
+
, 
252 (
65
Zn+L-2H)
+
[ZnCl2(L
1
Pr
n
)] Colourless
50 % 
(CH3CN)
Calc. C, 44.2%; H, 5.4%; N, 11.9%. 
Found. C, 44.3%; H, 5.5%; N, 11.8%.
3085m, 3063m, 3010m (aromatic C-H); 2968s, 2925s, 2877s, (sp3 C-
H); 2856s (aldiminine C-H); 1649m, (aldimine C=N); 1596, 1468s, (ring 
stretching)
m/z 249 (M+2L)
2+
[ZnCl2(L
1
Pr
i
)] Colourless
59 % 
(CH3CN)
Calc. C, 44.2%; H, 5.4%; N, 11.9%. 
Found. C, 44.1%; H, 5.5%; N, 11.8%.
3080m, 3048m, 3010m, (aromatic C-H); 2973s, 2908s, (sp3 C-H); 
2871s (aldiminine C-H); 1651m, (aldimine C=N); 1595, 1470s, (ring 
stretching)
m/z  316 (
65
Zn+L+H2O+OH-H)
+ 
[ZnCl2(L
1
Bu
n
)] Colourless
63 % 
(CH3CN)
Calc. C, 47.2%; H, 6.1%; N, 11.0%. 
Found. C, 46.9%; H, 6.1%; N, 11.0%.
3075m, 3028m, (aromatic C-H); 2955s, 2927s, 2890s, (sp3 C-H); 
2857s, (aldiminine C-H); 1650m, (aldimine C=N); 1590s, 1465s, (ring 
stretching) 
m/z 723 (2(
65
Zn)+2L+3Cl-H])
+
, 344 
(
65
Zn+L+H2O+OH-H)
+
[ZnCl2(L
1
Bu
2
)] Colourless
51 % 
(CH3CN)
Calc. C, 47.2%; H, 6.1%; N, 11.0%. 
Found. C, 47.5%; H, 6.0%; N, 10.9%.
3075m, 3030m, (aromatic C-H); 2970s, 2929s, (sp3 C-H); 2869m, 
(aldiminine C-H); 1647m, (aldimine C=N); 1590s, 1460s, (ring 
stretching)
m/z 344 (
65
Zn+L+H2O+OH-H)
+
, 277 
(
65
Zn+2L)
2+
[ZnCl2(L
1
Bu
i
)] Colourless
70 % 
(CH3CN)
Calc. C, 47.2%; H, 6.1%; N, 11.0%. 
Found. C, 47.3%; H, 6.1%; N, 11.0%.
3092m, 3061m, 3044m, (aromatic C-H); 2970m, 2950m, 2922m (sp3 C-
H); 2867m, (aldiminine C-H); 1652m, (aldimine C=N); 1591s, 1475m, 
(ring stretching)
m/z 344 (
65
Zn+L+H2O+OH-H)
+
[ZnCl2(L
1
Bu
t
)] Colourless
60 % 
(CH3CN)
Calc. C, 47.2%; H, 6.1%; N, 11.0%. 
Found. C, 47.5%; H, 6.3%; N, 11.4%.
3070m, 3030m, 3023m, (aromatic C-H); 2966s, 2929s, (sp3 C-H); 
2870m, (aldiminine C-H); 1644m, (aldimine C=N); 1595s, 1464s, (ring 
stretching) 
m/z 344 (
65
Zn+L+H2O+OH-H)
+
[Zn(NO3)2(L
1
Bu
t
)] Colourless
70 % 
(CH3CN)
Calc. C, 41.4%; H, 5.3%; N, 16.1%. 
Found. C, 41.6%; H, 5.3%; N, 16.2%.
3080m, 3048m, 3030m, (aromatic C-H); 2970s, 2945s, (sp3 C-H); 
2875m, (aldiminine C-H); 1645m, (aldimine C=N); 1595s, 1473s, (ring 
stretching) 1490s, 1293s, 1018s nitrato N-O)
m/z 371 (
65
Zn+L+NO3-H)
+
, 277 
(
65
Zn+2L)
2+
H (270 MHz, (CD3)2CO) 8.62 (2H, s, HC=N); 8.55 (H
4
, 1H, t, J = 
7.7Hz); 8.23 (H
3/5
, 2H, d, J = 7.7 Hz); 3.70 (H 
a
,4H, d, J = 6.6 Hz); 
2.72 (H
b
, m, 2H, J = 7.0 Hz); 0.90 (H 
c
,12H, d, J = 6.8 Hz)
H (270 MHz,(CD3)2CO) 8.77 (HC=N, 2H, s); 8.54 (H
4
, 1H, t, J = 
8.1 Hz); 8.22 (H
3/4
, 2H, d, J = 8.1 Hz); 1.54 (H
b
, 18H, s)
H (600 MHz, (CD3)2SO) at 50 °C) 9.07 (HC=N, 2H, s); 8.88 (H
4
, 
1H, t, J = 7.7 Hz); 8.55 (H
3/4
, 2H, d, J = 7.8 Hz); 0.90 (H
b
, 18H, s); 
8.81 (HC=N, 1H, s); 8.58 (H
4
, 0.5H, t); 8.28 (H
3/4
, 1H, d, J = 7.4 
Hz); 1.38 (H
b
, 9H, s)  
a
H (270 MHz, CD3CN) 8.51 (2H, s, HC=N); 8.36 (H
4
, 1H, t, J = 8.1 
Hz); 7.96 (H
3/5
, 2H, t, J = 8.1 Hz); 4.13 (H 
a
,2H, m, J = 6.7 Hz); 1.46 
(H
b
, d, 12H, J = 8.1 Hz)
H (270 MHz, (CD3)2CO) 8.65 (2H, s, HC=N); 8.54 (H
4
, 1H, t, J = 
7.6 Hz); 8.20 (H
3/5
, 2H, t, J = 7.7 Hz); 3.90 (H 
a
,4H,t, J = 6.7 Hz); 
1.98 (H
b
, m, 4H, J = 7.7 Hz); 1.36 (H
c
, m, 4H, J = 7.6 Hz); 0.93 (H
d
, 
t, 6H, J = 7.3 Hz)
H (600 MHz, (CD3)2CO) 8.69 (2H, s, HC=N); 8.57 (H
4
, 1H, t, J = 
7.8 Hz); 8.23 (H
3/5
, 2H, d, J = 7.8Hz); 3.81 (H 
b
,2H, m, J = 7.2 Hz); 
2.17 (H
c/c’
, 2H, m, J = 6.6 Hz); 1.79 (H
c/c’
, 2H, m, J = 5.5 Hz); 1.52 
(H
a
, d, 6H, J = 5.4 Hz); 0.88 (Hd, 6H, t, J = 7.6 Hz) 
H (600 MHz, (CD3)2SO at 100 °C) 8.60 (2H, s, HC=N); 8.35 (H
4
, 
1H, bt); 8.09 (H
3/5
, 2H, d, J = 7.4 Hz); 3.81 (H 
a
,4H, q, J = 6.4 Hz); 
1.36 (H
b
, t, 6H, J = 6.5 Hz).
1H NMR
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Table 15. Characterisation data for Zn
II
 complexes of L
1
R continued; a) Insoluble. 
 
 
 
Compound Colour
Yield 
(solvent)
Microanalysis Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum ESI+
[Zn(AcO)2(L
1
Bu
t
)] Colourless
44 % 
(CH3CN)
Calc. C, 53.2%; H, 6.8%; N, 9.8%. 
Found. C, 53.0%; H, 6.9%; N, 9.7%.
3073w, 3055w, 3025w, (aromatic C-H); 2974s, 2937m, (sp3 C-H); 
2876w, (aldiminine C-H); 1635s, (aldimine C=N); 1616s, (Coordinated 
OAc C=O); 1591s, 1468m, (ring stretching); 1326m, (OAc C-O)
m/z 427 (
65
Zn+L+2AcO-H)
+
, 344 
(
65
Zn+L+H2O+OH-H)
+ 
[ZnCl2(L
1
Cy)] Colourless
63 % 
(CH3CN)
Calc. C, 52.6%; H, 6.3%; N, 9.7%. 
Found. C, 52.8%; H, 6.6%; N, 9.6%.
3070m, 3042m, (aromatic C-H); 2930s, (sp3 C-H); 2850m, (aldiminine 
C-H); 1648w, (aldimine C=N); 1592s, 1465m, (ring stretching) 
m/z 396 (
65
Zn+L+H2O+OH-H)
+
, 360 
(
65
Zn+L-2H)
+
,
 
329 (
65
Zn+L-2H)
2+
[ZnCl2(L
1
CyMe)] Colourless
65 % 
(CH3CN)
Calc. C, 54.9%; H, 6.4%; N, 9.1%. 
Found. C, 54.2%; H, 6.4%; N, 9.1%.
3070m, 3035m, 3025m, (aromatic C-H); 2930s, (sp3 C-H); 2851s, 
(aldiminine C-H); 1648m, (aldimine C=N); 1593s, 1469s, (ring 
stretching) 
m/z 424 (
65
Zn+L+H2O+OH-H)
+ 
[ZnCl2(L
1
Ph)] Yellow
70 % 
(CH3CN)
Calc. C, 54.1%; H, 3.6%; N, 10.0%. 
Found. C, 54.1%; H, 3.6%; N, 9.9%.
3064, 3044, 3005 (aromatic C-H); 1585, 1495s, (ring stretching) m/z 348 (
65
Zn+L-2H)
+
[ZnCl2(L
1
PhMe)] Yellow
92 % (DMF 
: Water)
Calc. C, 56.1%; H, 4.3%; N, 9.3%. 
Found. C, 55.9%; H, 4.3%; N, 9.3%.
3067m, 3049m, 3005m (aromatic C-H); 2956m, 2919m (sp3 C-H); 2869 
(aldiminine C-H); 1555s, 1480s, (ring stretching) 
m/z 689 (
65
Zn+2L-H)
+
, 376 (
65
Zn+L-
H)
+
, 345 (
65
Zn+L-H)
+
[ZnCl2(L
1
PhCl)] Yellow
 100 % 
(CH3CN)
Calc. C, 46.5%; H, 2.7%; N, 8.6%. 
Found. C, 46.7%; H, 2.6%; N, 8.4%.
3073m, 3050m, 3025m (aromatic C-H); 1637w (aldimine C=N) 1589m, 
1490s (ring stretching) 
FAB-MS m/z 772 (
65
Zn+2L)+, 454 
(
65
Zn+L-Cl)
+
[ZnCl2(L
1
PhNO2)] Yellow
90 % 
(CH3CN)
Calc. C, 44.6%; H, 2.6%; N, 13.7%. 
Found. C, 44.6%; H, 2.3%; N, 13.4%.
3101m, 3075m, 3032m, (aromatic C-H); 2932w, (sp3 C-H); 2851w, 
(aldiminine C-H); 1604w, (aldimine C=N); 1586m, 1490m, (ring 
stretching); 1520s, 1349s, (N=O).
FAB-MS m/z 474 (
65
Zn+L+Cl)
+
a
a
H (270 MHz, (CD3)2SO at 100
o
C) 8.81 (HC=N, 2H, s); 8.27 (H
4
, 
3H, t, J = 5.0 Hz); 8.26 (H
3/4
, 2H, brs); 7.43 (H
a/b
, 4H, brd, J = 6.8 
Hz); 7.29 (Ha/b, 4H, d, J = 8.4 Hz); 2.37 (H
c
, 6H, s)
H (270 MHz, CD3OD),  ppm: 8.63 (HC=N, 2H, s); 8.39 (H
4
, 1H, t, 
J = 7.8 Hz); 8.06 (H
3/4
, 2H, d, J = 7.7 Hz); 1.80 (H
OAc
, 6H, s); 1.54 
(H
b
, 18H, s)
H (600 MHz, ((CD3)2SO)) 8.67 (2H, s, HC=N); 8.49 (H
4
, 1H, t, J = 
7.6 Hz); 8.12 (H
3/5
, 2H, d, J = 7.9 Hz); 3.67 (H 
a
,2H, t, J = 11.0 Hz); 
1.88 (H
b/b’
, d, 4H, J = 11.0 Hz); 1.80 (H
b/b’
, d, 4H, J = 12.0 Hz); 
1.76(H
c/c’
, d, 4H, J = 15.5 Hz); 1.61 (H
d/d’
, d, 2H, J = 12.7 Hz); 1.27 
(H
c/c’
, q, 4H, J = 12.7 Hz); 1.01 (H
d/d’
, q, 2H, J = 13.1 Hz). 
H (600 MHz, CD3CN) 8.49 (2H, dd, HC=N, J = 2.76 Hz, J = 6.9 
Hz); 8.33 (H
4
, 1H, tt, J = 3.12 Hz, J = 7.7 Hz); 7.94 (H
3/5
, 2H, dt, J = 
7.02 Hz, J = 7.9 Hz); 3.76 (H
a
,1H, m, J = 5.16 Hz); 3.69 (Ha,1H, 
bm); 2.30-0.88 (remaining cyclohexyl and methyls, mm, 24H)
H (600 MHz, (CD3)2SO at 100 °C) 8.75 (HC=N, 2H, s); 8.28 (H
3/5
, 
3H, d, J = 6.9 Hz); 8.18 (H
4
, 2H, t, J = 7.2 Hz); 7.45 (H
a/b
, 8H, m, J 
= 7.1 Hz); 7.33 (H
c
, 2H, t, J = 6.9 Hz)
1H NMR
  
85 
Table 16. Characterisation data for Co
II
 complexes of L
1
R. 
 
Compound Colour
Yield 
(solvent)
Microanalysis Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum ESI+ eff 1H NMR
[CoCl2(L
1
Et)] 
[CoCl2(L
1
Pr
n
)] Dark Red
  80 % 
(CH3CN : 
Et2O)
Calc. C, 45.0%; H, 5.5%; N, 12.1%. 
Found. C, 44.6%; H, 5.5%; N, 11.7%.
3065m, 3035m, (aromatic C-H); 2967s, 2931s, (sp3 C-H); 2875m, 
(aldimine C-H); 1630m, (aldimine C=N); 1585s, 1471s, (ring stretching)
m/z 311 (
59
Co+L+Cl-H)
+  4.13 BM
H (270 MHz, CD3OD) 220.32 (HC=N, 2H, bs); 140.31 
(H
b
, 2H, bs); 105.00 (H
3/5
, 1H, bs); 43.3 (H
4
, 4H, bs); -
4.26 (H
c
, 6H, bs); -6.86 (H
a
, 4H, bs)
[CoCl2(L
1
Pr
i
)] Dark Red
55 % 
(CH3CN : 
Et2O))
Calc. C, 45.0%; H, 5.5%; N, 12.1%. 
Found. C, 44.6%; H, 5.6%; N, 11.9%.
3061m, 3030m, (aromatic C-H); 2975s, 2930m, (sp3 C-H); 2880m, 
(aldimine C-H); 1630w, (aldimine C=N); 1591s, 1475s, (ring stretching) 
m/z 311 (
59
Co+L+Cl-H)
+ 4.92 BM
H (270 MHz, CD3OD) 202.47 (HC=N, 2H, bs); 98.17 
(H
3/5
, 2H, bs); 40.91 (H
4
, 1H, bs); -4.79 (H
b
, 12H, bs); -
9.43 (H
a
, 2H, bs).
[CoCl2(L
1
Bu
n
)] Dark Red
60 % 
(CH3CN)
Calc. C, 44.2%; H, 5.7%; N, 10.3%. 
Found. C, 44.1%; H, 5.8%; N, 10.2%.
3066m, 3025m, (aromatic C-H); 2954s, 2932s, (sp3 C-H); 2870s, 
(aldimine C-H); 1631w (aldimine C=N); 1590m, 1466m, (ring 
stretching) 
m/z 339 (
59
Co+L+Cl-H)
+ 4.49 BM
H (270 MHz, CD3OD) 202.47 (HC=N, 2H, bs); 98.17 
(H
3/5
, 2H, bs); 40.91 (H
4
, 1H, bs); -4.79 (H
b
, 12H, bs); -
9.43 (H
a
, 2H, bs).
[CoCl2(L
1
Bu
2
)]. 2(H2O) Dark Red
 63 % 
(CH3CN)
Calc. C, 48.0%; H, 6.2%; N, 11.2%. 
Found. C, 48.3%; H, 6.2%; N, 11.5%.
3069m, 3030m, (aromatic C-H); 2973s, 2939s, (sp3 C-H); 2877m, 
(aldimine C-H); 1634m, (aldimine C=N); 1585s, 1467s, (ring stretching)
m/z 553 (
59
Co+2L)
+
, 341 
(
59
Co+L+Cl)
+ 
4.81 BM
H (270 MHz, CD3OD) 198.08 (HC=N, 2H, bs); 93.20 
(H
3/5
, 2H, bs); 38.28 (H
4
, 1H, bs); 3.04 (H
a
, 1H, bs); -
0.21, -0.46 (H
d
, 6H, 2s); -3.89, -4.25 (H
b
, 4H, 2s); -8.57, -
9.44 (H
c
, 6H, 2s)
[CoCl2(L
1
Bu
i
)]. 1.5(H2O) Dark Red
68 % 
(CH3CN)
Calc. C, 44.8%; H, 6.5%; N, 10.5%. 
Found. C, 44.7%; H, 6.2%; N, 10.5%.
3063m, 3028m, (aromatic C-H); 2959s, 2931s, (sp3 C-H); 2857s, 
(aldimine C-H); 1634w, (aldimine C=N); 1587m, 1471s, (ring 
stretching)
m/z 372 (
59
Co+L+2Cl-H)
+
, 303 
(
59
Co+L)
+
4.22 BM
H (270 MHz, CD3OD) 221.18 (HC=N, 2H, bs); 148.81 
(H
a
, 4H, bs); 103.15 (H
3/5
, 2H, bs); 42.60 (H
4
, 1H, bs); 
0.83 (H
b
, 2H, bs); -3.90 (H
c
, 12H, bs).
[CoCl2(L
1
Bu
t
)] Green
 50% 
(CH3CN)
Calc. C, 48.0%; H, 6.2%; N, 11.2%. 
Found. C, 48.2%; H, 6.2%; N, 11.4%.
3060m, 3025m, (aromatic C-H); 2962s, 2931s, (sp3 C-H); 2864s, 
(aldimine C-H); 1636w (aldimine C=N); 1590m, 1472s, (ring stretching)
m/z 339 (
59
Co+L+Cl-H)
+ 4.63 BM
H (270 MHz, CD3OD) 222.00 (HC=N, 2H, bs); 103.15 
(H
3/5
, 2H, bs); 42.60 (H
4
, 1H, bs); 8.88 (Ha, 18H, bs)
[CoCl2(L
1
Cy)] Dark Red
 97 % 
(CH3CN)
Calc. C, 53.4%; H, 3.4%; N, 9.8%. 
Found. C, 53.2%; H, 6.1%; N, 9.6%.
3060m, 3025m, (aromatic C-H); 2927s, (sp3 C-H); 2852s, (aldimine C-
H); 1631wbr, (aldimine C=N); 1580m, 1468w, (ring stretching) 
 m/z 391 (
59
Co+L+Cl-H)
+
, 326 
(
59
Co+2L)
2+
4.53 BM
H (600 MHz, D2O) 168.02 (HC=N, 2H, bs); 121.84 (H
a
, 
2H, bs); 50.21 (H
3/5
, 2H, bs); 24.89 (H
4
, 1H, bs); 1.76 
(H
b/b’,c/c’
, 4H, bs); 0.13 (H
d/d’
, 2H, bs); -0.20 (H
d/d’
, 2H, 
bs); -1.22 (H
b/b’,c/c’
, 4H, bs); -9.34 (H
b/b’,c/c’
, 4H, bs); -
15.19 (H
b/b’,c/c’
, 4H, bs)
[CoBr2(L
1
Cy)] Dark Red
 38 % 
(CH3CN)
Calc. C, 44.2%; H, 5.3%; N, 8.1%. 
Found. C, 44.3%; H, 5.2%; N, 8.0%.
3057m, 3025m, (aromatic C-H); 2930s, (sp3 C-H); 2852s, (aldimine C-
H); 1631wbr, (aldimine C=N); 1582m, 1466w, (ring stretching) 
m/z 326 (
59
Co+2L)
2+ 4.58 BM
H (600 MHz, D2O) 167.89 (HC=N, 2H, bs); 121.89 (H
a
, 
2H, bs); 50.28 (H
3/5
, 2H, bs); 24.79 (H
4
, 1H, bs); 1.79 
(H
b/b’,c/c’
, 4H, bs); 0.15 (H
d/d’
, 2H, bs); -0.18 (H
d/d’
, 2H, 
bs); -1.18 (H
b/b’,c/c’
, 4H, bs); -9.31 (H
b/b’,c/c’
, 4H, bs); -
15.12 (H
b/b’,c/c’
, 4H, bs).
No solid products could be isolated.
  
86 
Table 17. Characterisation data for Co
II
 complexes of L
1
R continued; a) Uninterpretable, b) Insoluble. 
 
Compound Colour
Yield 
(solvent)
Microanalysis Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum ESI+ eff 1H NMR
[Co(L
1
Cy)2][NO3]2 Dark Red
 63 % 
(CH3CN : 
Et2O)
Calc. C, 54.4%; H, 6.5%; N, 15.0%. 
Found. C, 54.1%; H, 6.7%; N, 14.9%.
3082w, 3037w, (aromatic C-H); 2931m, (sp3 C-H); 2851m, (aldimine C-
H); 1630wbr, (aldimine C=N); 1587m, 1467w, (ring stretching); 1385s, 
(N-O)
m/z 326 (
59
Co+2L)
2+ 4.52 BM
H (600 MHz, D2O) 168.18 (HC=N, 2H, bs); 121.98 (H
a
, 
2H, bs); 50.45 (H
3/5
, 2H, bs); 24.91 (H
4
, 1H, bs); 1.86 
(H
b/b’,c/c’
, 4H, bs); 0.24 (H
d/d’
, 2H, bs); -0.10 (H
d/d’
, 2H, 
bs); -1.12 (H
b/b’,c/c’
, 4H, bs); -9.25 (H
b/b’,c/c’
, 4H, bs); -
15.10 (H
b/b’,c/c’
, 4H, bs).
[Co(L
1
Cy)2][BF4]2. 2(H2O). 
(CH3CN)
Dark Red
 64 % (Ac2O 
: Et2O)
Calc. C, 53.1%; H, 6.8%; N, 10.8%. 
Found. C, 53.0%; H, 6.7%; N, 11.0%.
3080w, 3037w, (aromatic C-H); 2931m, (sp3 C-H); 2857m, (aldimine C-
H); 1630wbr, (aldimine C=N); 1587m, 1467w, (ring stretching); 1385s, 
(N-O)
m/z 326 (
59
Co+2L)
2+ 4.59 BM
H (600 MHz, D2O) 171.48 (HC=N, 2H, bs); 124.58 (H
a
, 
2H, bs); 54.07 (H
3/5
, 2H, bs); 25.57 (H
4
, 1H, bs); 1.82 
(H
b/b’,c/c’
, 4H, bs); 0.18 (H
d/d’
, 2H, bs); -0.10 (H
d/d’
, 2H, 
bs); -1.28 (H
b/b’,c/c’
, 4H, bs); -10.05 (H
b/b’,c/c’
, 4H, bs); -
16.53 (H
b/b’,c/c’
, 4H, bs)
[Co(L
1
Cy)2][Co(SCN)4] Dark Red
99% 
(CH3CN)
Calc. C, 53.4%; H,5.8%; N, 14.8%. 
Found. C, 53.5%; H,5.8%; N, 15.0%.
2930m, (sp3 C-H); 2855m, (aldimine C-H); 2070s, (isothiocyanate 
C≡N); 1632wbr, (aldimine C=N); 1587w, 1470w, 1448w, (ring 
stretching) 
m/z 326 (
59
Co+2L)
2+ 4.88 BM a
[Co(AcO)2(L
1
Cy)] Red
 68 % 
(CH3CN : 
Et2O)
Calc. C, 58.2%; H, 7.0%; N, 8.9%. 
Found. C, 58.1%; H, 7.1%; N, 8.5%.
3067w, 3020w, 3004w, (aromatic C-H); 2990w, 2931s, (sp3 C-H); 
2857m, (aldiminine C-H); 1702m, (unidentate OAc C=O); 1624s, 
(aldimine C=N); 1591s (bidentate OAc C=O), 1580s, 1443s, (ring 
stretching); 1420s (OAc  C-O)
m/z 415 (
59
Co+L+AcO)
+
, 326 
(
59
Co+2L)
2+ 
4.38 BM
H (600 MHz, D2O) 168.02 (HC=N, 2H, bs); 121.84 (H
a
, 
2H, bs); 50.21 (H
3/5
, 2H, bs); 24.89 (H
4
, 1H, bs); 1.76 
(H
b/b’,c/c’
, 4H, bs); 0.13 (H
d/d’
, 2H, bs); -0.20 (H
d/d’
, 2H, 
bs); -1.22 (H
b/b’,c/c’
, 4H, bs); -9.34 (H
b/b’,c/c’
, 4H, bs); -
15.19 (H
b/b’,c/c’
, 4H, bs).
[CoCl2(L
1
CyMe)]. 2.5(H2O) Dark Red
 26 % 
(CH3CN)
Calc. C, 50.6%; H, 6.9%; N, 8.4%. 
Found. C, 50.3%; H, 6.7%; N, 8.3%.
3062m, 3025m, (aromatic C-H); 2927s, (sp3 C-H); 2870m, (aldiminine 
C-H); 1640wbr, (aldimine C=N); 1585s, 1474s, (ring stretching) 
m/z 419 (
59
Co+L+Cl-H)
+
, 384 
(
59
Co+L-H)
+
, 355 (
59
Co+2L)
2+
4.77 BM a
[CoCl2(L
1
Ph)] Brown
  95 % 
(CH3CN)
Calc. C, 55.0%; H, 3.6%; N, 10.1%. 
Found. C, 52.3%; H, 3.7%; N, 10.9%.
3055m, 3053m, 3024m, 3000m (aromatic C-H); 2931m (aldiminine C-
H); 1622w (aldimine C=N); 1567, 1486s, (ring stretching)
m/z 379 (
59
Co+L+Cl-H)
+
, 344 
(
59
Co+L-H)
+
, 314 (
59
Co+2L)
2+
4.41 BM
H (600 MHz, D2O) 165.63 (HC=N, 2H, bs); 47.70 (H
3/5
, 
2H, bs); 26.28 (H
4
, 1H, bs); 12.33 (H
a
, 4H, bs); -0.13 
(H
c
, 2H, bs); -15.30 (H
b
, 4H, bs).
[CoCl2(L
1
PhMe)] Brown
 84 % 
(CH3CN)
Calc. C, 56.9%; H, 4.3%; N, 9.5%. 
Found. C, 57.2%; H, 4.0%; N, 9.4%.
3065m, 3042m, 3006m, (aromatic C-H); 2950m, 2925m, 2920m, (sp
3
 C-
H); 2851m (aldiminine C-H); 1595s, 1550s, 1495s, (ring strecthing)
m/z 343 (
59
Co+2L)
2+ insol b
[CoCl2(L
1
PhCl)] Brown
  95 % 
(DMSO : 
DCM)
Calc. C, 47.1%; H, 2.7%; N, 8.7%. 
Found. C, 47.2%; H, 2.6%; N, 8.7%.
3078m, 3050m, 3025m (aromatic C-H); 1620brw (aldimine C=N) 
1586m, 1488s (ring stretching) 
FAB MS m/z 765 (
59
Co+L+(L-
Cl)+Cl)
+
insol b
[CoCl2(L
1
PhNO2)] Brown
  94 % 
(CH3CN)
Calc. C, 45.2%; H, 2.6%; N, 13.9%. 
Found. C, 45.2%; H, 2.7%; N, 13.7%.
3101w, 3085w, 3052w, 3035w, (aromatic C-H); 2850w, (aldiminine C-
H); 1602m (aldimine C=N); 1587s, 1490w, (ring stretching); 1522m, 
1339s, (N=O)
FAB MS m/z 809 (59Co+2L-H)
+ insol b
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Table 18. Characterisation data for Ni
II
 complexes of L
1
R. 
 
 
 
 
Compound Colour
Yield 
(solvent)
Microanalysis Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum ESI+ eff
[NiCl(H2O)2(L
1
Et)]Cl Green
  69 % 
(CH3CN)
Calc. C, 37.2%; H, 5.4%; N, 11.8%. 
Found. C, 37.6%; H, 5.0%; N, 11.5%.
3353s, 3158s, (coordinated H2O); 2981m, 2934m, (sp3 C-H); 2869w, 
(aldimine C-H); 1639brw, (aldimine C=N); 1592m, 1471m, (ring 
stretching)
m/z 264 (
58
Ni+L+OH )
+ 3.41 BM
2-Cl-[NiCl(L
1
Pr
n
)] 2.H2O Green
  55 % 
(CH3CN)
Calc. C, 42.8%; H, 5.8%; N, 11.5%. 
Found. C, 42.8%; H, 5.6%; N, 11.9%.
3425 (lattice H2O); 3053w, 3005w, (aromatic C-H); 2968s, 2925s, (sp3 
C-H); 2876m (aldimine C-H); 1634w, (aldimine C=N); 1585s, 1474m, 
(ring stretching)
m/z 310 (
58
Ni+L+Cl-H)
+ 3.27 BM
[NiCl2(L
1
Bu
n
)] Green
  73 % 
(CH3CN)
Calc. C, 48.1%; H, 6.2%; N, 11.2%. 
Found. C, 48.0%; H, 6.5%; N, 11.5%.
3060m, 3025m, (aromatic C-H); 2965s, 2925 (sp3 C-H); 2867m 
(aldimine C-H); 1634w, (aldimine C=N); 1585m, 1472m, (ring 
stretching)
m/z 274 (
58
Ni+2L-H)
2+ 3.15 BM
[NiCl2(L
1
Cy)] Green
  75 % 
(CH3CN)
Calc. C, 53.4%; H, 6.4%; N, 9.8%. 
Found. C, 53.0%; H, 6.3%; N, 9.8%.
3070m, 3031m, (aromatic C-H); 2928s, (sp3 C-H); 2855m (aldiminine C-
H); 1632w, (aldimine C=N); 1585m, 1470m, (ring stretching)
m/z 326 (
58
Ni+2L-H)
2+ 3.25 BM
[Ni(AcO)2(L
1
Cy)]. CH3CN Green
  71 % 
(CH3CN)
Calc. C, 58.3%; H, 7.0%; N, 10.9%. 
Found. C, 58.4%; H, 7.1%; N, 10.9%.
3074m, 3020m, (aromatic C-H); 2934s, (sp3 C-H); 2860s (aldiminine C-
H); 1652, (AcO C=O);1620w, (aldimine C=N); 1587m, 1455m, (ring 
stretching)
m/z 414 (
58
Ni+L+AcO)
+
, 326 
(
58
Ni+2L)
2+ 
3.27 BM
[NiCl2(L
1
Ph)] Orange
  50 % 
(CH3CN)
Calc. C, 55.0%; H, 3.6%; N, 10.1%. 
Found. C, 55.0%; H, 3.7%; N, 10.6%.
3067w, 3005w, (aromatic C-H); 1640m, (aldimine C=N); 1585m, 
1495m, (ring stretching) 
m/z 315 (
58
Ni+2L)
2+ 3.43 BM
[NiCl2(L
1
PhMe)] Orange
  52 % 
(CH3CN)
Calc. C, 56.9%; H, 4.3%; N, 9.5%. 
Found. C, 56.7%; H, 4.3%; N, 9.5%.
3070m, 3008m, (aromatic C-H); 2928m, 2924m, (sp3 C-H); 2860m 
(aldiminine C-H); 1632wbr, (aldimine C=N); 1592m, 1578w, 1508m, 
1470m, (ring stretching)
m/z 406 (
58
Ni+L+Cl-H)
+
, 343 
(
58
Ni+2L)
2+ 
3.34 BM
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Table 19. Characterisation data for Cu
II
 complexes of L
3
R. 
 
 
 
Compound Colour
Yield 
(solvent)
Microanalysis Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum FAB
[CuCl2(L
3
Bu
n
)] Yellow
(CH3CN) 
53%
Calc. C, 54.9%; H, 5.5%; N, 11.7%. 
Found. C, 54.6%; H, 5.7%; N, 11.3%.
3038m, 3012m, (aromatic C-H); 2956s, 2935s, (sp
3
 C-H); 2864s, (aldimine 
C-H); 1637s, (uncoordinated aldimine C=N); 1615s, (coordinated aldimine 
C=N); 1604s, 1570s 1492s, (C=C)
m/z 445 [
63
Cu+L+Cl]
+
, 410 [
63
Cu+L]
+ 
[CuCl2(L
3
Bu
2
)] Yellow
(CH3CN) 
51%
Calc. C, 54.9%; H, 5.5%; N, 11.7%. 
Found. C, 55.0%; H, 5.3%; N, 11.5%.
3049m, 3015m, 3012w, (aromatic C-H); 2962s, 2925s, (sp
3
 C-H); 2870m, 
(aldimine C-H); 1644w, (uncoordinated aldimine C=N); 1610m, 
(coordinated aldimine C=N); 1585w, 1567m, 1492s, (C=C)
m/z 445 [
63
Cu+L+Cl]
+
, 410 [
63
Cu+L]
+ 
[CuCl2(L
3
Bu
i
)] Yellow
(CH3CN) 
56%
Calc. C, 54.9%; H, 5.5%; N, 11.7%. 
Found. C, 55.0%; H, 5.5%; N, 12.0%.
3067m, 3042m, 3015w, (aromatic C-H); 2956s, 2925s, (sp
3
 C-H); 2863s, 
2833m (aldinine C-H); 1647m, (uncoordinated aldimine C=N); 1604m, 
(coordinated aldimine C=N); 1585m, 1567m, 1492s, (C=C)
m/z 445 [
63
Cu+L+Cl]
+
, 410 [
63
Cu+L]
+ 
[CuCl2(L
3
Bu
t
)] Yellow
(CH3CN) 
48%
Calc. C, 54.9%; H, 5.5%; N, 11.7%. 
Found. C, 55.3%; H, 5.6%; N, 11.8%.
3066m, 3040m, 3012w, (aromatic C-H); 2957s, 2928s, (sp
3
 C-H); 2863s 
(aldimine C-H); 1640m, (uncoordinated aldimine C=N); 1610m, 
(coordinated aldimine C=N); 1585m, 1566m, 1492s, (C=C)
m/z 445 [
63
Cu+L+Cl]
+
, 410 [
63
Cu+L]
+ 
[CuCl2(L
3
Cy)] Yellow
(DMF) 
44%
Calc. C, 58.6%; H, 5.7%; N, 10.5%. 
Found. C, 58.6%; H, 5.7%; N, 10.4%.
3066m, 3020w (aromatic C-H); 2968, 2925s (sp
3
 C-H); 2870s (aldimine C-
H); 1641m, (uncoordinated aldimine C=N); 1610m, (coordinated aldimine 
C=N); 1585m, 1560m, 1499s (C=C)
m/z 497 [
63
Cu+L+Cl]
+
, 462 [
63
Cu+L]
+ 
[CuCl2(L
3
Ph)] Brown
(DMF) 
65%
Calc. C, 60.0%; H, 3.5%; N, 10.8%. 
Found. C, 59.6%; H, 3.4%; N, 10.9%.
3049m, 3012m (aromatic C-H); 2925m (aldimine C-H); 1653s 
(uncoordinated aldimine C=N); 1615w, (coordinated aldimine C=N); 
1605w, 1570m, 1498s, (C=C)
m/z 485 [
63
Cu+L+Cl]
+
, 450 [
63
Cu+L]
+
 418, [
63
Cu+2L-H]
2+  
[CuCl2(L
3
PhMe)] Brown
(DMF) 
76%
Calc. C, 61.3%; H, 4.0%; N, 10.2%. 
Found. C, 58.9%; H, 3.9%; N, 9.8%.
3055m, 3045m, 3030m, 3005m (aromatic C-H); 2925m (sp3 C-H); 2864w 
(aldimine C-H); 1660s (uncoordinated aldimine C=N); 1616w, 
(coordinated aldimine C=N); 1605w, 1574m, 1497s, (C=C)
m/z 513 [
63
Cu+L+Cl]
+
, 477 [
63
Cu+L]
+  
[CuCl2(L
3
PhCl)] Brown
(DMF) 
71%
Calc. C, 53.0%; H, 2.7%; N, 9.5%. 
Found. C, 53.0%; H, 2.5%; N, 10.0%.
3086m, 3049m, 3030m, 3000m, (aromatic C-H); 2937m,(aldimine C-H); 
1670s, (uncoordinated aldimine C=N); 1615w, (coordinated aldimine 
C=N); 1600w, 1573m, 1495s, (C=C)
m/z 553 [
63
Cu+L+Cl]
+
, 518 [
63
Cu+L]
+   
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Table 20. Characterisation data for Zn
II
 complexes of L
3
R; a) Insoluble. 
 
 
 
 
Compound Colour
Yield 
(solvent)
Microanalysis Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum 
FAB
[ZnCl2(L
3
Bu
n
)] Colourless
(CH3CN) 
68%
Calc. C, 54.7%; H, 5.4%; N, 11.6%. 
Found. C, 54.7%; H, 5.3%; N, 11.7%.
3066w, 3025w, (aromatic C-H); 2956m, 2928m, (sp
3
 C-H); 2864, 
(aldimine C-H); 1641s, (uncoordinated aldimine C=N); 1618m, 
(coordinated aldimine C=N); 1604m, 1563m, 1490w, (ring breathing).
m/z 445 
[
65
Zn+L+Cl]
+
H (600 MHz, (CD3)2SO) 9.25 (2H, s, HC=N), 8.73 (H
3/8
, 2H, d, J = 8.4 Hz), 8.45 
(H
4/7
, 2H, d, J = 8.4 Hz), 8.30 (H
5/6
, 2H, s),4.03 (H
a
, 4H, t, J
 
= 7.0 Hz), 2.03 (H
b
, 4H, 
m, J = 7.0 Hz), 1.62 (H
c
, 4H, m, 7.6 Hz), 1.05 (H
d
, 6H, t, J = 7.5 Hz)
[ZnCl2(L
3
Bu
i
)] Colourless
(CH3CN) 
65%
Calc. C, 54.7%; H, 5.4%; N, 11.6%. 
Found. C, 54.9%; H, 5.4%; N, 11.9%.
3075m, 3020m, (aromatic C-H); 2956m, 2928m, (sp
3
 C-H); 2873m, 
(aldimine C-H); 1646s, (uncoordinated aldimine C=N); 1618m, 
(coordinated aldimine C=N); 1609m, 1563m, 1490w, (ring breathing)
m/z 445 
[
65
Zn+L+Cl]
+
H (600 MHz, (CD3)2SO) 9.21 (2H, s, HC=N), 8.76 (H
3/8
, 2H, d, J = 8.4 Hz), 8.44 
(H
4/7
, 2H, d, J = 8.4 Hz), 8.29 (H
5/6
, 2H, s),  3.98 (H
a
, 4H, d, J
 
= 6.6 Hz), 2.20 (H
b
, 
2H, m, J = 6.6 Hz), 1.13 (H
c
, 12H, d, J = 6.3 Hz)
[ZnCl2(L
3
Bu
2
)] Colourless
(CH3CN) 
56%
Calc. C, 54.7%; H, 5.4%; N, 11.6%. 
Found. C, 54.5%; H, 5.1%; N, 11.7%.
3066m, (aromatic C-H); 2964m, 2928m, (sp
3
 C-H); 2870m, (aldimine C-
H); 1638m, (uncoordinated aldimine C=N); 1618m, (coordinated aldimine 
C=N); 1609m, 1563m, 1490w, (ring breathing)
m/z 445 
[
65
Zn+L+Cl]
+
H (600 MHz, CD3CN:(CD3)2CO:CD3OD) 9.23 (2H, s, HC=N), 8.86 (
H3/8
, 2H, d, J = 
8.4 Hz), 8.50 (H
4/7
, 2H, d, J = 8.4 Hz), 8.22 (H
5/6
, 2H, s), 3.86 (H
a
, 2H, m, J
 
= 6.5 
Hz), 2.03 (H
b/b'
, 1H, m, J = 7.5 Hz), 1.90 (H
b/b'
, 1H, m, J = 7.5 Hz) 1.56 (H
d
, 6H, d, J 
= 6.5 Hz), 1.04 (H
c
, 6H, t, J = 7.3 Hz)
[ZnCl2(L
3
Bu
t
)] Colourless
(CH3CN) 
57%
Calc. C, 54.7%; H, 5.4%; N, 11.6%. 
Found. C, 54.5%; H, 5.3%; N, 11.6%.
3066m, 3012m (aromatic C-H); 2964, 2928s (sp
3
 C-H); 2863s (aldimine 
C-H); 1636m, (uncoordinated aldimine C=N); 1618m, (coordinated 
aldimine C=N); 1585m,1563m, 1490m, (ring breathing)
m/z 445 
[
65
Zn+L+Cl]
+
H (270 MHz, (CD3)2SO) 9.23 (2H, s, HC=N), 8.99 (H
3/8
, 2H, d, J = 8.1 Hz), 8.53 
(H
4/7
, 2H, d, J = 8.1 Hz), 8.33 (H
5/6
, 2H, s), 1.47 (Ha, 18H, s)
[ZnCl2(L
3
Cy)] Colourless
(CH3CN) 
59%
Calc. C, 58.4%; H, 5.7%; N, 10.5%. 
Found. C, 58.7%; H, 5.8%; N, 10.4%.
3061m, 3025m (aromatic C-H); 2969s, 2937s, (sp
3
 C-H); 2882s, (aldimine 
C-H); 1641s, (uncoordinated aldimine C=N); 1618m, (coordinated 
aldimine C=N); 1610m, 1511m, 1567m, 1468w, (ring breathing)
m/z 497 
[
65
Zn+L+Cl]
+ 
H (600 MHz, (CD3)2SO, 100°C) 9.14 (2H, s, HC=N), 8.90 (H
3/8
, 2H, d, J = 7 Hz), 
8.43 (H
4/7
, 2H, d, J = 7 Hz), 8.24(H
5/6
, 2H, s), 3.66 (H
a
, 2H, br), 2.00-1.0 (H
b/c/d
, 20H, 
br mm)
[ZnCl2(L
3
Ph)] Yellow
(DMF) 
70%
Calc. C, 59.7%; H, 3.5%; N, 10.7%. 
Found. C, 59.6%; H, 3.3%; N, 11.0%.
3092w, 3069w, 3050w, (aromatic C-H); 2870w, 2860w, (aldimine C-H); 
1620m, (uncoordinated aldimine C=N); 1610w, (coordinated aldimine 
C=N); 1590w, 1581w, 1501w, (ring breathing)
m/z 485 
[
65
Zn+L+Cl]
+ 
H (270 MHz, (CD3)2SO, 30°C) 9.58 (2H, s, HC=N), 9.11 (H
3/8
, 2H, d, J = 8.4 Hz), 
8.73 (H
4/7
, 2H, d, J = 8.4 Hz), 8.42 (H
5/6
, 2H, s), 7.79 (H
a
, 4H, d, J = 7.3 Hz), 7.59 
(H
b
, 4H, t, J = 7.3 Hz), 7.46 (H
c
, 2H, t, J = 7.3 Hz)
[ZnCl2(L
3
PhMe)] Yellow
(DMF) 
77%
Calc. C, 61.1%; H, 4.0%; N, 10.2%. 
Found. C, 61.0%; H, 4.0%; N, 10.2%.
3089w, 3060w, 3024w, (aromatic C-H) 2963w, 2919w, (sp
3
 C-H); 
2857w, (aldimine C-H); 1624m, (uncoordinated aldimine C=N); 1610w, 
(coordinated aldimine C=N); 1590w, 1581w, 1501w, (ring breathing)
m/z 478 
[
65
Zn+L+Cl]
+ 
H (270 MHz, (CD3)2SO, 60°C) 9.58 (2H, s, HC=N) 9.08 (H
3/8
, 2H, d, J = 8.3 Hz), 
8.68 (H
4/7
, 2H, d, J = 8.3 Hz), 8.39 (H
5/6
, 2H, s), 7.70 (H
a
, 4H, d, J = 8.1 Hz), 7.38 
(H
b
, 4H, d, 8.1 Hz), 2.41 (H
c
, 6H, s) 
[Zn(NO3)2(L
3
PhMe)] Yellow
(CH3CN) 
74%
Calc. C, 55.7%; H, 3.7%; N, 13.9%. 
Found. C, 55.9%; H, 3.9%; N, 13.8%.
3089w, 3060w, 3024w, (aromatic C-H) 2963w, 2919w, (sp
3
 C-H); 
2857w, (aldimine C-H); 1624m, (uncoordinated aldimine C=N); 1610w, 
(coordinated aldimine C=N); 1590w, 1581w, 1501w, (ring breathing)
m/z 540 
[
65
Zn+L+NO3]
+ a
[ZnCl2(L
3
PhCl)] Yellow
(DMF) 
45%
Calc. C, 52.8%; H, 2.7%; N, 9.5%. 
Found. C, 52.6%; H, 2.7%; N, 9.6%.
3089w, 3060w, 3024w, (aromatic C-H) 2963w, 2919w, (sp
3
 C-H); 
2857w, (aldimine C-H); 1624m, (uncoordinated aldimine C=N); 1610w, 
(coordinated aldimine C=N); 1590w, 1581w, 1501w, (ring breathing)
m/z 553 
[
65
Zn+L+Cl]
+
H (270 MHz, (CD3)2SO, 100°C) 9.44 (2H, s, HC=N), 8.96 (H
3/8
, 2H, d, J = 8.3 Hz), 
8.66 (H
4/7
, 2H, d, J = 8.3), 8.30 (H
5/6
, 2H, s), 7.71 (H
b
, 4H, d, J = 8.6 Hz), 7.54 (H
a
, 
4H, d, J = 8.5 Hz)
1H NMR
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Table 21. Characterisation data for Zn
II
 complexes of L
2
R. 
 
 
Table 22. Characterisation data for Ru
III
 complex of L
1
R. 
 
 
Compound Colour
Yield 
(solvent)
Microanalysis Infra-red Spectrum (KBr)  max cm
-1 Mass Spectrum 
ESI+
[ZnCl2(L
2
Cy)] Colourless
(CH3CN) 
42%
Calc. C, 51.1%; H, 5.4%; N, 14.9%. 
Found. C, 51.0%; H, 5.2%; N, 14.9%.
not obtained
m/z 563 
[
65
Zn+L+2NO3]
+
, 
501 
[
65
Zn+L+NO3]
+ 
H (270 MHz, (CD3)2SO, 140°C) 8.88 (2H, br s, HC=N), 8.60 (H
3/8
, 2H, d, J = 8.0 
Hz), 8.28 (H
4/7
, 2H, br t), 8.13 (H
5/6
, 2H, d J = 8.0 Hz), 3.61 (H
a
, 2H, br m), 2.00-
1.00 (H
b,c,d
, 20H, br mm)
[Zn(NO3)(H2O)(L
2
PhMe)][NO3] Yellow
(CH3CN) 
63%
Calc. C, 53.9%; H, 3.8%; N, 14.5%. 
Found. C, 53.8%; H, 3.6%; N, 14.6%.
not obtained
m/z 579 
[
65
Zn+L+2NO3]
+
, 
517 
[
65
Zn+L+NO3]
+ 
H (600 MHz, CDCl3:CD3OD:CD3CN ) 9.06 (2H, br s, HC=N), 8.72 (H
3/8
, 2H, d, J = 
9.0 Hz), 8.54 (H
4/7
, 2H, t, J = 8.9 Hz), 8.27 (H
5/6
, 2H, d, J = 9.0 Hz), 7.53 (H
a
, 4H, d, 
J = 8.3 Hz), 7.35 (H
b
, 4H, d, J = 8.1 Hz), 2.46 (Hc, 6H, s)
1H NMR
Compound Colour
Yield 
(solvent)
Microanalysis Infra-red Spectrum (KBr)  max cm
-1
Mass Spectrum ESI+
[RuCl3(L
1
PhMe)] Deep Red
90%      
(EtOH)
Calc. C, 48.4%; H, 3.7%; N, 8.1%. 
Found. C, 48.1%; H, 3.4%; N, 8.1%.
not obtained m/z 526 (Ru+L+2Cl+CH3CN-H)
+
-
1H NMR
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2.2. Biological Methods 
2.2.1. In vitro Cell Culture and Chemosensitivity 
 
All media and supplements were obtained from Gibco BRL (Paisley, UK) unless 
otherwise stated. All other chemicals were obtained from Sigma-Aldrich (Dorset, UK) 
unless otherwise stated. Three tumour cell lines were used for cytotoxicity assays, these 
were the human cell lines H460 (human Non Small Cell Lung Carcinoma), HT-29 
(human colon adenocarcinoma) and DLD-1 (human colon adenocarcinoma), obtained 
from the ECACC. All cells were routinely maintained as monolayer cultures at 37 
o
C in 
a humidified, CO2-enriched (5%) environment and cultured in RPMI 1640 
supplemented with 10% foetal calf serum, sodium pyruvate (2 mM), L-glutamine (2 
mM) and buffered with HEPES (25 mM). In vitro chemosensitivity was determined 
using the MTT assay in 96-well cell-culture clusters. All experiments were carried out 
in an aseptic environment, in a class II laminar air flow cabinet (Hepaire Manufacturing 
Ltd, UK). 
2.2.1.1. Routine Subculture of Cells 
 
Cells were allowed to reach confluence before subculture was undertaken. All cell lines 
adhered to the bottom of the flask. The old culture medium was discarded and the cell 
monolayer washed twice with Hanks Balanced Salt Solution (HBSS, 2x10 ml). Trypsin-
EDTA (0.25% trypsin, 0.02% EDTA), was added (0.5 ml in 25 cm
2
 flask), and the flask 
incubated for 5 min. The flask was then gently agitated to remove cells adhered to the 
base of the flask. Once the cells had detached, culture medium (10 ml) was added and 
the cells were detached by gentle shaking. The number of cells in suspension was 
determined using an improved Neubauer haemoctometer, as described in section 
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2.2.1.2. Cell suspensions of 1x10
4
 cells ml
-1
 of fresh culture medium were made and 
aliquots (10 ml) were incubated in 25 cm
2
 flasks. This procedure was routinely followed 
in order to maintain all cell lines. 
2.2.1.2. Counting Cells in Suspension 
 
An improved Neubauer haemocytometer was used to count the number of cells in 
suspension. The haemocytometer is a modified microscope slide, which has two 
polished surfaces, each of which has a ruled grid. The grid has 9 primary squares, with 
sides of 1 mm, which are limited by 3 lines 2.5 µm apart. These lines are used to decide 
which cells should and indeed should not, be included when counting cells in the grid. 
Each primary square is further divided into smaller squares to help with counting. This 
is shown in Figure 14. The plane of the grid lies 0.1 mm below ridges and these support 
a cover slip. There is a bevelled edge at the outer edge of each surface, where cell 
suspension is added and drawn across the grid by capillary action. The number of cells 
in the top left, top right, bottom left, bottom right and centre primary squares are 
counted. If the haemocytometer is correctly loaded, then the volume of cell suspension 
occupying each primary square is 1x10
-4
 ml. 
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Figure 14. The improved Neubauer haemocytometer.
134
 
 
 
 
The average number of cells per primary square is then determined from the sum of the 
cells in the 5 counted primary squares. The total cell concentration is then given by:- 
 
No. Cells per ml = average number of cells per primary square x 10
4 
2.2.1.3. MTT Colorimetric Assay 
 
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazoliumbromide) colorimetric 
assay is a quantitative method, developed to enable visualisation of growth inhibition in 
in vitro chemosensitivity experiments. MTT is converted to coloured formazan crystals 
(Figure 15) by mitochondrial dehydrogenase activity in living cells. Although the 
amount of dehydrogenase content varies between cell lines, it is fairly consistent 
amongst cells of the same origin. The amount of coloured formazan produced is 
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proportional to viable cell number and can therefore be used to provide a visual 
indication of the quantity of viable cells.
135
 
 
Figure 15. Reduction of MTT to formazan due to mitochondrial dehydrogenase 
activity. 
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MTT was stored as a 5 mg ml
-1
 solution in distilled water at 4°C. MTT solution (20 µl) 
was added to each well of a 96-well cell culture cluster, which was requiring analysis 
post drug-exposure, or during validation experiments. The cell culture cluster was then 
incubated for 4 h. All of the MTT solution and old culture medium was removed by 
suction and replaced with DMSO (150 µl per well). The DMSO and formazan crystals 
were carefully mixed by repeat pipetting. The absorbance of the resulting solution was 
read at 550 nm, using a multiskan plus V2.03 plate reader and the data collected by the 
Genesis V1.6 software package (Labsystems). 
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2.2.1.3.1. Validation of the MTT Assay 
 
In order to confirm the assumption made in the previous section that the amount of 
formazan produced in the MTT assay is proportional to cell number, a simple validation 
assay was carried out. In short, a plot of cell number against absorbance should be 
linear. A 25 cm
2
 flask of confluent H460 cells was used. A suspension of cells in cell 
culture medium was obtained as described in section 2.2.1.1. The number of viable cells 
in suspension was determined using the improved Neubauer haemocytometer as 
outlined in section 2.2.1.2. Cells were transferred to 96 well plates (range of cell 
numbers used was typically 0-2x10
5
 cells per well, with 8 wells used per cell density) 
and MTT (17 µl per well) added. Following a 4h incubation, the MTT assay as 
described in section 2.2.1.3, was employed to provide a measure of the absorbance in 
each well. The mean absorbance of each lane was calculated. Graphs of mean 
absorbance against cell number were constructed. The relationship between cell number 
and formazan production, is shown in Figure 16. 
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Figure 16. Plot of absorbance against number of cells for the MTT validation assay, 
showing that number of cells is proportional to absorbance in the cell densities of this 
study. Each value represents the mean +/- standard deviations of (n=8) for a single 
experiment. Two independant experiments were conducted (only the results of one 
experiment are shown here).  
 
2.2.1.3.2. MTT assay 
 
All drugs were dissolved in DMSO or distilled water at a concentration of 100mM and 
stored at -20
o
C. Cells in exponential growth were exposed to a range of drug 
concentrations for 120 h and a select few compounds for 1 h (at 37 
o
C) under aerobic 
conditions. Trypsinised cells from cultures in exponential growth were washed twice 
with Hanks Balanced Salt Solution, re-suspended in RPMI 1640 growth medium and 1 
x 10
4
 cells plated into lanes 2-12 of a 96-well plate. Lane 1 was left empty for the 
addition of a blank at a later stage. The cell culture cluster was then incubated 
overnight. A 1 in 2 serial dilution in cell culture medium of the drug under test was then 
carried out to give 10 samples of decreasing drug concentration. The highest dose was 
100µM and the lowest was 0.39µM. Culture medium was then removed from the cell 
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culture cluster. Fresh culture medium (150µl) was added to each well of lane 1. Cell 
culture medium (150µl per well) either alone or containing 0.1% DMSO was added to 
lane 2 as a control (DMSO concentration during drug exposure was no more than 0.1% 
for the highest concentrations in all cases). A sample of the lowest drug concentration 
(150µl per well) was added to lane 3 and repeated in lanes 4-12 inclusively, adding the 
next most concentrated drug solution each time. Following incubation at 37 
o
C for 6 
days, medium was removed and replaced with fresh RPMI 1640 (150µl) prior to 
addition of MTT (20 µl, 5 mg ml
-1
) per well. After a 4 h incubation at 37 
o
C media plus 
MTT solution was removed and formazan crystals were dissolved in 150 µl of DMSO. 
The absorbance of the resulting solution was read at 550 nm using an ELISA 
spectrophotometer and percent cell survival determined as the corrected absorbance of 
treated wells divided by the corrected absorbance of the control (corrected absorbance = 
absorbance of test well – absorbance of blank well). Each experiment was repeated in 
triplicate. Plots of percentage survival for the concentration range were constructed and 
IC50 values (drug concentration required to inhibit 50% of the cell population) were 
determined. Reported IC50 values given in the biological evaluation section therefore 
represent the mean +/- standard deviation (n=3) for three independent experiments.    
 
2.2.2. DNA Damaging Assay 
 
The ability of a range of complexes to cause single-strand breaks in DNA, was assessed 
by following in vitro the conversion of supercoiled plasmid-DNA to the relaxed circular 
configuration.
136
 The DNA-damaging abilities of the remaining library of compounds 
was not investigated due to insuffeiceint laboratory time. All complexes were 
synthesised as outlined in section 2.1. EO9 was obtained from the New Drug 
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Development Office, Amsterdam. All drugs were stored as 100 mM solutions in either 
DMSO or water at -20°C. 
2.2.2.1. Harvesting and Lysis of Bacteria 
2.2.2.1.1. Harvesting 
 
E.Coli cells transfected with pRSET B plasmid were obtained from Dr RM Philips 
(Institute of cancer therapeutics, University of Bradford). A single bacterial colonywas 
transferred into LB medium (2 ml) containing ampicillin (1g/ml) in a loosely capped 
15 ml tube. The culture was incubated overnight at 37 °C with vigorous shaking. The 
culture (1.5 ml) was poured into a microfuge tube and centrifuged at 12,000 g for 30 
seconds at 4 °C in a microfuge. The medium was then removed by aspiration with a 
micropipette leaving the bacterial pellet as dry as possible. 
2.2.2.1.2. Lysis by Alkali 
 
1. The bacterial pellet (obtained in the harvesting stage) was resuspended in 100 µl 
of ice cold Solution I by vigorous vortexing. 
 
Solution I 
  50 mM glucose 
  25 mM Tris.Cl (pH 8.0) 
  10 mM EDTA (pH 8.0) 
Solution I was prepared in batches of approximately 100 ml, autoclaved 
for 15 minutes at 10 lb / sq. in. on liquid cycle and stored at 4 °C. 
 
2. Then 200 µl of freshly prepared Solution II was added. 
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Solution II 
  0.2 N NaOH (freshly diluted from 10 N stock) 
  1% SDS 
 
The tube was closed tightly and the contents were mixed by inverting the tube 
rapidly five times. It was essential that the entire surface of the tube came into 
contact with Solution II. The tube was then stored on ice. 
 
3. 150 µl of ice-cold Solution III was then added. 
  
 Solution III 
  5M potassium acetate 60 ml 
  Glacial acetic acid 11.5 ml 
  H2O 28.5 ml 
The resulting solution is 3M with respect to potassium and 5M with 
respect to acetate. 
 
The tube was then closed and gently vortexed in an inverted position for 10 seconds to 
disperse Solution III through the viscous bacterial lysate. The tube was then stored on 
ice for 5 mins. 
 
4. The tube was then centrifuged at 12,000g for 5 minutes at 4 °C in a microfuge. 
The supernatant was then transferred to a fresh tube. 
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5. The double stranded DNA was then precipitated with 2 volumes of ethanol at 
room temperature. The contents were mixed by vortexing. The mixture was then 
allowed to stand for 2 mins at room temperature. 
6. The tube was centrifuged at 12,000g for 5 minutes at 4 °C in a microfuge. 
7.  The supernatant was removed by gentle aspiration. The tube was allowed to 
stand in an inverted position on a paper towel to allow all of the fluid to drain 
away. Any drops of fluid adhering to the walls of the tube were also removed.  
8. The pellet of double stranded DNA was rinsed with 1 ml of 70 % ethanol at 4 
°C. The supernatant was then removed as in step 7 and the pellet of nucleic acid 
was allowed to dry in air for 10 mins. 
9. The nucleic acid was then dissolved in 50 µl of TE (pH 8.0) containing DNAase 
free pancreatic RNAase (20 µg/ml), vortexed briefly and stored at -20 °C until 
needed. 
2.2.2.2. Treatments of Plasmid DNA for Assay 
 
The assay was carried out according to Walton et al.
136
 12 reactions were made of the 
following mixtures to give 100μl total volume each containing plasmid DNA (10µl) 
isolated by method 2.2.2.1.2, sodium phosphate buffer (0.1 M, pH 7.4 + 0.14% BSA 
[volume as quoted below]):- 
 
Lane 1 (Blank control): Phosphate buffer (90 µl) 
Lane 2 (H2O2 control): H2O2 (10µl, 5mM); Phosphate buffer (90 µl) 
Lane 3 (Positive control): NQO1 (2µl, [77.8ng µl
-1
]); EO9 (1µl, [10mM]); NADH 
(10µl, [10mM]) 
Lane 4 (Cisplatin): Cisplatin (10µl, [10mM]); Phosphate buffer (80 µl) 
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Lane 5: [CuCl2(L
1
Pr
n
)] (10µl, [1mM]); Phosphate buffer (80 µl) 
Lane 6: [CuCl2(L
1
Pr
n
)] (10µl, [1mM]); H2O2 (10µl, [5mM]) Phosphate buffer (70 µl) 
Lane 7: [CoCl2(L
1
Cy)] (10µl, [1mM]); Phosphate buffer (80 µl) 
Lane 8: [CoCl2(L
1
Cy)] (10µl, [1mM]); H2O2 (10µl, [5mM]) Phosphate buffer (70 µl) 
Lane 9: [ZnCl2(L
1
Bu
i
)] (10µl, [1mM]); Phosphate buffer (80 µl) 
Lane 10:[ZnCl2(L
1
Bu
n
)] (10µl, [1mM]); H2O2 (10µl, [5mM]) Phosphate buffer (70 µl) 
Lane 11: [CuCl2(L
3
Bu
i
)] (10µl, [1mM]); Phosphate buffer (80 µl) 
Lane 12:[CuCl2(L
3
Bu
i
)] (10µl, [1mM]); H2O2 (10µl, [5mM]) Phosphate buffer (70 µl) 
 
All final drug and H2O2 concentrations were 100µM and 500µM respectively. All 
reaction tubes were incubated for 1h at 37°C. After this period, stop buffer (25 µl of a 
solution in distilled water of 5 mM EDTA, 0.5% SDS, 60% (v/v) glycerol and 0.01% 
bromophenol blue), was added to each tube. Samples (40 µl), were separated on an 
ethidium bromide stained 1% agarose gel containing 0.5 x TBE buffer. Running 
conditions were 100 V for 3h, using 0.5 x TBE buffer. The gel was visualized under 
ultraviolet light and scanned to preserve the result. 
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3. Synthesis of Precursors and Ligands 
 
In order to improve reactions, an understanding of the reaction mechanism is often a 
good starting point. From this understanding, certain parameters can be manipulated in 
order to promote the desired course of a reaction. Clearly the building block approach 
adopted in this study requires efficient synthesis of precursor compounds, not only is it 
advantageous to optimise yield, but also less toxic and more environmentally friendly 
routes are generally desired. In the following sections the reaction mechanisms, route 
selections, subsequent reaction optimisations and product characterisations from the 
syntheses carried out in section 2.1 are described and compared to established methods.  
 
3.1. Oxidation to Dialdehydes 
 
Oxidations of the three precursor head groups to their corresponding dialdehydes, P
1
, P
2
 
and P
3
, were carried out by two methods. At least one of these methods was successful 
in producing the pure dialdehyde for each of the compounds P
1
, P
2
 and P
3
.  
 
The first method used was by controllably oxidizing the corresponding dimethyl 
precursors to their corresponding dialdehydes using selenium dioxide (with the 
exception of P
1
, which was prepared from the dimethanol). The controlled oxidation of 
a methyl substituted aromatic using selenium dioxide is a reliable and well established 
method
137
 and preferred to other common controllable oxidizing agents such as 
pyridinium chlorochromate and manganese dioxide.
138
 In particular selenium dioxide 
has been widely applied to the selective oxidation of methyl pyridines including the 
oxidation of pyridine-2,6-dimethanol, 6,6’-dimethyl-2,2’-bipyridine and 2,9-dimethyl-
1,10-phenanthroline. 
124, 127, 129
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This work had variable success and some problems were encountered with selenium 
contamination of products (isolated products often turned pink on prolonged standing). 
After completion of the reaction, the selenium separates as a dark red/black form which 
is difficult to filter, and some of it is retained in solution as a solute or colloid, which is 
evident when a black selenium precipitate is obtained over time from retained filtrate 
mother liquors. (Also the oxidation of 6,6’-dimethyl-2,2’-bipyridine to P2 was not 
totally successful when attempted with SeO2, with impure product being isolated). In 
addition, from an environmental viewpoint the replacement of SeO2 by another oxidant 
is desirable, hence iodine and DMSO was used later in the program.  
 
The mechanism of selenium dioxide oxidation of methyl precursors is generally 
accepted to involve two steps. Firstly an ene reaction to yield the arylsellenic acid, 
which rearranges to the aryl selenoxate, which is cleaved thermally or hydrolytically 
(Figure 17).
139
 This mechanism consumes two moles of selenium dioxide per mole of 
substrate, hence explaining the larger relative quantities used in comparison with 
oxidation of the methanol analogue. This mechanism has limited support by the 
observed series of colour changes of the reaction mass corresponding to the +4 and +2 
oxidation states of selenium and finally precipitating solid selenium at the end.   
 
 
 
 
 
 
  
104 
Figure 17. Plausible mechanism of selenium dioxide oxidation of methyl precursors. 
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Hence the relative success of application of this reaction in preparation of  P
1
, P
2
 and P
3
 
correlates with the acidity of the precursors methyl protons. As the structures go from 
pyridine to phenanthroline the relative acidity of their methyl protons increases. This 
can be nicely demonstrated by the proton NMR signals 2.50, 2.61 and 2.80 ppm of 
pyridine, bipyridine and phenanthroline respectively. This is related to the stabilisation 
of the anion with the extended aromatic structure of phenanthroline. This gives some 
support to the proposed mechanism in Figure 17, where the first step of the reaction 
involves deprotonation of the methyl group.   
 
The Mechanism of selenium dioxide oxidation of 2,6-pyridine dimethanol however is 
not fully understood and an extensive search of the literature did not provide the answer. 
From the reaction stoichiometry of the literature preparation and by comparing the 
isolated yield obtained in this study to the equivalents of selenium dioxide used in the 
lab preparation does suggest that the mechanism is almost certainly not the same as for 
the methyl precursors. The mechanism is likely to consume one mole of selenium 
dioxide for every two alcohol units (i.e. for every mole of pyridine dimethanol). In the 
first preparation of P
1
 using the literature procedure, ~ 80% conversion of the mono-
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aldehyde intermediate was observed. This was likely a consequence of not using freshly 
distilled and dried 1,4-dioxan. Residual water in the solvent is likely to hydrolyse any 
selenous intermediates preventing further oxidation (may stop at alcohol).  Later 
modifications using a larger quantity (quantity was still less than 2 equivalents), of 
selenium dioxide and dry dioxane soon overcame this problem. A plausible mechanism 
has been proposed for this particular transformation and can be seen in Figure 18. 
 
Figure 18. Proposed mechanism for the transformation of pyridine dimethanol to 
pyridine dialdehyde, P
1
 with selenium dioxide. 
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In order to overcome some of the disadvantages of SeO2 based oxidations, a second 
method was used to form dialdehydes. This proved to be a much cleaner procedure but 
also had varying success. Iodine in refluxing DMSO method has been used to 
controllably oxidise methyl to formyl groups in heteroaromatic derivatives.
128
 The 
method was later improved by using t-butyl iodide.
130
 The role of the t-butyl iodide is to 
presumably act as a free radical initiator to aid in the halogenation of the methyl group 
in the first step of the reaction. But although this has been reported as an improved 
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method, this method was utilized to prepare P
3
 only.  The method has been previously 
applied to the oxidation of 2,6-dimethylpyridine
128
 and 2,9-dimethyl-1,10-
phenanthroline,
130
 but had not been used for 6,6’-dimethyl-2,2’-bipyridine and therefore 
herein is reported an improved synthesis of P
2
.  
 
The oxidation of methyl heteroaromatics to formyl heteroaromatics involves treatment 
of the dimethyl precursor with 2 equivalents of iodine in DMSO. The solution is heated 
to 140-160
o
C, where upon a vigorous exothermic reaction occurs and dimethyl sulfide 
is evolved. The mechanism in the conversion of methylpyridines into pyridinealdehydes 
potentially proceeds through the following sequence (Figure 19), with 2,6-
dimethylpyridine as an example. 
 
Figure 19. Mechanism of controllable oxidation of methyl heteroaromatics utilising 
DMSO and I2. 
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The initial 2,6-dimethylpyridine-iodine complex, on heating, forms the transient 2,6-
diiodomethylpyridine, which reacts with DMSO to form 2,6-pyridyloxydimethyl 
sulfonium iodide. The latter decomposes on heating (or by treatment with base), to form 
pyridine-2,6-dicarboxaldehyde  and dimethyl sulphide.
128
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3.1.1. Pyridine-2,6-dicarbaldehyde, P1 
 
As mentioned in the previous section the precursor compound P
1
 was prepared by two 
methods. The first method was the most common method found in the literature for this 
compound, and involved the selective oxidation of  pyridine-2,6-dimethanol by 
selenium dioxide in refluxing 1,4-dioxane.
124, 137
 By this method, the product was 
isolated in very good yields (70-80%), and of fairly high purity, although trace 
contamination with selenium was often a problem and this was indicative when the 
cream compound turned slightly pink over time.  This method was also the main 
method of choice for this work mainly due to the high yields, good purity and 
practicality of the synthesis. With DMSO and iodine the potential of obtaining the 
desired product without any selenium contamination was desirable, although not 
essential. This method was also potentially much more desirable since it utilised the 
much cheaper 2,6-lutidine. The synthetic method was carried out as described in the 
literature,
128
 only to obtain a very small amount of a dark liquid substance after 
extraction. NMR of the oil revealed that two main compounds were present; one was 
the starting material and the other the desired product in a ratio of 1:2 respectively. With 
some modification this method could have potential but time did not permit and so this 
method was abandoned for P
1
. 
 
Initial attempts to prepare P
1
 via the SeO2
 
method
 
yielded a mixture of the desired P
1
 
and the monocarbaldehyde (Ca. 4:1 respectively by NMR of isolate). Enough residual 
intermediate was present at the end of reaction to impair the resulting literature 
crystallization procedure. Every time the product P
1
 came out of solution it was joined 
by the intermediate as an amorphous precipitate or microcrystalline material. 
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Characterisation of the mixture provided firm evidence for the monoaldehyde. From the 
MS it was possible to differentiate between monoaldehyde and dialdehyde by isotopic 
distributions. The MS revealed a peak at m/z 136 significantly greater than the expected 
13
C satellite peak for that of the dicarbaldehyde at m/z 135, which indicated the mono 
carbaldehyde. The IR spectrum revealed a sharp medium peak at 3400 cm
-1
, indicating 
the presence of a OH group. The NMR spectrum showed peaks consistent with the 
dicarbaldehyde and extra peaks at 10.0 ppm, peaks overlapping with the pyridyl peaks 
of the dicarbaldehyde, and a peak at 4.83 ppm, which corresponded with the 
monocarbaldehyde in approximately 20% (Figure 20).  
 
Figure 20. 
1
H NMR Spectrum (270MHz in CDCl3) of attempted oxidation of pyridine-
2,6-dimethanol to pyridine-2,6-dicarbaldehyde. The annotated peaks correspond to 
proton signals of the intermediate mono-oxidised species. 
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As a result of this initial problem, the quantity of selenium dioxide was increased and 
the isolated product was identified as pure desired P
1
 in good yield (typically 72 %), and 
its melting point (132-134 
o
C), consistent with that of the literature.
124
  
3.1.2. 2,2’-bipyridine-6,6’-dicarbaldehyde, P2 
 
Synthesis of P
2
 involved three steps: Synthesis of 2-bromo-6-methyl pyridine followed 
by coupling the 2-bromopyridine to form the 6,6’-dimethylprecursor. At each step 
products were isolated and characterised by MS, NMR and IR. Two methods were 
investigated for oxidation of 6,6’-dimethyl-2,2’-bipyridine in the preparation of the 
target compound P
2
. The use of DMSO and iodine proved to be more efficient than 
other methods, requiring only one step and was a much more practical synthesis and P
2
 
was obtained in good yield (71%), with high purity. This is the first time this compound 
has been prepared by this method 
3.1.2.1. Step 1 – 2-bromo-6-methylpyridine, P2a 
 
This nucleophilic substitution of an aromatic ring is typically carried out by a 
Sandmeyer reaction
140
 which goes via in situ generation of the aryl diazonium salt at 
low temperature, followed by raising the temperature in the presence of a nucleophile 
(in our case bromide) to give the bromo substituted aromatic as shown in Figure 21. 
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Figure 21. Steps in the nucelophilic aromatic substitution analogous to the Sandmeyer 
reaction. 
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2-bromo-6-methylpyridine was isolated in moderate to good yield (68 %), as a clear, 
liquid after vacuum distillation (b.p. at 1.6 – 1.7 mmHg, 54 – 56 oC), consistent with the 
literature.
141
 MS revealed the [M]
+.
; at m/z 171, along with the 
81
Br satellite with equal 
intensity.
142
 The characteristic fragment corresponding to [M-Br]
+.
; was also observed at 
m/z 92. IR revealed the symmetric and asymmetric C-H stretching vibrations of the 
methyl group around 2900 cm
-1
, along with the C=N/C=C ring skeletal stretch at 1590 
cm
-1
, and a strong band at ca. 580 cm
-1
, which can be attributed to the C-Br stretch. 
NMR gave rise to 3 aromatic peaks with the expected splitting pattern of two doublets 
and a triplet each integrating to 1H and a singlet in the aliphatic region integrating to 3H 
which corresponds to the lone methyl group. 
3.1.2.2.  Step 2 – 6,6’-dimethyl-2,2’-bipyridine, P2b 
 
Nickel is a common reagent in biaryl synthesis.
143
 Rayney nickel has been used to 
couple the two aryl groups in this clean but low yielding reaction. P
2b
 was isolated by 
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recrystallisation from pet spirit (b.p. 40-60) as cream crystals in low yield (19 %) with a 
m.p. of 92-94 
o
C. This all agreed with that of the literature. The low yield can probably 
be attributed to the fact that the rayney nickel slurry would contain significant water 
impurity which would lead to the hydrolysis or aquation of the nickel(II)bromide 
complex and loss of P
2b
. The MS afforded peaks at m/z 184, 183 and 169, which 
correlated to [M]
+.
; [M-H]
+.
; and [M-CH3]
+.
; respectively. The IR spectrum revealed 
peaks at similar positions to 2-bromo-6-methyl pyridine. The methyl stretches along 
with the skeletal aromatic C=N / C=C stretches at 2900 cm
-1
 and 1400-1500cm
-1
, 
respectively and also no intense band at ca. 580cm
-1
 was observed, indicating that C-Br 
had been replaced. 
3.1.2.3. Step 3 – 2,2’-bipyridine-6,6’-dicarbaldehyde, P2 
 
Synthesis of P
2
 was initially attempted by controlled oxidation with selenium dioxide 
under conditions used successfully for P
1
 and P
3
. A literature report
127
 that P
2
 has been 
prepared previously using selenium dioxide as oxidant but experimental details were 
incomplete and no quantities of reagents were given for the procedure. The same 
equivalents of selenium dioxide to P
2a
, as for the preparation of P
3
 were used and the 
mixture was refluxed in glacial acetic acid for 24 h. Upon cooling, a white precipitate 
formed and was isolated by filtration. However the precipitate showed properties 
inconsistent with dialdehyde.
127
 Soxhlet extraction of the solid with xylene was 
employed and upon cooling the extract in the fridge, cream crystals formed. The IR 
spectrum of the crystals showed features characteristic of the dicarbaldehyde product 
with a very strong absorption at 1703 cm
-1
 for the carbonyl group. The EI-MS gave the 
[M]
+.
; at m/z 212, and the characteristic fragmentation peaks for [M-CO]
+.
; and [M-
(CO)(CHO)]
+.
; at m/z 184 and 155 respectively. The NMR spectrum was recorded in 
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DMSO but while the desired product was clearly present, significant quantity of mono-
oxidised impurity was present. 
 
Due to inadequate characterization and purification of P
2
 a second method was 
attempted, using the DMSO / iodine method.
128
 This time the highly pure product was 
isolated in good yield (71%). The 
1
H NMR revealed only the fully oxidized 2-fold 
symmetric product P
2
 was present, as identified by loss of the single methyl peak at 2.61 
ppm and three aromatic peaks integrating equally, with the correct fine structure of two 
doublets and a triplet.  The 2-fold symmetry also indicates P
2
 has a low barrier to 
rotation at the pyridyl bridge, and indicates the anti and syn conformations are in fast 
equilibrium at ambient temperature. Once again the MS revealed the same [M]
+.
; at m/z 
212, and the characteristic fragmentation peaks for [M-CO]
+.
; and [M-(CO)(CHO)]
+.
; at 
m/z 184 and 155 respectively. 
 
The crystal structure of the isolated P
2
 (Figure 13) was also obtained after 
recrystalisation by slow evaporation of a chloroform solution. Interestingly the structure 
identified the syn-conformation of the bipy nitrogens, a coplanar ring system and both 
aldehyde groups in trans geometries. 
3.1.3. 1,10-phenanthroline-2,9- dicarbaldehyde, P3 
 
P
3
 was prepared in moderate to good yield (65-75%), as very fine cream needle crystals, 
(m.p. > 235 
o
C), consistent with literature values.
129
 EI-MS gave rise to peaks at m/z 
235, 208 and 180. The highest peak was attributed to that of [M]
+.
; and the peaks at m/z 
208 and 180 were assigned to the characteristic fragmentations of [M-CO]
+.
; and [M-
2(CO)]
+.
; respectively. The IR spectrum produced very strong absorption at 1702 cm
-1
, 
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characteristic of the carbonyl stretching frequency and loss of the methyl stretching 
bands around 2900-3000 cm
-1
, indicating the product was fully oxidized. 
1
H NMR 
spectroscopy identified that the pure compound was isolated, showing four sets of peaks 
required for the four distinct hydrogen environments of P
3
, with 2-fold symmetry, three 
sets of the peaks appearing in the aromatic region of the spectrum and a singlet 
appearing slightly downfield as expected, for the aldehyde proton. All peaks integrated 
to equal area, and the three sets of aromatic peaks demonstrated the correct splitting 
pattern of two doublets and a singlet expected for P
3
.  
 
3.2. Schiff Base Ligands 
 
The formation of the Schiff base ligands was possible by reacting the diformyl 
precursors with two equivalents of the appropriate primary amine, in a Schiff base 
condensation. The mixture could be refluxed or stirred at room temperature.  
 
The reaction mechanism involved in the formation of a Schiff base compound is very 
well known and involves nucleophilic addition of the primary amine to the electron 
deficient aldehydic carbon, followed by elimination of a water molecule (Figure 22).
144, 
145
  
Figure 22. The mechanism of addition elimination in a Schiff base condensation. 
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This reaction is reversible and so to ensure the reaction proceeds to completion there are 
several principles that could be utilised to drive the equilibrium to the products. By Le 
Chateliers principle, a system in equilibrium will react to oppose any changes imposed 
upon it,
146
 therefore by introducing excess amine and keeping the initial mixture and 
also reaction mixture as dry as possible (using dry solvents, molecular sieves and 
carrying out the reaction under nitrogen), will force the equilibrium to the products. The 
reaction can also be catalysed by the presence of catalytic quantities of acid, which 
would protonate the carbonyl oxygen making the carbonyl carbon more electrophilic 
and the reaction more facile. This however depends upon the pKa and reactivity of the 
subsequent amine. If the pH of the mass is lowered two units below the pKa of the 
reacting amine, 99.9% of the amine will be in the non reactive salt form.
147
 Base can 
also be used as a reagent to deprotonate less basic amines. 
  
Schiff base ligands of aliphatic amines were found to form orange to tan coloured 
viscous oils after reflux and evaporation of solvent. The reactions were generally 
complete within 60 mins and good yields were isolated after optimisation of conditions 
(as discussed later in this section).  
 
When forming the Schiff base ligands with aromatic tail groups, they were generally 
isolated as yellow to green crystalline solids. The reaction mixtures were refluxed and 
were typically complete within 90 mins). The aromatic ligands were isolated in good 
yield, and were analytically pure due to their crystalline nature.   
 
A preliminary reaction of P
1
 with Pr
n
Amine to generate the L
1
Pr
n
 alkyl ligand carried 
out with GPR grade solvents and also without any molecular sieves, showed the 
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reaction did not fully go to completion. The approximate amount of monoimine present 
on isolation was determined by NMR, and was in the order of ~5%. Conditions were 
further improved (slight excess amine, dried solvents, molecular sieves), and the 
reaction went to completion with minimal residual starting material and monoimine 
(just at the limit of detection by NMR <1%, see Figure 23).  
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Figure 23. 
1
H NMR Spectra (600 MHz  in CD3OD) of isolated material from synthesis 
of L
1
Pr
n
. The top overlay spectrum identifies desired product along with approximately 
5% monoimine under initial conditions. The bottom spectrum identifies desired product 
along with a significant reduction in undesired monoimine intermediate after 
optimization of conditions. 
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It was possible to follow the disappearance of P
1
 to approximate the reactivity of the 
various amines with dialdehyde. The conversion times roughly follow the trend of 
amine basicities (Table 23) as would be expected. 
 
Table 23. Crude conversion times and isolated yields for Schiff bases of L
1 
Ligand Time to 
convert P
1
 / 
mins 
(By TLC 
analysis) 
Isolated Yield 
/ % 
 
Calculated  
pKa of 
Protonated 
amine. 
L
1
Et 30 98 10.6 
L
1
Pr
n
 30 97 10.7 
L
1
Pr
i
 15 99 10.9 
L
1
Bu
n
 15 96 10.7 
L
1
Bu
i
 15 98 10.5 
L
1
Bu
2
 15 99 10.6 
L
1
Bu
t
 30 97 10.9 
L
1
Cy 15 98 10.6 
L
1
CyMe 15 97 10.5 
L
1
Ph 45 80 4.2 
L
1
PhMe 45 95 5.7 
L
1
PhCl 45 97 4.0 
 
The formation of diimine from dialdehyde is a consecutive reaction which is second 
order in both forward steps and in reverse (Figure 24).
148
 
 
Figure 24. Kinetic parameters of diimine formation 
Dialdehyde Monoimine Diimine
k2f RNH2k1f RNH2
k1r H2O k2r H2O  
 
The effect of altering the conditions to obtain the maximum amount of product can be 
demonstrated using mathematical modelling software.
149
 Using the equilibria in Figure 
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24 the basic stoichiometric reaction can be shown to reach equilibrium as in Figure 25 
below. 
 
Figure 25. Predicted profile of the stoichiometric reaction of primary amine to 
dialdehyde. 
 
 
Figure 25 depicts the standard reaction from the method taken from Lions procedure
131
 
and the original procedure used for the first aliphatic ligand L
1
Pr
n
 generated in this 
thesis (i.e. 2 equivalents of primary amine to 1 equivalent of dialdehyde under reflux). 
The forward and reverse rate constants have been manipulated to give ~5% residual 
monoimine at equilibrium and to give almost full conversion of dialdehyde after ~30 
minutes (subsequent 2
nd
 order rate constants used for both forward steps was 7.5 M
-1
 
min
-1
 and both reverse steps was 0.05 M
-1
 min
-1
, see appendix 1.1). It is clear since 
monoimine conversion is not complete there is ~5% loss in yield and the isolation 
method of aliphatic tail groups uses no purification step (TLC analysis was hampered 
by problems with products sticking to silica and alumina columns). Figure 26 however 
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predicts the profile of the same reaction with simulated molecular sieves added i.e. a 
pathway is added to simulate water removal (see Appendix 11.1).  
 
Figure 26. Predicted profile of the stoichiometric reaction of primary amine and 
dialdehyde with molecular seives added (water removal). 
 
 
It is clear from the profile that there has been a further yield improvement at 
equilibrium. The intermediate monoimine has been reduced to ~2% (Figure 26). The 
conditions of this reaction have been used to generate ligands with aromatic amine 
precursors in this study, since when tried with an excess of amine crystallisation gave 
poor yields (<60%) and often it was difficult to remove the residual amine, even after 
several washes, presumably the residual amine forms a fraction of co-crystals which is 
isolated. Whereas since the aliphatic amines were volatile and the excess could be easily 
removed at the end of reaction, an excess of amine was possible.  
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Figure 27. Predicted profile with a slight excess of amine added to the reaction with 
dialdehyde. 
 
 
Figure 27 shows the effect of adding an excess of amine and clearly demonstrates firstly 
how the reaction rate increases, the time at which equilibrium is achieved is quicker and 
also 100% conversion of dialdehyde and monoimine is observed. These small 
modifications to the original reaction show how yield, time and purity benefits can be 
achieved. Also although the formation of aromatic ligands was slower than aliphatic 
ligands, the fact that aromatic ligands are fully conjugated would likely mean the 
equilibrium constant is more in favour of the diimine.  
  
Although the Schiff base reactions of the p-anilines to form L
1
Ph, L
1
PhMe, L
1
PhCl, 
worked well, the Schiff base reactions of p-nitroaniline and 2-aminobenzimidazole did 
not proceed to completion. Particularly the reaction of p-nitroaniline which did not 
proceed at all, this was verified by TLC and NMR. This could be explained due to the 
poor basicity of the amines. Because p-nitroaniline contains the electron withdrawing 
nitro group, the lone pair of the amine are likely to be strongly involved in resonance 
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and are therefore unavailable for donation, as with 2-aminobenzimidazole the lone pair 
is also involved in resonance with the imidazole ring, which also makes the amine a 
poor base. The ease of formation of the Schiff bases of these aromatic amines can be 
rationalized by looking at their pKa.(Figure 28). 
 
Figure 28. Calculated pKa of cyclic amines used in this study (pKa calculations using 
chem office).  
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3.2.1. Characterisation of Ligands 
3.2.1.1. IR Spectroscopy 
 
The formation of the free Schiff base ligands was initially analysed by IR spectroscopy 
to identify loss of C=O stretching bands for P
1
 and P
3
 precursors around 1720 and 1702 
cm
-1
, respectively and the appearance of the imine C=N stetching bands between 1680-
1600 cm
-1
. Then the mass and NMR spectra were obtained to further characterize the 
compounds made and to identify the purities.  
 
The IR spectra of all aliphatic ligands have very much the same pattern. Due to all of 
the aliphatic ligands being oils the spectra were obtained as thin films between KBr 
windows and all bands were particularly intense. All contained a lone weak aromatic C-
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H stretch between 3063-3045 cm
-1
, followed by strong absortions between 3000-2840 
cm
-1
 corresponding to the stretching vibrations of the aliphatic C-H’s of the tail groups. 
Schiff bases of aromatic tail groups were obtained as solid KBr discs and showed C-H 
stretching in the region of 3086-3000 cm
-1
, as would be expected, but unusually several 
C-H stretching bands were also observed below 3000 cm
-1
, which must be aromatic C-
H stretching since several of such bands were observed. The bands closer to 3000 cm
-1
 
have been tentatively assigned to aromatic C-H and below 2900 cm-1 assigned to the 
aldimine C-H stretching. In all Schiff base compounds of the form L
1
R, substitution of 
the ring could also be confirmed by the appearance of four weak overtones between 
2000-1750 cm
-1
, characteristic of meta substitution.
150
 Confirmation of imine bond 
formation was evident by the appearance of a single band between 1653-1604 cm
-1
. For 
the Schiff bases of aliphatic tail groups the C=N stretch appeared between 1653-1644 
cm
-1
 and was very strong in intensity, on the other hand the Schiff bases with aromatic 
tail groups were much lower in intensity and wavenumber (1628-1604 cm
-1
). The effect 
in intensity is likely due to a change in the dipole moment of the fully conjugated 
system and the lowering in wavenumber is as expected since conjugation either side of 
the imine bond is now introduced, which gives rise to a greater amount of canonical 
structures and hence more single bond character for C=N. Further to the above 
mentioned observations, aromatic ring breathing vibrations were also present in all 
cases between 1597-1452 cm
-1
. 
3.2.1.2. 1H NMR Spectroscopy 
 
The NMR spectra of all the Schiff base ligands of L
1
R and L
3
R both showed 2-fold 
symmetric compounds which indicates the E,E; Z,Z; E,Z conformations are in rapid 
equilibrium. As examples the proton spectra of L
1
Bu
n
 and L
1
Ph are shown in Figure 29 
  
123 
and Figure 30 respectively and indicate the typical splitting pattern of the pyridyl and 
aldimine moieties and evidence of 2-fold symmetry. 
 
Figure 29 
1
H NMR (270 MHz) spectrum of L
1
Bu
n
 obtained in CDCl3. 
 
 
Figure 30  
1
H NMR (270 MHz) spectrum of L
1
Ph obtained in CDCl3. 
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All spectra of L
1
R showed peaks in the aromatic region corresponding to the m- and p- 
pyridyl protons, showing a doublet and a triplet, integrating to 2:1 respectively and a 
singlet downfield of the aromatic region integrating to two protons, which was assigned 
to the aldimine protons of the head group.  
 
Figure 31. 1H NMR (600 MHz) spectrum of L
3
PhMe obtained in CDCl3. 
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All of the 
1
H NMR spectra of L
3
R ligands showed three peaks in the aromatic region 
consisting of two doublets and a singlet of the 1,10-phenanthroline head protons 
integrating to two protons each, followed by a singlet downfield of the aromatic region 
integrating to two protons assigned to the aldimine moiety. 
 
 
 
 
  
125 
4. Synthesis of Metal Complexes 
 
 
To understand the role of the prepared complexes in section 2.1 to their biological 
activities given in section 7, a good knowledge of the structural chemistry of these 
compounds is required to aid this understanding. Since characterization of inorganic/co-
ordination compound geometries are not as straight forward as organic molecules, and 
in particular paramagnetic complexes, a variety of techniques have been utilised to 
determine their precise co-ordination chemistry in the solid state and in solution as 
reported herin.    
 
The formation of all complexes was achieved at room temperature. In nearly all cases 
the reaction products were isolated as analytically pure species on spontaneous 
precipitation usually as microcrystalline powders, when not they either crystallised by 
vapour diffusion or by crystallization from a suitable solvent. In both templated and 
non-templated reactions, yields recorded varied between 23-100 %, the Co
II
 and Cu
II
 
yields being no less than 73 %. As initial observations identified that templated yields 
were comparably greater than those of the free ligand and reactions were effectively 
complete at time of mixing, it was decided that it was advantageous to preferentially 
prepare the complexes via the template method. Also this way a greater overall yield 
would be achieved in a one pot one step synthesis. The template synthesis of this class 
of open (acyclic), Schiff base ligands has not been observed in any of the literature, and 
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the non-templated preparation has been the only method seen previously for this class of 
compound. 
 
4.1. The Template Reaction 
 
Coordination complexes are traditionally prepared by mixing the preformed organic 
ligand with an appropriate metal source.
151
 It is a pre requisite of this approach that the 
organic ligand must be stable and isolable. Many problems arise when the ligand sizes 
become large, particularly for macrocyclic compounds, and the conformation control in 
bringing the two ends of a chain together in the final cyclization step can be 
troublesome.
151
 The template effect is a widely used strategy which circumvents these 
problems.
152, 153
 In essence the method involves the incorporation of additional donor 
atoms into the chain and performing the cyclization reaction in the presence of a metal 
ion that can coordinate to these. The idea is that the metal ion will coordinate to the 
donor atoms and pre-organize the various intermediates in the conformation required to 
give the desired cyclic products. This is shown schematically (Figure 32) along with an 
example in Figure 33. 
 
 
 
 
 
 
 
 
 
  
127 
Figure 32. Schematic view of the cyclisation step involved in a template macrocycle 
synthesis. The filled and red circles represent mutually reactive functional groups and 
the squares are additional donor atoms. The binding of the metal to the donor atoms pre-
organises the ligand into the conformation required for cyclisation. 
 
M M
 
 
Figure 33. The template synthesis of a Nickel
II
 macrocylcic complex.
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The metal atom plays a number of roles in the above reaction. The stabilization of the 
acyclic intermediate is achieved in a number of ways. As a free ligand, 20 possesses 
nucleophilic thiol and electrophilic imine groups and cyclisation arises by attack of the 
thiol upon the carbon of the imine to give 21. When 20 is coordinated to Ni
II
, the 
nucleophilicity of the thiolate is reduced because it is bonded to an electropositive 
centre, the thiolate is constrained so that it cannot approach the imine and the imine is 
made less electrophilic by the back donation of the d-electron density into the π* 
orbitals. The metal also pre-organises the two thiolate groups so that they are correctly 
orientated for reaction with the electrophilic 1,2-bis(bromomethyl)benzene to give the 
macrocyclic ligand.
155
  
 
But for the complexes prepared via the template reaction in this study, no macrocycles 
were formed. These complexes can be best described as coordination macroacyles and 
this class of complex is not generally prepared via the template synthesis. Previous 
groups preparing similar compounds used the non-template method only.
25, 156-158
 The 
reason for this is because these ligands cannot form cyclic compounds, since 
condensation is with mono amine precursors, and no bridging can therefore occur. This 
in addition makes synthesis of the free ligand simpler due to there being no possibility 
of polymerization or any higher order cyclic compounds being made. 
159-162
  
 
In contrast to the traditional metal template approach, the role of the metal ion in the 
template reaction of these complexes is proposed to work in a slightly different 
mechanism to that of the example in Figure 33. It is plausable that the metal does work 
by stabilising and organizing a conformation of the dialdehyde, but because the metal is 
a lewis acid it has empty d orbitals to accept a lone pair of electrons from the two 
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carbonyl oxygens. Therefore the metal acts analogously to a bronstead acid by 
increasing the electrophilicity of the carbonyl carbon by withdrawing electron density 
through the oxygen, and therefore increasing the rate of condensation compared to 
reactions without a metal source. Also the conformation of the dialdehyde is maintained 
in a planar configuration and nucleophilic attack can occur freely from above or below 
the plane of the molecule at the Bürgi-Dunitz angle,
163
 which is favourable for 
nucleophilic addition to a carbonyl carbon (Figure 34).
164
 
 
Figure 34. Proposed mechanism of the acyclic Schiff base template reaction.  
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This mechanism is given some support from observations during the preparation. When 
the copper(II)chloride salt is added to a solution of P
1
 in acetonitrile, a colour change is 
observed from colourless to orange, suggesting a complex is formed between the 
dialdehyde and metal (copper(II)chloride in acetonitrile is green).  
 
The main differences between our proposed mechanism and the one described in Figure 
33 is the opposite co-ordination of the metal. In our example the metal initially co-
ordinates to dialdehyde which would be facilitated by the pyridine nitrogen. This can be 
best described as carbonyl activation and quite readily speeds up the condensation 
reaction compared to the non-templated approach (as evident in observed reaction 
times). The template reaction described in Figure 33 shows that the diamine reactant 
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firstly co-ordinates to the metal and pre-organises itself. This in itself would sequester a 
lot of the negative charge of the amine and render it less reactive.   
 
The added bonus of the template reaction is that the final Schiff base is stabilized by 
coordination to a metal centre. Schiff bases are -acceptors and therefore hydrolysis is 
less likely, so there is very little or no Schiff base equilibrium. The reactions are 
visually observed as being complete at time of mixing or shortly thereafter, by colour 
change or precipitation of product. However one disadvantage to this approach is when 
the free ligand is required and to remove the metal reductive demetallation is a common 
procedure, although the amine is thus produced. Addition of cyanide to sequester the 
metal as the cyano complex is also possible to generate the free ligand,
155
 experiments 
of this type were not necessary in this project. 
 
4.2.  Characterisation of Metal Complexes 
 
On the basis of elemental analyses, all complexes (whatever was the method of 
preparation), exhibited an unequivocal metal-to-ligand stoichiometry of 1:1, with the 
exception of complexes of Cu(BF4)2, Co(BF4)2 Co(NCS)4, Co(NO3)2 salts, where no 
matter what the method of preparation (even when 1:1 equivalents of metal to ligand 
were used), the complexes exhibited metal-to-ligand stoichiometry of 1:2 (bis complex). 
In some cases half, one or two molecule of solvent was present (CH3CN, H2O, DMF), 
and often a mixture of two. Moreover the CHN data showed that all complexes present 
existed as monomers with the exception of [Cl2-{NiCl(L
1
Pr
n
)}2].  
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Data obtained by ESI-MS indicated that monocationic species were observed. They 
predominantly correspond to the complex ligand/metal having lost one proton [L + M – 
H]
+
 or having retained one of the two anionic labile ligands [L + M + X
-
]
+
. The presence 
of one or two solvent molecules (CH3CN, MeOH, H2O), are usually observed. In 
addition, minor peaks were observed, probably generated in the MS machine, 
corresponding to bis species of the type 2:1 (cases of M + 2L – H, M + 2L, M + 2L –H, 
plus M + 2L + Cl). But in several cases dicationic species having relative intensities of 
100%, corresponding to the bis species of the type 2:1 were also observed. 
 
4.3. Complexes of the Ligand L1PhNO2 
 
Although attempts to produce the free ligand of L
1
PhNO2 were unsuccessful, attempts 
to produce its transition metal complex [MCl2(L
1
PhNO2)] via the template method were 
not and all compounds were isolated as analytically pure powders after spontaneous 
precipitation from acetonitrile solvent. Analysis of these complexes in the solid state 
indeed show they had been prepared and in excellent yield. Microanalysis results 
showed a ligand to metal stoichiometry of 1:1, and colours agreed with the colours seen 
for other aromatic complexes of the particular metals used, (cobalt(II) - brown, 
copper(II) - orange, zinc(II) – yellow).  Infrared spectra identified characteristic bands 
for C=N at 1602-1605 cm
-1
and the absence of any primary amine stretches around 
3200-3400 cm
-1
 neither any aldehyde C=O stretch at 1700 cm
-1
, were consistent with 
formation of the complex. Attempts to crystallize the complexes proved unsuccessful 
due to their very poor solubilities in nearly all organic and polar solvents. The 
complexes showed solubility in hot DMSO, but crystallization attempts with 
temperature or anti-solvent approaches were unsuccessful. Therefore further 
characterization by single crystal x-ray diffraction was not possible. 
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FAB mass spectrometry ultimately provided the concluding evidence that the desired 
complexes had been formed and in all cases fragments for the molecule having lost one 
Cl
-
 were observed with the correct isotope patterns. The complex [ZnCl2(L
1
PhNO2)] is 
given as an example in Figure 35 and identified that the complex cation 
[ZnCl(L
1
PhNO2)]
+
 had been generated having lost one H and a Cl giving m/z 474. The 
isotope pattern subsequently matched the predicted pattern almost identically which 
concluded that the desired complexes had indeed been generated. 
 
Figure 35. FAB mass spectrum of [ZnCl2(L
1
PhNO2)] (a) and the calculated isotope 
pattern for the observed fragment [ZnCl(L
1
PhNO2)]
+
 (b). 
 
a) 
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b) 
 
 
1
H NMR of the zinc and cobalt complexes in DMSO-d6 solution at elevated temperature 
were consistent with hydrolysis of the ligand. The zinc spectrum was somewhat 
complex with a mass of peaks abundant in the aromatic region, there was also the 
appearance of two singlets in the region of an aldehydic proton and also in the region 
for an aldiminic proton. There were also several doublets in the region of the free p-
nitroaniline area, along with broad peaks which could be assigned to exchangeable 
protons of an amine. The spectrum therefore identified that in DMSO solution and with 
heating the intact complex is not observed and a mixture of free ligand to starting 
materials are most likely observed. The presence of water in DMSO could be the reason 
why the ligand hydrolyses back to the aldehyde and amine along with heating. This 
hydrolysis can then explain the poor solubility of the compound in cold DMSO yet after 
dissolution in hot DMSO the compound does not come back out of solution after 
cooling, the solubility of the starting materials are different to the actual intact complex. 
 
For the Cobalt complex the expected isotropically shifted and singlet broadened peaks 
would be expected due to the paramagnetic nature of the cobalt centre, instead peaks 
C19H13N5O4ZnCl
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more distinguishable as diamagnetic resonances are observed and again a somewhat 
complex spectrum is observed. This is indicative of hydrolysis of the metal and ligand.  
 
4.4. Vibrational Spectroscopy of Complexes 
 
Although IR spectroscopy is a difficult technique to unequivocally assign stretching 
modes of all functional groups, it is still a good tool to tentatively deduce certain 
features of a complex and has been used in combination with Raman spectroscopy to 
help interrogate the coordination characteristics of this class of complex. 
 
The IR and Raman spectra of the complexes nearly all show aromatic C-H and C=C / 
C=N, stretches in their anticipated regions (3200-3000 cm
-1
 and 1600-1400 cm
-1
 
respectively), and they all show weak to medium aldimine C=N stretches. Figure 36 
shows the typical pattern of peaks for L
1
R ligands and its complexes. Also included in 
the figure is the spectrum of the dialdehyde precursor P
1
. Clearly the aldehyde C=O 
stretch disappears, from P
1
 to the ligand and in all complexes. The slight shift to lower 
frequency and decrease in the imine C=N stretch around 1625 cm
-1
 is also evident going 
from L
1
Ph to the complexed ligand. 
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Figure 36. Stack plot of Raman spectra of precursor P
1
 to the Ligand L
1
Ph through its 
complexed form. 
 
 
The infra-red spectra of the complexes gave interesting trends for the imine stretching 
frequencies for different metal centres. The Co
II
 complexes demonstrated that aldimine 
stretches are observed between 1640-1622 cm
-1
, for the Cu
II
 complexes the stretches are 
also observed in the same region. However for the Zn
II
 complexes the window is shifted 
to higher frequency, between 1650-1622 cm
-1 
(Table 24). 
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Table 24. FT-IR Imine stretching frequencies for various ligands and their Co
II
, Ni
II
 
Cu
II
 and Zn
II
 dichloride complexes. 
    Free Ligand Co
II
 Ni
II
 Cu
II
 Zn
II
 
 
  L
1
Et 1644 s - 1639 w 1637 w 1650 m 
  L
1
Pr
n
 1644 s 1630 w 1634 w 1634 w 1649 m 
  L
1
Pr
i
 1644 s 1630 w - 1634 w 1651 m 
Aliphatic 
  L
1
Bu
n
 1653 s 1631 w 1634 w 1627 w 1650 m 
  L
1
Bu
2
 1647 s 1634 w - 1628 w 1647 m 
  L1Bu
i
 1653 s 1634 w - 1628 w 1652 m 
   L
1
Bu
t
 1655 s 1636 w - - 1644 m 
   L
1
Cy 1647 s 1631 w 1632 w 1638 w 1648 w 
   L
1
CyMe 1647 s 1640 w - 1628 w 1648 w 
Aromatic 
  L
1
Ph 1625 m 1622 w 1640 w No band No band 
  L
1
PhMe 1628 m No band 1632 w No band No band 
  L
1
PhCl 1628 m 1620 w - 1620 w 1637 w 
  L
1
PhNO2 - 1602 w - 1605 w 1604 w 
 
As for trends across the ligand variation it is fairly difficult to see any other than for 
aromatic tail groups. Clearly the C=N stretch of complexes of L
1
PhNO2 shifts quite 
dramatically to lower frequency, (compared to L
1
PhCl), this is not surprisisng since the 
electron withdrawing power of the p-nitro group would reduce the imine bond strength. 
By the same token, it is strangely observed that the C=N stretches of the p-Cl variants 
seem to actually increase from the L
1
Ph complexes which is rather counterintuitive 
based on the same reasononing as the nitro group.  
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When we compare the free ligands to the complexed ligands a clear difference is 
observed in C=N stretching frequency. For ligands of alkyl tail groups, the stretching 
frequency is lowered on coordination to transition metals Co
II
, Ni
II
, Cu
II
 and raised on 
coordination to Zn
II
. It was not possible to make this distinction for aromatic ligands, 
and in fact the opposite is observed. An explanation for the reason that transition metals 
shift the peaks to lower frequency is because of π-back donation from d-electrons of 
transition metals to the π* antibonding orbitals of the C=N bond (Figure 37). 
 
Figure 37. Orbitals and bonding of Schiff base ligands with transition metals. 
N
M
C
M N C
 donation  back donation
 
 
When C=N acts as a ligand where the σ-orbital acts as a donor to a metal atom and 
forms a σ bond with the central metal atom (Figure 37). The LUMO’s of the imine are 
the π* orbitals. These two orbitals play a crucial role because they can overlap with 
metal d orbitals that have local π symmetry (such as the dxy, dxz, dyz orbitals for square 
based pyramidal and octahedral complexes). The π interaction leads to the 
delocalization of electrons from the filled d orbitals on the metal atom into the empty π* 
orbitals on imine ligands, so the ligand acts as a π acceptor. Population of the π* orbitals 
weakens C=N by withdrawing electron density from C=N making it more single bond 
in character, therefore lowering the vibrational frequency. 
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As for the Zn
II
 complexes, since they contain no empty d-orbitals (Zn d
10
) to accept the 
σ electrons of the ligand, it is not possible for π back donation from the ZnII centre into 
the π* orbitals of C=N and therefore does not effect the imine frequency in the same 
sense. However Zinc is the most electropositive metal of this series and so electron 
density may be pushed toward the imine bond from Zn
II
 generating a stronger C=N 
bond and hence an increase in the vibrational frequency.   
4.4.1. Binding Modes of Parent Ligands 
  
All infra-red and raman spectra of the L
1
 complexes showed ligand bands overlaying  
those of the bands in the complexes, with slight shifts in peaks and intensity and 
additional peaks likely of metal-ligand vibrations and metal-anion vibrations. The 
biggest noticable shifts were as expected for the C=N stretch, which in all cases was a 
single stretch in the 1600-1650 cm
-1
 region of the spectrum. This indicated that there 
was no loss in ligand symmetry and it was likely the  ligands were acting as tridentate 
ligands with approximate C2 symmetry.  
 
However when the infra red spectra of the L
3
 complexes was inspected, two distinct 
bands for the imine were observed along with a more complex mass of peaks, indicating 
a loss in the C
2
 symmetry of the free ligand. Also one  imine stretch was generally 
unchanged from the free ligand band in both frequency and intensity, whereas the other 
band was lower in frequency and in intensity. This indicated the L
3
 ligand was acting in 
a tridentate mode with one bound and one free imine group. 
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4.4.2. Binding Modes of  Anionic Ligands 
4.4.2.1. Nitrato complexes 
 
The nitrate anion can coordinate to the metal in one of two ways: 
 
N
OO
O
N
OO
O
M
N
OO
O
M
Free ion (D3h) Unidentate (Cs) Bidentate (C2v) 
 
The bidentate mode can also be bridging. The free ion which is a planar 4 atom 
molecule (XY3) of D3h symmetry is lowered to Cs and C2v upon coordination. It is pretty 
difficult to differentiate between these structures by vibrational spectroscopy since the 
symmetry of the nitrate ion differs very little among them. Even so, vibrational 
spectroscopy is still useful in distinguishing unidentate and bidentate ligands. It is 
commonly perceived that the unidentate NO3 group exhibits three NO stretching bands, 
as expected for its C2v symmetry.
165
 For example [Ni(en)2(NO3)] (unidentate) shows 
three bands as follows: 
 
ν5 (B2) 1420 cm
-1
 νa (NO2) 
ν1 (A1) 1305 cm
-1
 νs (NO2) 
ν2 (A1) (1008) cm
-1
 ν (NO2) 
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whereas [Ni(en)2(NO3)]ClO4 (chelating bidentate) exhibits three bands at the following: 
 
ν1 (A1) 1476 cm
-1
 ν (N=O) 
ν5 (B2) 1290 cm
-1
 νa (NO2) 
ν2 (A1) (1025) cm
-1
 νs (NO2) 
 
The separation of the two highest frequency bands is 115 cm
-1
 for the unidentate 
complex, whereas it is 186 cm
-1
 for the bidentate complex. 
  
In this study, five nitrato complexes were prepared overall,  three complexes of the L
1
 
series were prepared [Cu(NO3)2(L
1
Pr
n
)], [Zn(NO3)2(L
1
Bu
t
)], [Co(L
1
Cy)2][NO3]2 along 
with one of the L
2
 and L
3
 ligands [Zn(NO3)(H2O)(L
2
PhMe)][NO3], and 
[Zn(NO3)2(L
3
PhMe)] respectively. Unfortunately an interpretable infra-red and raman 
spectrrum of the phenanthroline complex could not be collected for some reason and 
only the raman spectrum of the bipyridine complex was possible. Below are listed the 
observed bands and predicted coordination mode for the nitrato complexes.  
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Table 25. (NO3
-
) infrared and Raman stretching modes observed for complexes of 
Ligand L
1
R and L
2
R.  
Complex 
Mode of 
coordination 
ν5 ν1 ν2 
[Cu(NO3)2(L
1
Pr
n
)] 
Unidentate 
Bidentate 
1412 (IR) 
1486 (IR) 
1313 (IR) 
1289 (IR) 
1011 (IR) 
980 (IR) 
[Co(L
1
Pr
n
)2] [NO3]2 
Non-
cordinated 
- 1381 (IR) 1029 (IR) 
[Zn(NO3)2(L
1
Bu
t
)] Unassigned 1473 (IR) 1314 (IR) - 
[Zn(NO3)(H2O)(L
2
PhMe)][NO3] Unidentate 1424 (R) 1324 (R) 1028 (R) 
 
Both complexes in Table 25 show differences in their infrared spectra. The Cu
II
 
complex showed several bands for NO3
-
. It can be best interpreted that since there are 
more bands than anticipated there must be a mixture of chelating modes or a distinct 
difference in symmetry between the two NO3
-
 ions in the complex. Bands were 
observed at 1412 and 1313cm
-1
 and correspond to ν5 and ν1 of a unidentate chelate 
respectively and bands 1486 and 1289 correspond to ν5 and ν1 of a bidentate chelate 
respectively. The differences in the bands agrees with the numbers in the example above 
proposed for the two chelation types. 
 
The Zinc complex on the other hand appeared much more straight forward and only two 
bands of a chelated NO3
-
 ion were observed. The difference between the two bands (159 
cm
-1
) being somewhere between the numbers for unidentate and bidentate chelates. This 
made the assignment of the coordination difficult and so none could be directly inferred 
from this data alone. But when considering that only one particular type of nitrato 
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ligand is observed, it is highly unlikely that a bidentate mode of coordination is possible 
since it would mean a unidentate or spectator nitrate would be present. These very 
different species would likely give rise to two sets of stretching vibrations in the IR 
spectrum. However it was very interesting to observe by 
1
H NMR spectroscopy, that in 
DMSO-d6 solution at 50°C, this particular complex gave rise to  two particular species, 
which could possibly be a mixture of the unidentate-unidentate nitrato complex and the 
unidentate-bidentate nitrato complex. Otherwise aquation of the metal centre may have 
occurred giving rise to the second spectrum.  
 
The structure of [Co(L
1
Cy)2][NO3]2 was inferred first of all from its CHN analysis 
which identified that a ratio of 2:1:2 for ligand:metal:anion. This strongly suggested a 
bis ligated complex with both NO3
-
 ions as spectators which would require the NO3
-
 as a 
free ion. This was difficult to interpret in the infra-red spectrum since the only bands 
that could be drawn out were ones at 1381 cm
-1
 and 1029 cm
-1
 which do have a similar 
correlation to observed bands for salt like NH4NO3  of 1350 cm
-1
 and 1050 cm
-1
 
corresponding to the ν3 and ν1 N-O of the NO3
-
 ion with C2v symmetry. 
 
For the bipyridine complex [Zn(NO3)(H2O)(L
2
PhMe)][NO3], only the Raman spectrum 
was obtained and sharp bands were observed for the N-O vibrations.  In total three 
bands were observed as shown in Table 25 and these are very consistent with bands of a 
unidentate coordination mode of the nitrate ion, strangely no other bands for nitrate 
were observed and so it was not possible to assign with confidence in this case. 
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4.4.2.2. Acetato complexes 
 
In this study three acetato complexes were prepared, namely [Zn(AcO)2(L
1
Bu
t
)], 
[Co(AcO)2(L
1
Cy)] and [Ni(AcO)2(L
1
Cy)]. The infrared spectra of such complexes was 
consulted to help elucidate the coordination modes of the acetate ion. 
 
The acetate ion may coordinate to a metal in the same fashion as the nitrate ion: 
 
OO
O
O
M
OO
M
Free ion (C2v) Unidentate (Cs) Bidentate (C2v) 
 
Unlike the nitrate ion free acetate and its bidentate chelate have the same symmetry, but 
similarly to the nitrate ion acetate can also form a bridging bidentate chelate. Previous 
research making careful examinations of many acetates having known X-ray crystal 
structures arrived at the following conclusions about the acetate stretching frequencies 
and chelating modes:
165
 
 
1. Unidentate complexes exhibit Δ values [νa(CO2
-
)-νs(CO2
-
)] which are much 
greater than the ionic complexes. 
2. Chelating (bidentate) complexes exhibit Δ values which are significantly less 
than the ionic values. 
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3. The Δ values for bridging complexes are greater than those of chelating 
(bidentate) complexes and close to ionic values. 
 
Table 26 lists some examples of infrared frequencies with chelating mode and their 
corresponding Δ values. 
Table 26. Infra-red stretching frequencies of various acetate complexes. 
165
 
Compound νa(CO2
-
) νs(CO2
-
) Δ Structure 
CH3COO
- 
(AcO
-
) 1578 1414 164 ionic 
Ru(AcO)(CO)2(PPh3) 1613 1315 298 Unidentate 
RuCl(AcO)(CO)(PPh3)2 1507 1465 42 Bidentate 
Ph2Sn(AcO)2 1610 1335 265 Asym. bidentate 
Rh2(AcO)2(CO)3(PPh3) 1580 1440 140 Bridging 
CrO2(AcO)2 
1710 
1610 
1240 
1420 
470 
190 
Unidentate 
Bidentate 
 
Table 27. Observed vibrational frequencies of the acetate anion and the assigned mode 
of coordination for three acetate complexes generated in this study.  
Complex νa(CO2
-
) νs(CO2
-
) Δ Structure 
[Co(AcO)2(L
1
Cy)] 
1703 (IR) 
1591 (IR) 
 
1420 (IR) 
 
171 
Unidentate 
Bidentate 
[Ni(AcO)2(L
1
Cy)] 
1652 (IR) 
1568 (IR) 
1345 (IR) 
1410 (IR) 
307 
158 
Unidentate 
Bidentate 
[Zn(AcO)2(L
1
Bu
t
)] 1616 (IR) 1326 (IR) 290 Unidentate 
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Taking into consideration the criteria for assigning the stretching frequencies of the 
acetate anion, it was possible to tentatively deduce the various binding modes present in 
the three complexes of this study. [Co(AcO)2(L
1
Cy)] provided three distinguishable 
bands for the acetato ligand. One single carbonyl stretch at 1703 cm
-1
 was assigned to 
that of the unidentate chelate based on similar observation for CrO2(AcO)2 as given in 
Table 26. A further two bands at 1591 cm
-1
 and 1420 cm
-1
 assigned to the assymetric 
and symetric stretches of a bidentate acetato chelate was consistent with those 
observations in Table 26 based on Δ. Since no crystal structure of this complex was 
obtained, the structural characterisation of [Co(AcO)2(L
1
Cy)] is based upon the 
vibrational spectroscopic assignements, NMR, MS, and CHN. Since CHN results 
suggest an analytically pure M:L 1:1 complex as suggested, and since it is highly 
unlikely that methathesis to cobalt tetraacetate would occur to give the bis complex, it 
can be reasonably assumed that a distorted octahedral structure is likely containing in 
the coordination sphere three N-donars of the L
1
Cy ligand, two O-donors of a bidentate 
acetate and one O-donar of a unidentate acetate. 
 
The Nickel (II) acetate complex obtained in this study gave infra-red bands consistent 
with that demonstrated by the crystal structure. Clearly two types of acetate were 
ditinguishable from the IR spectrum and gave rise to 4 bands (Table 27) distinguishable 
as a bidentate and unidentate acetate complex. This agrees with the symmetric and 
assymetric acetates identified from the crystal structure (Section 6.3.2) and M-O 
distances were consistent with unidentate and bidentate aceteates.  
 
The complex [Zn(AcO)2(L
1
Bu
t
)], gave rise to two distinguishable bands associated with 
assymetric and symmetric streches of a single aceteate moiety with a Δ value of 290. 
  
146 
This observation indicates only one type of acetate coordination in this complex, and 
from Δ it is most probable that this complex contains two coordinated unidentate 
acetates at the Zn
II
 centre.  
4.4.2.3. Isothiocyanato Complexes 
 
The [SCN]
- 
ions are called pseudohalide ions, since they resemble halide ions in their 
chemical properties. The SCN group may coordinate to a metal through the nitrogen or 
the sulphur or both as shown below: 
 
M-SCN thiocyanato complex 
M-NCS isothiocyanato complex 
M-NCS-M’ 
 
In general, harder metals (first transition series, such as Cr
II
, Mn
II
, Fe
II
, Co
II
, Ni
II
, Cu
II 
and Zn
II
) form M-N bonds, whereas softer metals (second half of the second and third 
series, such as Rh
II
, Pd
II
, Ag
I
, Cd
II
, Ir
II
, Pt
II
, Au
I
 and Hg
I
) form M-S bonds.
165 
However, 
other factors such as the oxidation state of the metal, the nature of other ligands in a 
complex and streric consideration, also influence the mode of coordination. 
 
Several empirical criteria have been developed to determine the bonding type of the 
NCS group in metal complexes.
165
 
 
1. The CN stretching frequencies <2050cm-1 in N-bonded complexes, near 
2100cm
-1
 in S bonded complexes and bridging (M-NCS-M’) exhibit ν(CN) well 
above 2100cm
-1
. 
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2. ν(CS) can be used for structural diagnosis: 860-780 for N-bonded and 720-690 
cm
-1
 for S-bonded complexes. 
 
The single isothiocyanato complex of this project was finally determined by single 
crystal X-ray diffraction (section 6.3.4), but it was initially anticipated that the 
monoligated complex with two isothiacyanato anions coordinated would have been the 
structure obtained as shown below. 
 
N
NN
M
N N
CyCy
S S  
 
After analysis of the isolated product by CHN gave a formula ML(NCS)2 and ESI-MS 
in positive mode identified the above molecular ion, it was anticipated that the structure 
was indeed that of the desired molecule. However the raman and infra-red spectra 
(Figure 38 and Figure 39 respectively), of the complex confused things slightly when a 
single ν(CN) band at 2064 cm-1 in the infra red spectrum was observed but two bands at 
2094 and 2067cm
-1
 were observed in the raman spectrum. The indication from the two 
bands was that two modes of coordination were present for the [NCS]
-
 ion, one being 
silent in the infra-red spectrum.  
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Figure 38. IR Spectrum of [Co(L
1
Cy)2][Co(NCS)]4 
 
Figure 39. Raman Spectrum of [Co(L
1
Cy)2][Co(NCS)]4, * denotes an artifact of the 
instrument laser line. 
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When comparing the raman stretching frequencies to the criteria outlined above it could 
be inferred that the stretch at 2094 cm
-1
 could be that of an S bound ligand and the 
stretch at 2067 cm
-1
 that of an N bound ligand. On the other hand infra-red spectra alone 
could have given rise to the assignment that only the N coordinated NCS
-
 ion is present. 
This observation was a difficult one to interpret and even when the crystal stucture of 
the complex was obtained it was still difficult to understand what was really happening 
in the raman spectrum. The crystal structure actually identified that the desired complex 
had not been prepared and instead a bis-ligated complex with a [Co(NCS)4]
2-
 counterion 
was obtained. The IR spectrum did indeed identify correctly that only N coordination 
was present at the coordination sphere, which also goes with a prediction based on the 
hardness of the Co and N atoms. The [Co(NCS)4]
2-
 complex was identified as 
tetrahedral with very slight distortion in the crystal structure. However the vibrational 
modes of the molecule that arise from stretching motions of the CN groups are the four 
combinations of the four CN displacement vectors. Reference to SALC’s of the Td point 
group identified that four atomic s orbitals give one A1 SALC and three T2 SALC’s. 
The analogous linear combinations of the CN displacements are depicted in Figure 40.   
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Figure 40. The CN stretching modes of [Co(NCS)4]
2-
. The A1 mode is non-degenerate; 
the T2 modes are triply degenerate. 



 


 
 
After consulting the character table for the Td point group it became apparant that the 
combination labelled A1 transforms like x
2
 + y
2
 + z
2
 indicating that it will be Raman 
active but not IR active. In contrast, x, y and z and the products xy, yx and zx transform 
as T2, so the T2 modes are both Raman and infrared active. Consequently the tetrahedral 
[Co(NCS)4]
2-
, fits nicely to the Raman and IR spectra and shows how by combining 
both techniques molecular symmerty can be inferred. One thing that does not quite fit 
from this explanation is why the assymetric vibration observed in both the Raman and 
IR spectra comes at lower frequency to the symmetric vibration. 
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5. Solution Studies of Metal Complexes 
 
5.1. Magnetic Susceptibility in Solution by NMR 
 
All complexes prepared in this study are paramagnetic, with the exception of the zinc 
complexes which do not have partially filled d-orbitals and are essentially therefore non 
transition metals. The magnetic moments of cobalt, copper and nickel complexes were 
determined by the Evans NMR method.
123
 The Co
II
 complexes afford magnetic 
moments between 4.2 and 5 μB, which suggests a high spin configuration of three 
unpaired electrons, the values are somewhat larger than the spin only value of 3.87 μB, 
but within the observed values for the Co
II
 centre, (4.3 – 5.2 μobs).
156, 166
 It has been 
generalized that departure from the spin-only magnetic moments is large for high spin 
d
7
 complexes.
166
 For Co
II
, altering the Schiff base ligand tail groups does not affect the 
high spin configuration of the metal centre, but the change in the total magnetic moment 
is evident due to orbital contributions, though no correlation can be drawn out. 
 
Assuming the Co
II
 complexes in solution form distorted trigonal bipyramidal or 
distorted square based pyramidal geometry, the frontier orbital energies have been 
proposed to be as shown in Figure 41. 
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Figure 41. The energy level diagrams of trigonal bipyramidal and square based 
pyramidal structures along with the high and low spin configurations of Co
II
.
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From the energy level diagrams predicted in Figure 41 it seems likely that Co
II
 
complexes are more likely to take on a trigonal bipyramidal geometry based on the 
observed magnetic moment, however it is not known what effects the ligands have on 
the splitting of the orbital energies, it is likely there could be some splitting between  dxz 
and dyz orbitals and the higher orbitals could actually be relatively close in energy. Since 
the magnetic susceptibilities were determined in solution, it is very likely that the 
geometry at the metal centre is dynamic, and the geometry could be constantly changing 
from square-pyramidal to trigonal-bipyramidal. In that case based on the model in 
Figure 41, a mixed magnetic moment between 1 and 3 unpaired electrons would likely 
arise, due to this dynamic process. Since this is not observed it does suggest that the 
energy levels dxy, dz
2
, dx
2
-dy
2
 are of similar energy and three lone electrons are free to 
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occupy the three orbitals. It is later observed in the crystal structure of [CoCl2(L
1
Ph)] 
that distorted trigonal bipyramidal geometry is evident in monoligated Co
II
 complexes. 
 
The copper complexes examined exhibited the expected magnetic moment for the +2 
oxidation state of 1.73 μB. Because Cu
II
 a d
9
 transition metal ion contains one unpaired 
electron and no high spin or low spin configurations are possible in any crystal field 
since its lone electron cannot be paired under any circumstance. Nevertheless the 
observation of a magnetic moment is further proof of a Cu
II
 oxidation state since Cu
I
 is 
diamagnetic. 
 
The Ni
II
 complexes typically exhibited magnetic moments between 3.15-3.43 μB which 
is consistent with that of the high spin Ni
II
 centre. The magnetic moment is slightly 
larger than that of the spin only value (2.83 μB) so orbital contributions must play a part 
in the total magnetic moment observed. It is clear that no low spin complexes form 
since in all cases there is a magnetic moment observed. In low spin Ni
II
 all 8 electrons 
are paired and hence no magnetic moment is possible. In a pure octahedral field (i.e. all 
ligands identical) it would only be possible for Ni
II
 to be high spin since the lower t2g 
energy levels would be forced to fill and the higher energy, doubly degenerate eg 
orbitals would each receive an unpaired electron. For the Ni
II 
complexes of this series 
however is it not possible that a pure octahedral splitting of the energy levels would 
occur and since each orbital would receive a different combination of ligands it’s likely 
there would be no degeneracy (Figure 42). In this model it is possible for Ni
II
 to be 
either high or low spin and so in the case of the ligands of this study, it is clear they 
lower the energy of the highest orbital or the two highest energy orbitals are 
approximately of similar energy, making it possible for two electrons to occupy their 
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own orbitals. The latter case is more likely true since imine ligands are π acceptors and 
would come high up in the spectrochemical series. The higher a ligand is in the 
spectrochemical series the the greater stabilization effect it will have on the ligand field 
splitting, so it is likely that it does not separate dz
2
 from dx
2
-y
2
 by too much.  
 
Figure 42. Proposed orbital spliting from pure octahedral to non-degeneracy in a non-
pure octahedral system. Relative orbital energies would vary depending on which 
combinations of ligand occupy or lie between them. 
d
x2-y2
, d
z2
d
xz
, d
yz
d
xy
d
x2-y2
d
xy
d
z2
d
xz
x
z
y
MN
N
N
Cl
Cl
Cl
E
N
E
R
G
Y
MX
X
X
X
X
X
d
yz
 
 
Evidently from the observed magnetic moments for Co
II
 and Ni
II
 complexes of the L
1
R 
ligand class, and by subsequently changing the anionic ligand in the monoligated 
complexes through the series placed roughly in the order of the spectrochemical 
series:
168
 
 
Cl
-
<Br
-
<H2O<AcO
-
<iNCS
-
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It is pretty clear that none of the ligands have any observed impact on the ligand field 
stabilization energy within the complex.  
 
5.2. NMR Studies 
 
NMR data was obtained for almost all complexes and ligands. Not all complexes could 
be studied due to lack of solubility or in the case of copper complexes with aromatic tail 
groups, no resonances could be detected by the NMR instrument, attributed to the rapid 
relaxation of the proton spin as a consequence of the paramagnetic copper centre, giving 
Heisenberg broadening of the isotropically shifted resonances.
169
 It was observed 
however after evaluating some copper
II
 complexes that if the tail groups were alkyl, 
then the resonances for those protons were observed and in some cases fine structure 
could be observed for those peaks. Also they didn’t appear to be isotropically shifted 
peaks since they were observed in the correct regions of the spectrum as for equivalent 
free ligand protons. Possibly due to the lack of aromaticity and conjugation in alkyl tail 
groups the electron spin of the copper couples weakly if not at all with the spin of the 
proton and normal resonances are observed as expected for diamagnetic compounds. All 
proton spectra were obtained in D2O for the copper complexes, most complexes were 
readily soluble and the spectra revealed in all cases the intact ligand was still present 
and its symmetry was retained. The fact that the pyridyl and aldimine shifts were barely 
observable due to Heisenberg broading is a good indicator that the ligand remains co-
ordinated to the copper in solution. D2O solubility indicates the complexes are ionic in 
nature. The bis-ligated complex gives rise to significantly broadened tail group 
resonances and all mono ligated complexes give rise to normal diamagnetic proton 
resonances indicating the monoligated complexes do not metathesise to the bis-complex 
during the experiments. 
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For cobalt complexes which are also paramagnetic, isotropically shifted resonances are 
observed which appear as broad singlets. These signals can be assigned on the basis of 
peak areas, proximity to the metal centre and comparison with spectra of similar 
paramagnetic structures; although not in all cases and 2D correlation techniques 
therefore need to be employed if obtainable.  
 
The following complexes [CoCl2(L
1
Ph)], [CoCl2(L
1
Bu
i
)] and [CoCl2(L
1
Cy)] are given 
here as examples of how the solution structures of paramagnetic complexes could be 
inferred from NMR spectroscopy. 
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5.2.1. 1H NMR Assignment of Complex [CoCl2(L
1
Ph)] 
 
Figure 43 Proton NMR Spectrum of [CoCl2(L
1
Ph)] obtained in D2O. 
 
 
The spectrum of  [CoCl2(L
1
Ph)] shown here in Figure 43 afforded six peaks, two of 
which integrated to four protons, three to two protons and one peak to one proton, as 
expected for the compound with 2-fold symmetry. Initially the first peak was assigned 
on the basis of integration, which was the peak at 26.28 ppm and integrates to 1H, 
therefore must be that of the p-pyridyl proton (H
4
). The downfield peaks at 165.63 and 
47.70 ppm which both integrate to 2H, are assigned to the aldimine protons (H
2’/6’
) and 
the m-pyridyl protons (H
3/5
), respectively, on the basis of their close proximity to the 
metal centre and comparison to similar lanthanide bis-(imino)pyridine complexes.
170
 
The next peak to be assigned, on the basis of integration was at -0.13 ppm which 
integrates to 2H and must be that of the p-phenyl proton. The remaining two peaks at 
12.33 and -15.30 could then be assigned to meta, (H
c
) and ortho, (H
b
), phenyl protons 
respectively, on the basis of comparison to similar iron bis(imino)pyridine 
complexes.
171
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5.2.2. 1H NMR Assignment of Complex [CoCl2(L
1
Bu
i
)]  
 
[CoCl2(L
1
Bu
i
)] reveals an NMR spectrum consisting of six peaks, one peak integrating 
to twelve protons, one peak integrating to four protons, three peaks integrating to two 
protons and one peak integrating to one proton as expected for the complex with 2-fold 
symmetry. Initially it is obvious that the peaks at 42.60 ppm, integrating to 1H, 148.81 
ppm integrating to 4H and -3.90 ppm integrating to 12H can be assigned to protons H
4
, 
H
a
 and H
c
, respectively on the basis of integration.  The peak at 221.18 ppm integrating 
to 2H can be assigned to the aldimine protons (H
2’/6’
), on the basis of proximity to the 
metal centre. The remaining m-pyridyl protons (H
3/4
) can be assigned to the peak at 
103.15 ppm integrating to 2H on the basis of comparison to other similar lanthanide 
bis(imino)pyridine complexes.
172
 Therefore the last remaining peak at 0.68 ppm 
integrating to 2H is assigned to H
b
.   
5.2.3. 1H NMR Assignment of Complex [CoCl2(L
1
Cy)] 
 
The complex [CoCl2(L
1
Cy)], gave rise to 10 isotropically shifted broad singlets in the 
1
H NMR spectrum, four of which integrated to four protons, five to two protons and one 
to one proton, as expected for the 2-fold symmetric compound. Again the obvious 
starting point was to assign the lone p-pyridyl proton to the lone peak integrating to 1H 
at 24.89 ppm. The broader downfield peaks at 168.01 and 121.84 ppm, both arising 
from 2H can be assigned, to the aldimine (H
2’/6’
) and cyclohexyl (H
a
), respectively. 
Noticeably these two protons appear downfield due to connections to the N atom 
through two bonds and the broadness of the peaks is a result of a greater coupling to the 
unpaired electron spins of cobalt consequently increasing the speed of relaxation of the 
proton nuclear spin. The remaining m-pyridyl proton, (H
3/5
), was next assigned to the 
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peak at 50.21 ppm, integrating to 2H, on the basis of comparison to similar lanthanide 
bis(imino)pyridine paramagnetic complexes,
172
 again it is noticeable from this and the 
previous spectrum of [CoCl2(L
1
Ph)], that the pyridyl resonances appear further 
downfield than for the tail group resonances, whether aromatic or not. This is possibly a 
consequence of the metal centre having greater electronic influence through the -
electrons of the C=N. The remaining six peaks are therefore those of the remaining 
cyclohexyl, protons. The reason six peaks are observed and not three, is due to the fact 
that the protons on the same carbon atom are magnetically inequivalent. The first two of 
these remaining six peaks at 0.13 and -0.20 ppm, integrating to 2H each, can be 
assigned to both the d and d’ protons. It is not possible to assign the remaining four 
peaks from the 
1
H spectrum by either 1D or 2D techniques. 
5.2.4. CoII Solution Chemistry 
 
As it can be seen from Table 28, the pyridyl and aldimine proton shifts are very much 
similar for ligands (L
1
Cy) and (L
1
Ph), varying by 1-2 ppm for each proton, indicating 
the aromaticity of the tail group in (L
1
Ph) has little or no electronic effects on the head 
group. Table 28 lists the pyridyl and aldimine proton shifts of all Co
II
 complexes 
obtained. There is a clear difference in shift for complexes obtained in D2O as opposed 
to CD3OD. Spectra obtained in CD3OD have shifts over 50 ppm downfield than those 
obtained in D2O for the aldimine and m-pyridyl protons. This solvent effect is more than 
likely due to solvolysis at the metal centre, or at least hydrolysis is certainly likely to be 
occurring in D2O. In CD3OD there is the possibility that the original anionic ligands are 
retained and the spectrum observed is that of the original complex. The fact that the 
complexes are soluble in D2O is a good indicator that the chloride ligand dissociates. 
Conductivity measurements would have been ideal in this instance to identify whether 
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the solvolysis gives the 1:1 or 1:2 electrolytes [CoX(Sol)(L
1
Cy)]
+ 
X
-
 and 
[Co(Sol)2(L
1
Cy)]
2+
 2X
- 
respectively, in either case 2-fold symmetry is retained.  
 
After obtaining the proton spectrum from Ca. 5 mins after sample preparation and 
monitoring after leaving the sample at ambient lab temperature for several minutes, 
hours and days no significant change occurred indicating the solvolysis process is fast 
and complete at time of mixing, the same was also observed in CD3OD.  
 
A further possibility is that the complexes could have undergone metathesis to the 2:1 
complexes forming [Co(L
1
R)2][CoX4]
2-
 species and hence why almost identical shifts 
are observed for the ligands. But after inspection of the D2O solvated ligand shifts, it is 
apparent that the only significant shift difference between complexes was between the 
bis complex [Co(L
1
Cy)2][BF4]2 when all its analogues [CoX2(L
1
Cy)] (all obtained in 
D2O), had identical shifts. This indeed indicates that the mono ligated complex is still 
present for those complexes of ligands with greater co-ordinating power. 
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Table 28. Pyridyl and aldimine proton shifts (in ppm) for various Co
II
 complexes of 
ligand L
1
. Proton NMR obtained in, a CD3OD, b D2O.  
N
N N
RR
H
4
H
3
H
5
H
2'
H
6'
 
Complex H
2’/6’
 H
3/5
 H
4
 
[CoCl2(L
1
Pr
n
)]
a 
220 105 43 
[CoCl2(L
1
Pr
i
)]
a 
203 98 41 
[CoCl2(L
1
Bu
n
)]
a 
198 93 41 
[CoCl2(L
1
Bu
2
)]
a 
221 103 43 
[CoCl2(L
1
Bu
i
)]
a 
222 103 43 
[CoCl2(L
1
Bu
t
)]
a 
221 103 42 
[CoCl2(L
1
Cy)]
b
 168 50 25 
[CoBr2(L
1
Cy)]
b 
168 50 25 
[Co(AcO)2(L
1
Cy)]
 
168 50 26 
[Co(L
1
Cy)2][BF4]2
b 
172 54 26 
[CoCl2(L
1
Ph)]
b 
166 48 26 
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5.2.5. NMR Spectra of Zinc Complexes of Bipyridine L2 and 
Phenanthroline L
3
 
 
NMR spectra of both Bipyridine and Phenanthroline ligands show 2-fold symmetry of 
the ligand and this is also carried forward into the complexed ligand, which suggests 
that the ligand is acting in a tetradentate fashion (Typical spectrum of ligand given in 
Figure 44).  
 
Figure 44. Proton NMR spectrum of [ZnCl
2
(L
3
PhMe)] obtained in (CD3)2SO at 60°C. 
 
 
This however is contradicted by the single crystal data, where these complexes exhibit 
tridentate co-ordination in the solid state (exception of [Zn(NO3)(H2O)(L
2
PhMe)][NO3] 
where tetradentate is observed). It is suggested however that in solution these 
complexes are actually tridentate and a fluxional process between the two Schiff base 
co-ordinating sites is actually occurring, whereby the co-ordinating sites are exchanging 
and the rate of this exchange is too fast to be observed on the NMR timescale. More 
exactly, for separate resonances to be observed corresponding to the two sites in 
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equilibrium, the rate of exchange between sites must be less than 2, where  is the 
difference between resonances of exchanging sites.   
 
Variable temperature experiments were carried out to identify if this was indeed the 
case and to determine the Gibbs free energy of activation for the exchange. Proton 
NMR spectra of the complex [ZnCl2(L
3
PhMe)] made to dissolve to ~ 1mg ml
-1 
in a 
mixed deuterated solvent system of CD3CN:CD3OD:(CD3)2CO of 3:2:1 were thus 
collected. Spectra were obtained from 25°C where 2-fold symmetry and fine structure 
was observed and spectra were collected every 10°C increment to -65°. Strangely no 
coalescence was observed and slight peak broadening at lower temperatures was 
attributed to increasing viscosity of the solution. It is difficult to understand what is 
exactly happening in the system for no coalescence to occur at -65°C, the possibility 
that the energy barrier to interconversion is so low is difficult to believe when similar 
fluxional processes where slow exchange can be resolved at temperatures as high as -
10°C have been demonstrated for terpyridine complexes of Pt
II
 and Ru
II
.
173
 Whether in 
the particular solution under study a symmetrical coordination mode was at play is a 
possibility since the crystals for the tridentate crystal structure were obtained by 
recrystalisation from DMF. It is possible therefore that acetonitrile may compete with 
the imine N-donors of the ligand as shown in Figure 45 below. 
 
Figure 45. Competition between solvent and imine donors for coordination sites. 
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6. X-Ray Structural Studies of Metal Complexes 
 
This section details the experimental description of the X-ray structure determination 
carried out for this study. Overall 35 crystal structures from this study were obtained, 
however it is beyond the scope of this thesis to list and report on every structure 
determined, instead an example of how the crystal structure of [Cu(NO3)2(L
1
Pr
n
)] was 
solved and refined is given followed by structure reports on a selection of the most 
interesting compounds. Details of data collection and refinement parameters for 
structures reported are given in following tables. Structure solution and refinement were 
performed using the SHELX-97
174
 suite of programmes operating with WinGX.
175
 All 
diagrams were generated using Mercury viewer. 
176
 
 
6.1. Data Collection 
 
X-ray data collection was carried out by standard methods for all compounds reported. 
Intensity measurements were collected on either a Stoe STADI-4 four circle 
diffractometer with single point detector or a Bruker Apex X8 with area detection using 
the Bruker smart software package.
177
 A crystal with maximum dimensions of  0.5 mm 
was selected and attached to a quartz fibre with epoxy resin or for air sensitive 
compounds the crystals were mounted under  oil and frozen solid under a stream of 
nitrogen at -170°C. The crystal was then mounted in the goniometer head of the 
diffractometer and centred. After the crystal had been centred the four circles were 
incrementally driven by the computer until 15 reflections [I >3σ(I)] were detected.   
From the position of these reflections, unit cell geometry and orientation with respect to 
the diffractometer geometry was determined by computer software. The resulting UB-
matrix gives four angles required to orient the crystal in the position necessary to 
  
165 
measure reflections from a particular set of planes (hkl) in the crystal. For each hkl the ω 
and 2θ circles synchronously scanned the diffracted beam with a suitable scan width 
(typically 1°) and the total counts, It, for the scan were recorded together with 
background counts at the beginning and end of the scan. To refine the matrix (and cell 
parameters) a set of reflections were selected that were well separated in reciprocal 
space (typically with high indices in h, k, l, h+k, h+l or k+l) and their Laue symmetry 
equivalents added. The resulting set of reflections was centred to determine the precise 
orientation matrix (and unit cell). Prior to data collection, reference reflections in the θ-
range 3-5° were chosen, typically 3 with high indices in h,k or l and then data collection 
was started. After data collection a precise determination of the unit cell was obtained 
from recording the set of high angle reflections at ±θ and where appropriate a set of 
reflections for χ-scan were collected (generally χ close to 90°). 
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Figure 46. Flow diagram showing a typical experiment in determining a crystal 
structure. 
Select suitable crystal and mount 
on goniometer head 
 
Centre crystal optically 
 
Search for and centre reflections 
 
Autoindex reflections 
 
Calculate least-squares unit cell 
and reduced primitive cell 
 
Add high angle centred reflections 
 
Determine precise unit cell and 
Bravais lattice 
 
Verify Laue symmetry 
 
Collect data 
 
Collect psi scan data 
 
Reduce data, determine space group 
 
Solve and refine structure 
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6.2. Structure Solution and Refinement for [Cu(NO3)2(L
1
Pr
n
)] 
 
Single turquoise/green crystals of [Cu(NO3)2(L
1
Pr
n
)] were grown by slow vapour 
diffusion of diethyl ether into a saturated acetonitrile solution of the named compound. 
The crystals were mounted on a glass fibre and X-ray intensity data was collected on a 
Bruker apex X8 diffractometer using graphite monochromated Mo-Kα radiation at 
273K. Preliminary inspection of the data set established no intensity relationship other 
than, Ihkl ≡ I-h-k-l, indicating a triclinic crystal system and the assignement is consistent 
with the unit cell dimension α ≠ β ≠ γ and  a ≠ b ≠ c. 
 
The density calculation indicated a density of 1.50 g cm
-3
 for four molecules in the unit 
cell using the proposed formula and hence the space group was assigned P-1 in the 
subsequent analysis. Data was corrected for absorption using a semi-empirical method 
based on χ2. 
 
The structure was solved using Patterson syntheses and the resulting fourier map gave 
rise to two copper atoms in the asu, along with 6 O atoms automatically labelled by the 
software. 
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Figure 47. Initial fourier map from Patterson syntheses of diffraction data with two 
independant Cu complexes apparent and N atoms modelled in the asu. 
 
 
Since it was plausible that the software had incorrectly assigned the O atoms, these were 
remodelled as nitrogen atoms since it looked like they could have been the N donor set 
of the terdentate ligands. This new model (Figure 47) was used to generate the 
difference fourier synthesis of the data (Figure 48), giving rise to a calculation of a 
difference fourier map R1 of 0.3583. Clearly from the resulting fourrier map the 
appearance of new Q peaks identified that some of the N atoms labelled in the previous 
model were indeed wrong and one in each independant molecule were relabelled as O 
atoms of co-ordinated nitrato ligands (Figure 49).  
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Figure 48. Fourier map after 1
st
 refinement of diffraction data identifying incorrect 
assignment of two N atoms and revealing further atoms. 
 
 
 
 
 
 
 
 
 
 
  
170 
Figure 49. Model generated after 1
st
 refinement cycle with partial assignment of nitrato 
and pyridyl head groups. 
 
 
Other non hydrogen atoms identifyable as parts of the nitrato moeity and L
1
Pr
n
 ligand 
were added to the new model and again a difference fourier synthesis was generated 
(Figure 50) and R1 reduced to 0.2406. In the resulting map the remainder of the non-
hydrogen atoms of the pyridyl ligand head group were identified along with the 
remainder of the nitrato ligand atoms. Some carbon atoms of the tail groups could also 
be observed and were subsequenctly modelled. 
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Figure 50. Fourier map after 2
nd 
refinement of diffraction data identifying remainder of 
nitrato ligands and pyridyl head groups. 
 
 
In the difference fourrier synthesis of the model, R1 reduced further to 0.1339 and the 
remainder of non-hydrogen atoms of the ligand tail groups were identifyable and 
subsequently modelled. The largest peaks that remained (>1 eÅ
-3
) were centred very 
close to the Cu atoms, these were subsequently identified as diffraction ripples and 
ignored (Figure 51). 
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Figure 51. Fourier map after 3
rd
 refinement of diffraction data identifying remainder of 
tail groups and Q peaks located next to the metal centre due to diffraction ripples . 
 
 
The resulting e-map gave R1 to be 0.0966. All non-hydrogen atoms were further refined 
by setting anisotropic displacement parameters and a weighting scheme w
-1
 = σ2Fo
2
 + 
(0.0488 P)
2
 + 0.000 P where P = [(max Fo
2
, 0) + 2Fc
2
)/3 was applied. A further least 
squares cycle gave R1 to be 0.0467. In the subsequent e-map all hydrogen atoms of the 
ligand were fixed in idealised positions, riding on the position of the parent carbon. 
Isotropic displacement parameters for all but methyl hydrogens were fixed as 1.2 Ueq of 
the parent carbon atom, Uiso for methyl hydrogens was 1.5 Ueq after a final least squares 
cycle refinement converged at R1 0.0361 [I ≥ 3σ(I)] and wR
2
 = 0.1007 (all data), mean 
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Δ/σ = 0.0000, max Δ/σ = 0.0000. The final map contained no features above 1 eÅ-3. The 
final model is given in Figure 52. 
 
Figure 52. Final fourier map after final least squares cycle with Q peaks omitted. 
 
 
6.3. Structural Descriptions and Comparisons 
6.3.1. CuII Complexes of L1R 
 
In all 10 crystal structures of copper(II)diacido complexes were solved in this study of 
them 5 of the structures are reported. Details of data collection and refinement 
parameters for structures reported are given in Table 29. On initial inspection of 
complexes of [MX2(L
1
Pr
n
)] it is clear that both halide complexes are isomorphous both 
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crystallising in the monclinic crystal system with similar unit cell dimensions and the 
same space group C2/c. The nitrato complex crystallised in a triclinic-P lattice. The 
complexes [CuCl2(L
1
PhMe)] and [CuCl2(L
1
PhCl)] are essentially isomorphous, both 
crystalise orthorhombic Fdd2 space group with very similar unit cell dimensions.  
 
All five copper complexes show a 5-coordinate geometry about the metal centre with all 
of the nitrogen donors of the the L
1
R ligands binding in a terdentate mode. The overall 
molecular symmetry of the complexes appears to depend on the nature of the ‘tail’ 
groups: all complexes with alkyl tail groups show molecular Cs symmetry whereas 
those with aromatic tails show two-fold symmetry around an axis incorporating metal, 
pyridyl nitrogen and the -CH unit of the pyridyl ring and hence are assigned to the C2 
point group (Figure 53).  
 
Figure 53. The molecular symmetry of [CuX2(L
1
R)] complexes: (a) the Cs symmetry of 
the alkyl-substituted ligands illustrated with [CuCl2(L
1
Pr
n
]; (b) the C2 symmetry of the 
aryl-substituted ligands illustrated with [CuCl2(L
1
PhCl)]. 
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Table 29. X-ray structure and refinement parameters for complexes of [CuX2(L
1
R)] 
Compound [CuCl2(L
1
Pr
n
)] [CuBr2(L
1
Pr
n
)] [Cu(NO3)2(L
1
Pr
n
)] [CuCl2(L
1
PhMe)] [CuCl2(L
1
PhCl)] 
Chemical Formula C13H19Cl2CuN3 C13H19Br2CuN3 C13H19CuN5O6 C21H19Cl2CuN3 C19H13Cl4CuN3 
Formula Weight 351.75 440.67 404.87 447.83 488.66 
Crystal System Monoclinic Monoclinic Triclinic Orthorhomic Orthorhomic 
Space Group C2/c C2/c P-1 Fdd2 Fdd2 
a / Å 17.405 (4) 17.8714 (3) 9.1643 (7) 11.6251 (17) 11.811 (2) 
b / Å 12.839 (3) 12.9305 (2) 14.3273 (10) 35.662 (5) 35.080 (6) 
c / Å 14.900 (3) 15.0986 (2) 14.6679 (11) 9.3523 (12) 9.3386 (15) 
α / ° 90 90 109.090 (4) 90 90 
β / ° 110.11 (3) 110.3380 (10) 92.799 (4) 90 90 
γ / ° 90 90 98.544 (4) 90 90 
V / Å
3
 3126.6 (11) 3271.56 (9) 1790.0 (2) 3877.2 (9) 3869.4 (12) 
T / K 293 (2) 273 (2) 273 (2) 273 (2) 273 (2) 
Z 8 8 4 8 8 
S 0.98 0.94 0.83 1.08 0.91 
No. unique data 
(Rint) 
2744 7217 12259 5717 5010 
No. measured 
reflections 
3381 31117 63213 32142 39665 
Robs/wR(F
2
)obs 0.031/0.073 0.055/0.130 0.035/0.087 0.049/0.110 0.054/0.136 
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For the nitrato complex, two crystallographically independent molecules (shown as a 
and b in Table 29 and diagramatically in Figure 54 form the asymmetric unit.  Each 
copper centre is coordinated to the Schiff-base ligand in an endodentate N3 mode with 
the coordination sphere completed by monodentate and pseudo-bidentate nitrato 
ligands. The two complexes differ by the relative arrangements of the nitrato ligands 
with respect to the ligand ‘tails’. The tails are aligned on one side of the N3 plane of the 
ligand and the coordinated nitrates on this side of the complex occupy a ‘cleft’ formed 
by the alky chains. In one complex this cleft is occupied by a pseudo-bidentate nitrate 
(labelled molecule, a), in the second, by a monodentate nitrate (b). 
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Figure 54. (a) Asymmetric unit of [Cu(NO3)2(L
1
Pr
n
)] showing the structure of two 
independent molecules (hydrogen atoms omitted for clarity). (b) Comparison of the 
structures of the two molecules in the asymmetic unit (a left; b right). 
(a)                                                           (b) 
 
 
 
 
 
 
 
 
 
As might be expected, these two arrangements influence the dimensions of the metal 
coordination spheres. Metal-oxygen interactions in the pseudo-bidentate nitrates are 
highly asymmetric and the longer M-O distances are in excess of 2.5 Å. Therefore 
geometry about the Cu
II
 centre for both independant molecules can be best described as 
distorted square pyramidal with oxygens of the monodentate nitrates [X(1) ≡ O(1) and 
O(11)] occupying the apical positions. The distortion to the square-pyramidal geometry 
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is illustrated by angles N(1)-Cu-X(1) of 103.84(6) and 102.62(7) compared to 90° for 
ideal square based pyramid. The interplay between the regular 5-coordinate geometries 
can be evaluated with the τ-parameter introduced by Reedijk and co-workers.178 In this 
context, the parameter is given by τ = (β – α)/60 [α = smallest angle between N(2)-Cu-
N(3) and N(1)-Cu-X(2) and β = largest angle between N(2)-Cu-N(3) and N(1)-Cu-
X(2)]. This gives the values 0.24 and 0.16 for the independent molecules, a and b 
respectively. Since τ is a parameter used as an index of the degree of trigonality,178 these 
values support a square pyramidal geometry (τ close to zero) and are in agreement with 
a structure closer to the perfect square pyramidal (τ = zero) than trigonal bipyramidal (τ 
= 1). Clearly there is a large difference in τ between the two independent molecules in 
the asymmetric unit, which can also be further demonstrated by comparing the X(1)-Cu-
X(2) bond angles. These show a relatively large difference: 85.00(6) vs. 90.14(6)° for a 
and b respectively.  The equatorial positions of the complex are occupied by the three 
nitrogen donors of the ligand and X(2) ≡ O(4) and O(14) with N(1)-Cu-X(2) angles of 
171.00 (6) and 167.05 (6)° for a and b respectively (180° for an ideal square pyramidal 
basal plane). The Cu-X bonds are noticably asymmetric with that to the apical bond 
being significantly longer [av 2.2266 (15) Å] than that to its basal counterpart [av 
1.9496 (14) Å]. 
 
It could be argued also that the complex is in fact distorted octahedral with the 
equatorialy bound nitrato group offering a bidentate geometry and a second donor in an 
axial position with an average distance [av Cu-X(3) = 2.630 Å], (X(3) ≡ O(6) and 
O(16)). In this context,  this asymmetry may be influenced by Jahn-Teller effects at the 
d
9
 Cu
II
 centre.
167
 Similar observations with regard to distorted octahedral M(NO3)2 
complexes have been repoted where highly asymmetrical nitrato co-ordination for the 
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Cu
II
 species have been made in the series of related trispyridine and 2,6-bis[1-
(phenylimino)ethyl]pyridine, L, complexes [(py)3M(NO3)2] and [M(NO3)2L] where (M 
= Co
II
, Cu
II
 and Zn
II
, 
179
 Ni
II
 and Cd
II
,
180
 ) given in Table 30.   
 
Table 30. Metal(II)–nitrato bidentate co-ordination in [M(NO3)2L] and [(py)3M(NO3)2] 
complexes and [Cu(NO3)2(L
1
Pr
n] for comparison. Δ = difference in M-O distance. 
 
Metal Complex M-O(eq) (Å) M-O(ax) (Å) Δ (Å) 
[(Py)3Cd(NO3)2] 2.444 (9) 2.491 (10) 0.047 
[Ni(NO3)2L] 2.070 (4) 2.138 (5) 0.068 
[(Py)3Co(NO3)2] 2.207 (9) 2.311 (9) 0.104 
[(Py)3Zn(NO3)2] 2.232 (13) 2.418 (12) 0.186 
[Cu(NO3)2L] 1.968 (3) 2.533 (5) 0.565 
[(Py)3Cu(NO3)2] 2.154 (7) 2.732 (9) 0.578 
[Cu(NO3)2(L
1
Pr
n
] 1.9496 (14) 2.630 0.680 
 
The structural identification of multiple bonding modes for the nitrato-ligands is 
consistent with the bulk sample analysis with infra-red spectroscopy which was also 
consistent with unidentate and bidentate co-ordination. Further support for the 
assignment of the apical nitrato anion as unidentate comes from close inspection of N-O 
bond lengths (Table 31). In ‘pure’ unidentatate coordination a local C2 rotational axis 
exists through the nitrato N(4)-O(1) bond (Figure 55). In the complex, the N-O(1) bond 
length is substantially longer than either N(4)-O(2) and N(4)-O(3). Importantly, the 
distances N(4)-O(2) and N(4)-O(3) are nearly identical (within error), consistent with 
delocalisation of the double bond about these two bonds. Clearly more single bond 
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character is inferred at the bond N(4)-O(1) . These observations are mirrored in the 
second complex in the asymmetric unit. 
 
Table 31. Nitrogen-oxygen bond lengths in the nitrato ligands of [Cu(NO3)2(L
1
Pr
n
)] 
N4-O1  1.262(2)  N5-O4  1.294(2) 
N4-O2  1.214(2)   N5-O5  1.219(2) 
N4-O3  1.229(2)   N5-O6  1.234(2) 
N14-O11 1.260(2)  N15-O14 1.300(2) 
N14-O12 1.207(2)  N15-O15 1.216(2) 
N14-O13 1.215(3)  N15-O16 1.239(2) 
 
Figure 55. Geometrical parameters about the equatorial ligated nitrato ligand. 
 
 
The complexes [CuCl2(L
1
Pr
n
)] and [CuBr2(L
1
Pr
n
)] are essentially isostrutural apart from 
subtle differences in metal co-ordination geometries. The bond lengths and angles for 
the co-ordination sphere and other bonds are listed in Table 44 and Table 45 (see 
Appendix 11.2). The only significant differences lie in the M-X bonds and angles 
M
O
14
N
O
15O16
124.31°
118.37°117.31°
1.239 A 1.216 A
1.300 A
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involving the halogen atoms. The difference in radius of the two halogens results in 
significantly different metal halogen bonds. In each structure (Figure 56), the metal 
geometry can be best described as intermediate between distorted square based 
pyramidal and trigonal bipyramidal. This is confirmed by τ-values178 of 0.33 and 0.41 
for the chloro and bromo complex respectively. If considering the structure to be 
distorted trigonal bipyramidal then the axial positions are occupied by two nitrogen 
atoms N(2) and N(3) [N(2)-M-N(3) = 155.45 (11)° and 155.77 (10)° for chloro and 
bromo complexes respectively]. The equatorial plane is made by the two halogen atoms 
and the atom N(1) of the pyridine fragment.  The most noticeable difference between 
the coordination spheres of the two complexes is in the difference of the M-X bond 
lengths in the complex: for the bromo complex the difference is 0.0282 Å [M-X: 
2.4333(4) Å and 2.4615 (5) Å], whereas the difference, at 0.0575 Å, is much larger in 
the chloro complex [M-X: 2.2839(9) and 2.3414 (10) Å]. This difference may originate 
in the relative donor strength of the ligands. This is exemplified in the spectrochemical 
series where Br
-
 comes lower than Cl
-
 in terms of its effect on increasing the energy of 
the LFSE.
167
 Halogens contribute to a small ligand-field splitting parameter since they 
come low down in the spectrochemical series, but since Cl
-
 is higher in the series than 
Br
-
 it would contribute to an increase in the LFSE and result in a greater axial distortion.  
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Figure 56. X-ray crystal structures of isostructural complexes (a) [CuBr2(L
1
Pr
n
)] and 
(b) [CuCl2(L
1
Pr
n
)]. 
(a)     (b) 
  
 
The packing in the crystal features offset face-to-face π-π interactions between pyridyl 
head groups of adjacent complexes (Figure 57). The isomorphous nature of the 
structures results from similar crystal packing requirements – importantly the nature of 
the halide appears to exert little differential influence. However, there is evidence of 
close contact between the coordinated halides and adjacent C-H systems in the 
structures. The C-H....halogen interaction has been studied in some detail,
181-184
 with 
chloride and bromide this is generally consistent with the halogen acting as a hydrogen 
bond acceptor with the strength of the interaction depending on the charge density of the 
halide. Two distinct CH...halide interactions are apparent: (i) halide...CH interactions to 
the aliphatic methyls of the n-propyl ‘tail’ unit and (ii) halide...CH interactions to the 
imine hydrogens. The aliphatic CH...X interactions lead to a centrosymmetric dimer 
motif  based on short CH...X contacts (2.92 and 3.00 Å for Cl
-
 and Br
-
 respectively) and 
nearly linear C-H...X orientation (166.4 and 161.0º for Cl
-
 and Br
-
 respectively) (Figure 
57 (b)). The imine CH...X interactions appear to support the face-to-face π-π 
interactions between pyridyl head groups. In these, the halides interact with two imine 
  
183 
CH units and may be regarded as a bifurcated acceptor in the formation of a tetrameric 
assembly (Figure 57 (b)). Again, the assembly is based on relatively short CH...X 
distances (2.92 and 2.79 Å for Cl
-
; 2.98 and 2.86 Å for Br
-
) but the essentially parallel 
arrangement of opposing pyridyl units moves the C-H...X angles away from a linear 
arrangement (117.0 and 142.3º for Cl
-
; 129.5 and 142.6º for Br
-
 respectively) consistent 
with the bifurcated nature of the interaction. Interestingly, the angles at the bifurcated 
halides are similar – 119.8º for Cl-, 120.1º for Br-. 
 
Figure 57. The crystal packing in isostructural complexes [CuBr2(L
1
Pr
n
)] and 
[CuCl2(L
1
Pr
n
)] features three distinct motifs: (a) a centrosymmetric dimer from methyl 
CH...halide interactions; (b) a centrosymmetric tetramer from bifurcated halide... HC 
imine in conjunction with offset face-to-face π-π interactions between pyridyl head 
groups of adjacent complexes; (c) the crystal packing of the complexes viewed down 
the a-axis of the unit cell.  
(a) 
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(b) 
 
(c) 
 
Copper complexes of L
1R where the substituent is an aromatic ‘tail’ group show 
contrasting structural chemistry to the alkyl analogues. Structures were obtained from 
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the complexes [CuCl2(L
1
PhMe] and [CuCl2(L
1
PhCl)]. The complexes give rise to 2-fold 
symmetric chiral molecular structures that are essentially isostructural and isomorphous. 
Each crystallises in an orthorhombic unit cell containing 8 molecules and structures 
were successfully determined in the Fdd2 space group (16 equivalent positions in the 
unit cell). The molecules have crystallographic 2-fold symmetry about an axis defined 
by the -CH and nitrogen atoms of the pyridyl ring, and the metal atom. In the setting 
for the asymmetric unit chosen, the remainder of the complex molecule is related by the 
symmetry operation –x+1, -y, z, consistent with the 2-fold axis parallel to the c-axis of 
the unit cell. In the complexes [CuCl2(L
1
PhMe] and [CuCl2(L
1
PhCl)], bond lengths and 
angles are very similar, apparently indicating negligible influence of the aromatic 
substituent on the complex. However, the respective roles of p-chloro and p-methyl 
groups in crystal packing interactions is worthy of detailed consideration as it might be 
expected that these may play a more significant role in determining the solid state 
structure.  
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Figure 58. X-ray crystal structures of isostructural complexes [CuCl2(L
1
PhMe)] (a) and 
[CuCl2(L
1
PhCl)] (b). 
(a) 
 
(b) 
 
 
The geometry at the Cu
II
 centre of the two aromatic complexes tends more toward 
distorted trigonal bipyramidal which is given by τ to be 0.51 and 0.50 for L1PhMe and 
L
1
PhCl complexes respectively. The two-fold rotational axis about M-N(1) imposes a 
trigonal equatorial plane, with bond angles [av N(1)-M-X(1) = 124.81° and av X(1)-M-
X(2) = 110.26°], these angles are much closer to the ideal trigonal angles of 120° than 
their related alkyl ‘tail’ group analogues. The fact that there is less distortion toward 
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square pyramidal in these two complexes indicates the ligand plays a big role in 
influencing the co-ordination geometry in this complex. 
 
When comparing bond lengths and angles for all the Cu
II
 complexes reported, there are 
a lot of similarities between structures but at the same time subtle differences are 
apparent. The main similarities between the complexes are the N-M-N angles and bond 
lengths which mainly arise due to constraints of the tridentate chelating ligand L
1
R. The 
metal salt and co-ordination has little influence on the bite angles [av N(1)-M-N(2)/N(3) 
= 77.77° for the halide complexes and 78.99° for the nitrato complex] however as 
insignificant as this 1° increase in the angle may seem, in reality it can be clearly 
explained when comparing the N-M bond lengths for the complexes. The slight increase 
in bite angle can be attributed to a contraction in bond length about the N(1)-M bond 
(average = 1.9252 Å for [Cu(NO3)2(L
1
Pr
n
)] compared to average 1.959 (2) , 1.957 (2) 
for the chloro and bromo analogue of the same ligand), this is clearly a consequence of 
the anionic ligands attached. This ligand field effect is also likely at play in the 
complexes [CuCl2(L
1
PhMe] and [CuCl2(L
1
PhCl)] where an elongation about the N(1)-
M bond[av N(1)-M = 1.986 Å] is brought about likely as a consequence of the electron 
rich ligands, this in turn gives rise to an axial elongation [av M-N(2) = 2.123 Å]. In all 
cases of this study (and in all crystal structures of other metal salts of L
1
R), the N-M 
bond distances where N is from the pyridyl moiety are shorter than the N-M bond 
distance where N is a Schiff base donor.  
 
For complexes containing alkyl ‘tail’ groups the imine C-N bond retains its double bond 
character with imine bond lengths in the range 1.255-1.275 Å comparable to standard 
imine bond lengths, (1,8-bis(imino)carbazolide, 1.273(3) Å)
185
 however a longer bond 
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length of 1.300(3) Å is observed in the complex [CuCl2(L
1
PhCl)] indicating either 
delocalisation of the imine electrons into the ring of the tail group or purely via the 
inductive effect of the p-chloro aryl ‘tail’ group or a larger degree of Cu-π* back 
bonding in this complex.   
 
The crystal packing in the isomorphous crystals of [CuCl2(L
1
PhCl)] and 
[CuCl2(L
1
PhMe)] is significantly different to the alkyl analogues. The higher C2 
symmetry of the complex allied to the steric demands of the aryl substitutents imposes a 
significant difference in the crystal packing. The most noticeable interaction is between 
the coordinated chlorides and the acidic imine hydrogens which give rise to chains 
running parallel to the a-axis of the unit cell (Figure 59 (b)). The imine CH…Cl 
distance is 2.7492(9) for L
1
PhMe but considerably longer at 2.801(1) Å in L
1
PhCl 
complexes. Both distances are considerably less than the sum of the respective Van der 
Waals radii.
186
 Additionally, the juxtaposition of complexes, introduces close contacts 
within a sandwich of phenyl rings and the pyridyl head unit of adjacent molecules. This 
‘stack’ may further stabilise the chain through - interactions. Further imine CH…Cl 
interactions produce a sheet of complexes parallel to the B-face of the cell. It is 
noticeable that the propagation of the sheet parallel to the c-axis involves complexes 
stacked above one-another (aligned along the 2-fold axis) and, in this arrangement, the 
cleft produced by the CuCl2 unit accommodates the pyridyl head unit of the adjacent 
complex. While the -pyridyl hydrogen to chloride distances are 3.062(1) Å, and 
therefore represent, at best, a weak halogen interaction, it is likely that this arrangement 
represents a ‘best fit’ for the complexes, optimising steric and Van der Waals 
interactions within the sheet. The symmetry of the space group repeats the sheets 
through glide planes parallel to the b-axis (Figure 59 (c)). There is some evidence of 
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weak interactions between the sheets due to the proximity of para-aryl substituent to the 
imine methine proton. In the L
1
PhCl complex (Figure 59 (d)), this results in a 
CH…ClPh distance of  2.848(1) Å with a C-H…Cl angle of 133.7(2)º. The interaction 
at the methine proton in this arrangement therefore may be considered as bifurcated 
with the Cl…H…Cl angle of 84.37(3)º and this may explain the elongation of 
chloride…HC distance in comparison to the 4-methyl analogue. In this L1PhMe 
complex, corresponding inter-sheet interactions are likely from similarly weak CH3…Cl 
hydrogen bonds.  Hence it is reasonable to conclude that the correspondence of 
interactions in the systems gives rise to very similar solid state structures. 
 
Figure 59. Packing motifs in the isomorphous crystal structures of [CuCl2(L
1
PhCl)] and 
[CuCl2(L
1
PhMe)] {illustrated with [CuCl2(L
1
PhMe)]}: (a) chains of complex molecules 
propagating parallel to the a-axis of the unit cell linked through imine CH…Cl 
interactions; (b) propagation of chains parallel to the B-face of the cell produces sheets 
described by further imine CH…Cl interactions and the steric demands of the complex; 
(c) crystal packing of [CuCl2(L
1
PhMe)] viewed parallel to the c-axis of the unit cell; (d) 
inter-sheet interactions in [CuCl2(L
1PhCl)] arising from the bifurcated Cl…H…Cl 
interaction at the imine methine proton due to the p-chloro substituent of the ligand. 
(a) 
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(b) 
 
(c) 
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(d) 
 
6.3.2. NiII Complexes of L1R 
 
Crystal structures were obtained for three nickel(II) complexes of L
1
R with ethyl, n-
propyl and cyclohexyl substituents. In contrast to the five-coordinate copper(II) species, 
the nickel(II) complexes exhibited 6-coordinate structures based on distorted octahedral 
coordination spheres. The primary distortion to the octahedron originates with the 
rigidity of ligand structure at the pyridyldimethimine unit that imposes a reduced bite 
angle for the 5-coordinate chelate rings of the NNN donor set of L
1
R. In all cases, the 
metal centres coordinate to one L
1
R ligand, with the metal coordination sphere being 
completed by coordinated anions {[Ni(AcO)2(L
1
Cy)] and [-Cl2{NiCl(L
1
Pr
n
)}2]} or 
aqua ligands {[NiCl(H2O)2(L
1
Et)]Cl}. 
 
In the complex, [Ni(AcO)2(L
1
Cy)], the six-coodinate sphere is completed by three 
oxygen donors from unidentate and bidentate acetates. The bidentate acetate introduces 
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a further distortion to the octahedral geometry (Table 46 to Table 48 and Figure 60). 
The coordination of the bidentate acetate is highly symmetrical with essentially metal-
oxygen distances {d[Ni-O(41)] = 2.111 (3) Å, d[Ni-O(42)] = 2.110 (3) Å}. The 
symmetrical character is reflected in the equivalent carbon-oxygen bond lengths 
{d[C(41)-C(41)] =  1.249, and d[C(41)-C(41)] = 1.257 Å} and angles at each oxygen 
donor atom {[Ni-O(41)-C(41)] = 89.18° and [Ni-O(42)-C(41)] = 88.96°}. Clearly, 
in this mode, the electron density is delocalised between the two C-O bonds of the 
acetate.  
 
The six-co-ordination about the Ni
II
 centre of the acetetate complex is completed by the 
unidentate acetate. The metal-oxygen bond is unremarkable {d[Ni-O(51)] = 1.961 Å} 
and the asymmetry of the carbon-oxygen bond lengths {d[O(51)-C(51)] = 1.260 Å; 
{d[O(52)-C(51)] = 1.215 Å} are consistent with localised single and one double bonds 
within the acetate group. The slight elongation of O(51)-C(51) coupled with a relatively 
short intermolecular contact to the water of crystallisation {d[O(51)…O(61)] = 2.869 
Å} is consistent with a C=O…HOH hydrogen bond.  
 
The cyclohexyl ‘tail’ groups adopt the favourable chair conformation within this 
structure and are aligned approximately perpendicular to the plane of the NNN donor 
set, presumably to minimise steric interactions as the acetates complete the metal 
coordination sphere.  
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Figure 60. X-ray crystal structure of the complex [Ni(AcO)2(L1Cy)], hydrogen atoms 
and solvate molecules omitted for clarity. 
 
 
  
194 
Table 32. X-ray structure and refinement parameters for Ni
(II)
 complexes of L
1
R. 
Compound [Ni(AcO)2(L
1
Cy)]. 
CH3CN.H2O 
[-Cl2{NiCl(L
1
Pr
n
)}2] 
Chemical Formula C25H33N4NiO5 C26H38Cl4N6Ni2 
Formula Weight 528.26 693.84 
Crystal System Monoclinic Monoclinic 
Space Group P21/c P21/c 
a / Å 9.2608 (12) 10.127 (2) 
b / Å 15.6053 (19) 11.982 (2) 
c / Å 18.191 (2) 13.116 (3) 
α / ° 90 90 
β / ° 91.220 (7) 103.75 (3) 
γ / ° 90 90 
V / Å
3
 2628.4 (6) 1545.9 (5) 
T / K 293 (2) 293 (2) 
Z 4 4 
S 1.036 1.023 
No. unique data (Rint) 13402 2712 
No. measured 
reflections 
122357 3410 
Robs/wR(F
2
)obs 0.088/0.272 0.025/0.069 
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The complex [-Cl2{NiCl(L
1
Pr
n
)}2] arises from a centrosymmetric -chloro dimer 
formed from two asymmetric units related through an inversion centre of symmetry. 
The complex features six coordinate nickel atoms, from coordination of three N atoms 
of the ligand L
1
Pr
n
 {d[Ni(1)-N(1)] = 1.9819 (18) Å, d[Ni(1)-N(2) = 2.1211 (19) Å, 
d[Ni(1)-N(3) = 2.1222 (19) Å], with the three remaining sites being occupied by two 
symmetry-related bridging chlorides and a single terminal chloride. Metal-chlorine 
distances cover a wide range, the bridging atoms show very different metal-chlorine 
distances {d[Ni(1)-Cl(2)] = 2.3313 (10) Å; d[Ni(1)-Cl(2’) = 2.5981 (7) Å}, while the 
final co-ordination site is finished with a terminal Cl ion {d[Ni(1)-Cl(1) = 2.4159 (7) 
Å}. 
 
Figure 61. Crystal structure of the dimeric [-Cl2{NiCl(L
1
Pr
n
)}2] with hydrogen atoms 
omitted for clarity showing the numbering of the asymmetric unit. 
 
In the 4-membered dimer, the Ni-Ni distance is 3.682 Å, while the Ni--Cl-Ni angle is 
96.61°. The distances and angles are comparable to those known for such Ni
II
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species,
187-190
 while the distances and angles of the ligand are comparable with those of 
the related Ni
II
 complexes of this series.  
 
The dimeric Ni
II
 complex crystalises in the primitive monoclinic unit. The crystal 
packing within the unit cell is dominated by CH…Cl contact, consistent with halogen 
bonds (see section 6.3.1). Again, the acidic imine CH groups of the ligand give rise to 
chain and ring structures in the crystal (Figure 62). 
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Figure 62. The crystal packing of [-Cl2{NiCl(L
1
Pr
n
)}2] showing molecular packing 
dominated by imine CH…Cl intermolecular interactions. (a) Linear chains of dimers 
and (b) -chloro dimers forming a ring structure through CH…Cl interactions 
(a) 
 
(b) 
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6.3.3. ZnII Complexes of L1R 
 
Several crystal structures of Zn
II
 complexes were obtained and provide an interesting 
comparison with the structures of the analogous Cu(II) and Ni(II) complexes. In 
particular, the structures demonstrate that the d
10
 configuration of Zn(II) imposes fewer 
geometric requirements on the metal coordination sphere than the transition metal 
analogues.  Principal bond lengths and angles in the metal coordination spheres are 
given in Table 49 and Table 50. Structures were obtained from two species with 
aliphatic tail groups { [Zn(NO3)2(L
1
Bu
t
)] and [ZnCl2(L
1
Bu
t
)].CH3CN }, and three with 
aromatic tail groups { [ZnCl2(L
1
Ph)].CH3CN, [ZnCl2(L
1
PhMe)] and [ZnCl2(L
1
PhCl)] }. 
 
Structures of three complexes with aromatic tail groups L
1
Ph, L
1
PhMe and L
1
PhCl are 
based on similar metal coordination geometries (Figure 63).  
 
 
 
 
 
 
 
 
 
 
 
 
  
199 
Figure 63. The metal complexes in the crystal structures of (a) [ZnCl2(L
1
Ph)].CH3CN, 
(b) [ZnCl2(L
1
PhCl)] and (c) [ZnCl2(L
1
PhMe)] showing the numbering scheme adopted. 
 
(a) 
 
(b) 
 
(c) 
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However even though the structures adopted in complexes are based on similar 
distorted trigonal bipyramidal structures with the coordinated chlorides lying 
approximately equidistant above and below the N3M plane: X(1)-Zn-X(2) bond angles 
are in the range 118.340(18) - 119.53(6)° and the axial bond angle N(2)-Zn-N(3) in the 
range 147.97(16) - 149.01(15)°. In common with all the complexes of the pyridyl-
diylimine, the N(2)-Zn-N(3) angle parameter is imposed by the bite of the tridentate 
ligand. Thus the complexes adopt distorted trigonal bipyrimidal coordination spheres. 
However, there are subtle differences in bond lengths and geometries around the 
respective coordination spheres. The complex [ZnCl2(L
1
PhCl)] exhibits the 
crystallographic 2-fold symmetry around an axis defined by -pyridyl carbon, the 
pyridyl nitrogen and the metal which imposes equal Zn-N(imine) bond lengths. In 
contrast, the complex [ZnCl2(L
1
Ph)] exhibits significantly different Zn-N(imine) bond 
distances {d[M-N(2)] = 2.304(4) Å; d[M-N(3)] = 2.336(4) Å}. Within this series of 
complexes, the relatively small differences in metal coordination sphere dimensions are 
difficult to ascribe to functional group changes with any confidence and while the 
ligand basicity may be influenced by differing inductive effects from para-substituents, 
such effects are likely to be outweighed by crystal packing forces.  
 
The orientation of the aromatic substituents within the complexes is interesting. While 
the 4-chlorophenyl and phenyl complexes show the same chiral propeller arrangement 
as observed in the copper analogues, the p-tolyl species is distinctly different. This 
shows a configuration of the phenyl rings that is considerably closer to coplanar with 
the pyridine ring. In this configuration, increased steric interaction between the imine 
hydrogen and the hydrogen in the ortho position of the aromatic ring might be 
anticipated. Close inspection of the crystal packing shows that this apparently 
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unfavourable arrangement facilitates extended face-to-face - stacking between 
complexes (Figure 64). Notably, this stacked arrangement compliments short contacts 
between imine hydrogens and chlorides from adjacent complexes {d[CH…Cl] = 2.842 
Å} that result in the formation of centrosymmetric structural units propagating parallel 
to the c-axis of the unit cell.  
 
Figure 64. - Stacking interactions propagating parallel to the c-axis in the crystal 
structure of [ZnCl2(L
1
PhMe)] complimented by imine-CH…Cl interactions. 
 
The [ZnCl2(L
1
Bu
t
)] and [Zn(NO3)2(L
1
Bu
t
) complexes of the t-butyl functionalised 
ligand show largely similar influences on metal coordination to the aromatic analogues. 
As might be expected, the dominant influence on the structure arises from nature of the 
coordinated counterions (Figure 65). The most noticeable feature is the differing 
conformation of the t-butyl group with respect to the pyridyldiylimine unit of the ligand. 
Torsion angles at the N-C(quaternary) bond show two distinct conformers: in the 
dichloro complex [ZnCl2(L
1
Bu
t
)], the methyl groups closest to the pyridyldiylimine 
plane in each ‘tail’ (C24 and C32) are antiperiplanar {[C11-N2-C21-C24] = 179.4(4); 
[C17-N3-C31-C32] = 158.7(2)} with respect to the imine bond while in 
[Zn(NO3)2(L
1
Bu
t
)], the corresponding methyl groups are synperiplanar {[C11-N2-C21-
C24] = 4.0(1); [C17-N3-C31-C34] = 27.2(1)}. Inspection of spacefilling models of 
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the complexes indicate that these arrangements might arise to accommodate the steric 
demands of the coordinated anions (Figure 66).  
 
Figure 65. The metal complexes in the crystal structures of (a) [Zn(NO3)2(L
1
Bu
t
)] and 
(b) [ZnCl2(L
1
Bu
t
)].CH3CN showing the numbering scheme adopted (hydrogens are 
omitted for clarity). 
 
(a) 
 
  (b) 
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Figure 66. Space filling models of the crystal structures of (a) [Zn(NO3)2(L
1
Bu
t
)] and 
(b) [ZnCl2(L
1
Bu
t
)] viewed parallel to M-N(py) vector showing the different 
conformations of the tert-butyl group that apparently arise from the steric demands of 
the coordinated anions. The N3 coordinating plane of the ligand lies approximately 
horizontal in each view. 
 
(a)      (b) 
       
 
 
Some consideration of crystal packing influences is worthwhile to indicate the potential 
origin of the monodentate and pseudo-bidentate binding modes for the nitrates of  
[Zn(NO3)2(L
1
Bu
t
)].  While the pseudo-bidentate nitrate interacts solely with the metal 
atom, the monodentate nitrate shows a close contact with the -pyridyl hydrogen of an 
adjacent complex molecule related by inversion symmetry {d[C14-H14…O5] = 
2.3826(9) Å, [C14-H14…O5] = 158.43(7)}. While relatively long, such contact 
parameters could be considered consistent with CH…nitrate hydrogen bonding. The 
resulting centrosymmetric dimer is likely to be stabilised through additional face-to-face 
- interactions between the pyridine units of adjacent complexes Figure 67.  
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Figure 67. The centrosymmetric dimer motif in the crystal packing of 
[Zn(NO3)2(L
1
Bu
t
)] featuring - stacking and potential pyH…nitrate hydrogen bonds. 
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Table 33. X-ray structure and refinement parameters for complexes of [ZnX2(L
1
R)]. 
Compound [Zn(NO3)2(L
1
Bu
t
)] [ZnCl2(L
1
Bu
t
)].CH3CN [ZnCl2(L
1
Ph)].CH3CN [ZnCl2(L
1
PhMe)] [ZnCl2(L
1
PhCl)] 
Chemical Formula C15H23N5O6Zn C15H23Cl2N3Zn C21H18Cl2N4Zn C21H19Cl2N3Zn C19H13Cl4N3Zn 
Formula Weight 434.75 381.63 462.66 449.66 490.49 
Crystal System Monoclinic Trigonal Monoclinic Triclinic Orthorhombic 
Space Group P21/c R3c P21/n P-1 Fddd 
a / Å 11.2793 (2) 26.048 (4) 7.5643 (8) 9.5167 (5) 12.0528 (4) 
b / Å 11.6999 (2) 26.048 (4) 14.7970 (17) 9.9677 (5) 35.4317 (14) 
c / Å 15.9061 (3) 15.046 (3) 19.292 (2) 12.5624 (5) 9.2326 (3) 
α / ° 90 90 90 89.7810 (10) 90 
β / ° 108.2450 (10) 90 96.085 (4) 90.0130 (10) 90 
γ / ° 90 120 90 61.4650 (10) 90 
V / Å
3
 1993.55 (6) 8840 (3) 2147.1 (4) 1046.90 (9) 3942.8 (2) 
T / K 273 (2) 293 (2) 273 (2) 273 (2) 273 (2) 
Z 4 16 4 2 8 
S 0.811 1.037 0.780 0.932 0.761 
No. unique data (Rint) 12683 6947 6518 6989 1790 
No. measured 
reflections 
207723 34268 92348 16387 10254 
Robs/wR(F
2
)obs 0.028/0.064 0.035/0.095 0.086/0.211 0.030/0.074 0.030/0.046 
  
206 
6.3.4. CoII Complexes of L1R 
 
Cobalt complexes of L
1
R cobalt complexes of L
1
R yielded few crystals suitable for 
structural study and of these, only one monoligated structure was obtained, the complex 
[CoCl2(L
1
PhCl)]. This complex is essentially isomorphous and isostructural to the 
copper complexes of the L
1
PhCl ligands (Figure 58) where they crystallise in the same 
space group (orthorhombic, Fdd2), with similar unit cell dimensions. 
 
The remaining crystal structures obtained for cobalt were bis-complexes of the ligand 
L
1
Cy. Three structures were obtained for the complex cation [Co(L
1
Cy)2]
2+
 with the 
nitrate, tetrafluoroborate and tetraisothiocyanatocobaltate(II) {[Co(NCS)4]
2-
} 
counterions. The complex cations of all three complexes are very similar with a 
distorted octahedral cobalt metal centre arising from coordination of two L
1
Cy ligands 
binding in a tridentate fashion (Figure 68).  
 
The distortion to octahedral co-ordination sphere originates in the bite imposed by the 
rigid nature of the terdentate pyridyl-diyldiimine donor unit. The deviation of N2-M-N3 
and N5-M-N6 bond angles from 180° arises because the approach of metal to the 
pyridyl nitrogens is limited, thereby promoting the observed geometry. 
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Figure 68. X-ray structure of the complex cation [Co(L
1
Cy)2]
2+
 in the complexes (a) 
[Co(L
1
Cy)2][NO3]2.2H2O.CH3CN and (b) [Co(L
1
Cy)2][BF4]2.2H2O.CH3CN showing 
the numbering schemes adopted. 
(a) 
 
(b) 
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Figure 69. Crystal structure of [Co(L
1
Cy)2][Co(SCN)4].CH3CN: (a) the asymmetric 
unit and (b) the crystal packing viewed down the a-axis showing the 
tetraisothiocyanatocobaltate(II) counterions in space fill. 
(a) 
 
(b) 
 
The coordination of the metal within the terdentate chelates is also asymmetric with 
each ligand showing significantly different metal-ligand bond lengths. In the complex, 
the two independent ligands (labelled L
1a
 and L
1b
) show similar but distinctly different 
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metal coordination. This asymmetry may be viewed as different (asymmetric) 
occupation of the chelate ‘pockets’ presented by the two ligands (Table 34) This 
situation is presented schematically in Figure 70. It is not totally understood why this 
asymmetry arises, but the role of the counterion in exerting different electrostatic crystal 
packing forces on the ligands may be important. Noticeably, counterion lies adjacent to 
L
1a
 intersecting the perpendicular ligand L
1a
 with the Co-N3 bond of L
1b
. It may be that 
the attraction of the counterion to the metal causes a steric repulsion of the counterion 
with ligand L
1b
 and hence pushing the ligand away from the metal. 
 
Figure 70. Pictoral depiction of the hole size of the two independant ligands L
1a
 and L
1b
 
in the complex [Co(L
1
Cy)2][CoNCS4]. 
 
 
The converse effect of the interaction of the cation with the counter dianion, is a slight 
distortion in the tetrahedral geometry which can be seen when looking at the N-Co-N 
bond angles of the complex (Table 52). The ideal bond angle of a symetrical tetrahedron 
is roughly 109°, clearly large deviations above and below this are observed for the 
dianion.[N(9)-Co-N(8) and N(10)-Co-N(8), bond angles of 115.8° and 105.2° 
respectively]. 
L1a
L1b
2.2702.233
1.942
1.882
2.010 2.031
L1b
L1a
90°
[CoNCS4]
2-
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Compound [CoCl2(L
1
PhCl)] 
[Co(L
1
Cy)2][BF4]2. 
CH3CN. 2H2O 
[Co(L
1
Cy)2][NO3]2. 
CH3CN. 2H2O 
[Co(L
1
Cy)2] 
[CoNCS4].CH3CN 
Chemical Formula C19H13Cl4CoN3 C19H31B2CoF8N3O2 C20H27Co0.50N4.50O4 C22H27CoN5.50S2 
Formula Weight 484.05 566.02 423.93 491.54 
Crystal System Orthorhombic Monoclinic Monoclinic Orthorhombic 
Space Group Fdd2 P21/n P21/n P212121 
a / Å 11.9376 (19) 17.8919 (9) 17.3547 (6) 12.8967 (6) 
b / Å 35.056 (6) 13.8446 (6) 13.9813 (5) 18.3596 (9) 
c / Å 9.2382 (13) 18.9099 (10) 18.4021 (6) 20.7305 (10) 
α / ° 90 90 90 90 
β / ° 90 98.948 (3) 96.394 (2) 90 
γ / ° 90 90 90 90 
V / Å
3
 3866.1 (11) 4627.1 (4) 4437.3 (3) 4908.5 (4) 
T / K 273 (2) 273 (2) 273 (2) 293 (2) 
Z 8 8 8 8 
S 1.036 1.030 1.093 0.829 
No. unique data (Rint) 1588 14610 9990 4480 
No. measured 
reflections 
11245 179646 181288 67529 
Robs/wR(F
2
)obs 0.049/0.103 0.073/0.239 0.067/0.204 0.047/0.098 
Table 34. X-ray structure and refinement parameters for Co
(II)
 complexes of L
1
R. 
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6.3.5. Complexes of L2R and L3R. 
 
The crystal structures of the complexes of L
2
 and L
3
 ligands were more difficult to 
obtain than for L
1
 complexes owing to several reasons. Firstly due to the smaller library 
of complexes prepared in this study, secondly due to the inherent insolubility of 
complexes of this particular ligand and thirdly the quality of the crystal obtained was 
not always satisfactory. However 4 crystal structures of this class of ligand were 
obtained and identified the denticity of such complexes appears to be very different to 
what was expected based on NMR data. The 4 complexes along with their refinement 
parameters are listed in Table 35, and their crystal structure diagrams are shown in 
Figure 71 a-d.  
 
Based on structural, particularly NMR, studies in solution  data, it was anticipated that 
the metal coordination of all ligands was through the potentially quadridentate ligand 
utilising all of its donors to produce a pseudo-two-fold symmetric complex. It was 
anticipated that the counterions might be involved in completing distorted six-
coordinate metal spheres.  
 
In the solid state, the ligands are observed to coordinate in a terdentate fashion giving an 
asymmetric ligand. Only the zinc complex [Zn(NO3)(H2O)(L
2
PhMe)][NO3], showed the 
ligand binding in a tetradentate fashion. However the similar complex [ZnCl2(L
3
PhMe)] 
is clearly terdentate in the crystal structure. The explanation could be purely down to the 
difference in ligand from bipyridine to phenanthroline, or it could be due to solvation 
effects, where a tight DMF solvate in [ZnCl2(L
3
PhMe)] could force a terdentate chelate.  
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Compound [ZnCl2(L
2
Cy)] 
[Zn(NO3)(H2O)(L
2
PhMe)] 
[NO3] 
[ZnCl2(L
3
PhMe)]. 2DMF [CuCl2(L
3
Bu
i
)].CH3CN.H2O 
Chemical Formula C26H32Cl2N5Zn C26H24N6O7Zn C32H29Cl2N6O2Zn C23H26Cl2CuN5O 
Formula Weight 551.34 597.88 656.88 519.43 
Crystal System Triclinic Monoclinic Monoclinic Monoclinic 
Space Group P-1 P21/n C2/c P21/n 
a / Å 11.9728 (16) 14.2027 (4) 24.1825 (12) 13.3340 (6) 
b / Å 14.6569 (19) 11.4274 (4) 15.1249 (8) 11.8161 (5) 
c / Å 16.3402 (16) 16.4237 (4) 16.9676 (8) 16.5059 (7) 
α / ° 87.116 (4) 90 90 90 
β / ° 76.631 (3) 105.531 (2) 91.652 (3) 105.477 (2) 
γ / ° 86.222 (4) 90 90 90 
V / Å
3
 2781.9 (6) 2568.23 (13) 6203.5 (5) 2506.30 (19) 
T / K 273 (2) 293 (2) 293 (2) 273 (2) 
Z 4 4 8 4 
S 1.118 0.711 0.756 0.905 
No. unique data (Rint) 5282 7105 10520 11572 
No. measured reflections 42335 51099 112784 118425 
Robs/wR(F
2
)obs 0.080/0.243 0.037/0.059 0.070/0.166 0.038/0.108 
Table 35. X-ray structure and refinement parameters for complexes of L
2
R and L
3
R. 
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However it is highly likely that the reason the dichlorocomplexes do not give a 
tetradentate complex is solely due to the steric effect of these bulky anions.  
 
The tetradentate complex contains a co-ordinated water ligand, which is much less 
sterically demanding than NO3
-
 or Cl
-
, and would mean the metal can more easily 
accommodate a tetradentate chelate. This can partly be backed up by another crystal 
structure that was solved but could not be satisfactorily refined for the complex 
[Zn(NO3)2(L
3
PhMe)]. This analogous structure was clearly observed to be terdentate 
with both nitrate anions co-ordinated to zinc in a unidentate fashion. 
 
Figure 71. Crystal structures of a) [ZnCl2(L
2
Cy)], b) [Zn(NO3)(H2O)(L
2
PhMe)], [NO3] 
anion omitted for clarity, c) [CuCl2(L
3
Bu
i
)], d) [ZnCl2(L
3
PhMe)].2DMF solvate 
ommited for clarity. 
(a) 
 
 
 
  
214 
(b) 
 
(c) 
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(d) 
 
 
The co-ordination geometry of the two terdentate zinc complexes [ZnCl2(L
2
Cy)] and 
[ZnCl2(L
3
PhMe)] can be best described as distorted triganol bipyramidal, where 
N(2),Cl(1),Cl(2) atoms make up the equatorial triganol plane. The bond angles being 
close to ideal 120° for trigonal (Table 58.), which is the same as what was observed for 
the analogous [ZnCl2(L
1
R)] complexes. On the other hand the copper complex exhibits 
a rather more distorted geometry, which is in between that of trigonal-bipyramidal and 
square based-pyramidal, again similar to that observed for [CuCl2(L
1
R)] complexes. 
 
The tetradentate complex [Zn(NO3)(H2O)(L
2
PhMe)][NO3], adopts what is best 
described as a distorted octahedral geometry, the distortion is controlled by the bite of 
the tetradentate N donar set of the bipyridine ligand, which make up a distorted square 
equatorial plane. The bite angles of the adjacent N doners to the metal are typically 73-
75°, which is the same for the bite angle in the terdentate zinc complexes. The ligands 
H2O and O bound NO3
-
 (unidentate) make up the apical positions of the octahedron, 
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which also give a very distorted axial bond angle [O(1)-Zn-O(2) = 149.61°] which is far 
from the ideal 180° bond angle of an octahedral complex.  
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7. Biological Evaluations 
7.1. Determination of in vitro Toxicity of Schiff Base Complexes Against a 
Panel of Human Tumour Cell Lines. 
 
The purpose of this research was to build on from earlier discoveries at Bradford 
University that demonstrated the particular class of Schiff base metal complex in this 
study showed high affinity for binding to DNA
26
 and also because of their similar 
chemistry to known metallopharmaceuticals. By assessing the in vitro toxicity of the 
prepared library of complexes against human tumour cells in a chemosensitivity assay it 
has been possible to identify if this class of complex show any cytotoxic response. 
 
In this section is reported the mean dose response curves and IC50 values obtained for 
each compound, following 6 days exposure (and 1 hour exposure of selected 
compounds) to each of the cell lines DLD-1, H460 and HT29 (Only a handful of 
compounds were tested against HT29 cells due to time constraints and problems with 
infection of these cells). The curves were generated as explained in section 2.2.1 and 
each represent the mean data from 3 independent assays ± SD unless otherwise stated. 
 
All of the drugs tested exhibited classical dose response curves. At low drug 
concentrations, there was little variation from the control in terms of percentage cell 
survival. As the drug concentration was gradually increased, the effect on percentage 
cell survival became more pronounced, with survival decreasing with increasing drug 
concentration. At concentrations which were considerably greater than the determined 
IC50 value, the percentage of cells surviving after 6 day drug exposure was low. The 
only exceptions to the classical dose response curves was compounds tested with 1 hour 
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exposure times, where in all but one case negligible effect on the cell population was 
observed in the concentration range of this study.  
 
All compounds displayed a wide range of IC50 values against the three cell lines, with 
the majority of the compounds having lower IC50 values against, and thus being more 
toxic towards the HT29 cell lines (some exceptions observed). No complexes showed 
enhanced potency to that of the benchmark test compound cisplatin, but some 
interesting responses were observed against HT29 cells for some complexes. 
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7.1.1. Variation of Ligand ‘Tail’ Group 
7.1.1.1. CobaltIIchloride Complexes of Ligand L1R 
Figure 72. Plots show the response of DLD-1, H460, HT29 cells following 6 day drug 
exposure to Cobalt
II
chloride complexes of L
1
R with cisplatin and Cobalt
II
chloride 
curves shown for comparison. Each point represents the mean of three independent 
experiments. 
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Table 36. Cytotoxic activity of Cobalt
II
chloride complexes, expressed as their mean 
IC50 values in M for three independant experiments, ± standard deviation in brackets. 
 
  
It was possible to test nearly all but a few of the cobalt complexes prepared in this 
study. The troublesome ones were namely [CoCl2(L
1
PhMe)] which hydrolyses to 
precipitate free ligand on dissolution in water and could not be tested on these grounds. 
The toxicity data for complex [CoCl2(L
1
PhCl)] was unobtainable due to its insolubility 
in aqueous and DMSO. All complexes showed moderate toxicity toward their cell lines 
(Figure 72 and Table 36) with a general cell line selectivity DLD-1 > HT29 ≥ H460, 
which is roughly the inverse of cisplatin selectivity towards these three cell lines. The 
average toxicities towards DLD-1, H460 and HT29 cells was 9.7, 22.5 and 22.4 µM 
respectively. 
 
There was no blatant relationship observed for any of the complexes in relation to 
structure and activity i.e. no trend with steric bulk,
191
 +I, -I effects,
192
 etc since the 
Compound DLD-1 H460 HT29 1Hr Exposure DLD-1 cLogP of Ligand
Cisplatin 1.08 (0.05) 0.52 (0.05) 2.6 (0.6) 2.5 (0.5) -
[CoCl2(L
1
Et)] not isolated not isolated - - 2.63
[CoCl2(L
1
Pr
n
)] 7.9 (1.1) 15.0 (3.8) - - 3.6
[CoCl2(L
1
Pr
i
)] 7.2 (0.4) 14.6 (2.3) 9.25 (1.1) - 3.27
[CoCl2(L
1
Bu
n
)] 7.5 (1.8) 41.8 (4.5) 53.5 (22) - 4.44
[CoCl2(L
1
Bu
2
)] 5.6 (0.4) 13.3 (1.3) 13.8 (2.5) - 4.24
[CoCl2(L
1
Bu
i
)] 15.3 (3.1) 48.1 (10.5) 41.0 (12.8) - 4.4
[CoCl2(L
1
Bu
t
)] 10.9 (3.7) 23.1 (3.1) 12.0 (4.1) - 3.7
[CoCl2(L
1
Cy)] 6.4 (0.5) 8.0 (1.2) - >100 5.05
[CoCl2(L
1
CyMe)] 12.7 (n=1) 21.2 (n=1) - - 5.71
[CoCl2(L
1
Ph)] 11.6 (0.9) 23.0 (1.8) - >100 5.28
[CoCl2(L
1
PhMe)] hydrolyses hydrolyses hydrolyses - 6.25
[CoCl2(L
1
PhCl)] insoluble insoluble insoluble - 6.4
[CoCl2(L
1
PhNO2)] 11.4 (0.3) 16.7 (3.8) 4.9 (1.9) - 3.68
IC50 M
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complexes tended to have IC50’s within the same order of magnitude and the scatter and 
standard deviation of some mean values was quite large (this was also observed for all 
metal salts of ligand L
1
).  
 
The most potent complex of this series appeared to come from the L
1
Cy and L
1
Bu
2
 
ligands with IC50’s of 6.4 and 5.6 µM respectively towards DLD-1 cells, which was in 
the same order of magnitude as cisplatin toxicity (1.08 µM). More interestingly the 
toxicity of the complex [CoCl2(L
1
PhNO2)] (4.9 µM) is merely two fold higher than that 
of cisplatin toward the HT29 cell line and for this complex the selectivity toward the 
three cell lines changes to what is typically observed for the other complexes.  
 
None of the complexes tested showed any acute toxicity after 1 hour exposure toward 
DLD-1 cells. As a control experiment CoCl2 showed no toxicity in the concentration 
range used for this series. (This control was utilised for all metal salts and cell lines and 
identifies that the ligand is essential for the observed toxicities of these complexes). 
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7.1.1.2. NickelIIchloride Complexes of L1R 
 
Figure 73. Plots showing the response of DLD-1, H460, HT29, cells following 6 day 
drug exposure to Nickel
II
chloride complexes of L
1
R with cisplatin and Nickel
II
chloride 
curves shown for comparison. Each point represents the mean of three independent 
experiments. 
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Table 37. Cytotoxic activity of Nickel
II
chloride complexes, expressed as their mean 
IC50 values in M for three independant experiments, ± standard deviation in brackets. 
 
 
Only a small number of Nickel complexes were tested due to the small number of 
Nickel complexes prepared in this study and also because of their low solubility. 
Looking at Figure 73 there was no obvious trend in activity with this class of ligand, 
virtually all toxicities were similar and within the same order of magnitude. Complexes 
were moderately toxic to all cell lines but were relatively distant from the values of 
cisplatin (at least greater than 10 fold, see Table 37). The most potent complex was that 
of [NiCl2(L
1
Pr
n
)] which showed an IC50 of 20.1 µM towards HT29 cells but strangely 
showed a much larger value of 70.4 µM against H460 cells which seems pretty 
anomalous looking at the values of the related compounds toward the same cell lines. 
The selectivity of the complexes toward the different cell lines also cannot be easily 
drawn out since all IC50 values are in a similar range.  
 
Not surprisingly the Nickel complexes of this series did not show any acute toxicity 
toward DLD-1 cell lines. 
Compound DLD-1 H460 HT29 1Hr Exposure DLD-1 cLogP of Ligand
Cisplatin 1.08 (0.05) 0.52 (0.05) 2.6 (0.6) 2.5 (0.5) -
[NiCl2(L
1
Pr
n
)] 27.2 (6.2) 70.4 (15.4) 20.1 (0.4) >100 3.6
[NiCl2(L
1
Cy)] 34 (2.4) 31.9 (6.3) - >100 5.05
[NiCl2(L
1
PhMe)] 35.2 (5.3) 40.2 (6.1) - >100 6.25
IC50 M
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7.1.1.3. CopperIIchloride Complexes of L1R 
 
Figure 74. Plots showing the response of DLD-1, H460, HT29, cells following 6 day 
drug exposure to Copper
II
chloride complexes of L
1
R with cisplatin and Copper
II
chloride 
curves shown for comparison. Each point represents the mean of three independent 
experiments. 
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Table 38. Cytotoxic activity of Copper
II
chloride complexes, expressed as their mean 
IC50 values in M for three independant experiments, ± standard deviation in brackets. 
 
 
Almost all copper complexes prepared in this series were tested against the cell panel, 
the exception being the [CuCl2(L
1
PhCl)] complex which is analogous to the 
[CoCl2(L
1
PhCl)] complex in both ligand and solubility properties. Clearly this particular 
ligand must provide the incorrect chemistry for this class of complex to achieve any 
solubility in DMSO or water. 
 
Again no clear trend in cytotoxicity is observed within this series of complex since the 
IC50 values are very similar for all three cell lines with a few exceptions (Figure 74 and 
Table 38). The most potent complexes being the aromatic complexes [CuCl2(L
1
Ph)] 
(8.8 µM, DLD-1) and [CuCl2(L
1
PhNO2)] (6.2 µM, HT29). The general order of 
selectivity toward the cell panel for the majority of complexes was HT29≈DLD-
1>H460, with averages of 15.7, 14.0, and 28.3 µM respectively. 
Compound DLD-1 H460 HT29 1Hr Exposure DLD-1 cLogP of Ligand
Cisplatin 1.08 (0.05) 0.52 (0.05) 2.6 (0.6) 2.5 (0.5) -
[CuCl2(L
1
Et)] 14.8 (4.0) 27.1 (8.1) 17.6 (2.3) - 2.63
[CuCl2(L
1
Pr
n
)] 18.2 (2.0) 31.1 (5.3) 26.5 (2.7) >100 3.6
[CuCl2(L
1
Pr
i
)] 16.5 (5.5) 32.6 (4.1) 7.3 (4.0) - 3.27
[CuCl2(L
1
Bu
n
)] 11.8 (1.3) 52.7 (6.8) 16.6 (n=1) - 4.44
[CuCl2(L
1
Bu
2
)] 19.6 (3.6) 27.1 (1.8) 19.8 (14.4) - 4.24
[CuCl2(L
1
Bu
i
)] 9.8 (1.0) 17.3 (0.4) - - 4.4
[CuCl2(L
1
Bu
t
)] not isolated not isolated not isolated - 3.7
[CuCl2(L
1
Cy)] 10.0 (1.7) 21.8 (0.7) - - 5.05
racemic -
[CuCl2(L
1
CyMe)]
16.7 (0.7) 22.9 (2.8) - - 5.71
[CuCl2(L
1
Ph)] 8.8 (0.4) 27 (1.5) - >100 5.28
[CuCl2(L
1
PhMe)] 16.6 (0.5) 27.2 (1.3) - - 6.25
[CuCl2(L
1
PhCl)] insoluble insoluble insoluble - 6.4
[CuCl2(L
1
PhNO2)] 11.9 (5.7) 24.7 (2.6) 6.2 (2.2) - 3.68
IC50 M
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The acute toxicity of this series of complexes was >100µM showing the complexes are 
slow working, especially when compared to cisplatin (2.5 µM) after a 1 hour exposure.  
  
227 
7.1.1.4. ZincIIchloride Complexes of L1R 
 
Figure 75. Plots showing the response of DLD-1, H460, HT29, cells following 6 day 
drug exposure to Zinc
II
chloride complexes of L
1
R with cisplatin and Zinc
II
chloride 
curves shown for comparison. Each point represents the mean of three independent 
experiments. 
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Table 39. Cytotoxic activity of Zinc
II
chloride complexes, expressed as their mean IC50 
values in M for three independant experiments, ± standard deviation in brackets. 
 
 
All water/DMSO soluble complexes of this series were tested against DLD-1 and H460 
cell lines with only two complexes tested against HT29. All but one of the aromatic 
complexes was insoluble in DMSO or water and so could not be tested.  
 
From Figure 75, it is clear the mass of lines intersect the 50% population mark at similar 
concentrations and therefore no trend is apparent from the data observed, all complexes 
are moderately toxic against DLD-1 and H460 cell lines with slightly greater potency 
toward the HT29 cell line (average IC50 for all complexes 15.2, 17.9 and 7.4 µM 
respectively, see Table 39). The selectivity of the complexes toward the three cell panel 
is generally in the order HT29>DLD-1≈H460. The most toxic complex appearing to be 
[ZnCl2(L
1
Et)], with its highest potency 6.5 µM against HT29 cells which is merely 2.5 
Compound DLD-1 H460 HT29 1Hr Exposure DLD-1 cLogP of Ligand
Cisplatin 1.08 (0.05) 0.52 (0.05) 2.6 (0.6) 2.5 (0.5)
[ZnCl2(L
1
Et)] 11.5 (3.9) 17.6 (6.6) 6.5 (3.0) >100 2.63
[ZnCl2(L
1
Pr
n
)] insoluble insoluble insoluble - 3.6
[ZnCl2(L
1
Pr
i
)] 15.16 (0.8) 15.8 (0.1) - - 3.27
[ZnCl2(L
1
Bu
n
)] 13.4 (3.6) 15.2 (2.9) 8.3 (1.7) - 4.44
[ZnCl2(L
1
Bu
2
)] 16.4 (2.1) 16.5 (1.9) - - 4.24
[ZnCl2(L
1
Bu
i
)] 16.4 (0.1) 17.5 (2.3) - - 4.4
[ZnCl2(L
1
Bu
t
)] 11.5 (1.7) 18.3 (3.1) - >100 3.7
[ZnCl2(L
1
Cy)] 16.7 (1.2) 20.8 (2.7) - - 5.05
racemic -
[ZnCl2(L
1
CyMe)]
18.6 (3.0) 16.3 (3.0) - - 5.71
[ZnCl2(L
1
Ph)] 17.4 (1.1) 22.7 (2.0) - >100 5.28
[ZnCl2(L
1
PhMe)] insoluble insoluble insoluble - 6.25
[ZnCl2(L
1
PhCl)] insoluble insoluble insoluble - 6.4
[ZnCl2(L
1
PhNO2)] insoluble insoluble insoluble - 3.68
IC50 M
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fold more than that of cisplatin (2.6 µM). The zinc complexes of this series also showed 
no acute toxicity toward DLD-1 cell lines.  
7.1.1.5. General Observations 
 
There are clearly no significant differences in IC50 values and no particular structure 
activity trends associated with the ligand observed for the dichloride metal salts. All 
complexes show approximately two fold selectivity towards DLD-1 cell lines than 
toward the H460 cell line, with the exception of nickel and zinc complexes where the 
values are comparable, and most complexes were more selective towards the HT29 
cells. In general most IC50 values against all cell lines were within the same order of 
magnitude and the initial presumption is that these complexes show little selectivity 
towards a particular cell line. Although this is only a presumption from the results 
obtained here and more tests against a wider array of cell lines would need to be carried 
out to fully identify the selectivity of this class of compound. However the limited 
selectivity data obtained from this screen indicates a reversal in selectivity to that shown 
by cisplatin. This would suggest these complexes are not working in an analogous 
manner to cisplatin and another mechanism must be at play. 
 
Because these compounds show little difference in activity between ligand groups, it is 
most likely that the complexes (of the same metal salt) are working by a similar 
mechanism. Since it has been shown the ligand is essential for the activity, a control 
experiment to obtain the cytotoxic activity of the free ligand would have been desirable 
to show the metal and ligand are both required for activity but unfortunately the free 
ligands were insoluble in DMSO and water. Although it was not possible to obtain the 
IC50 values of the free ligand due to their very poor solubilities, the fact there is a 
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difference between the different metal chloride complexes of the same ligands does 
suggest the metal and ligand both contribute to the toxicity observed. 
 
  
231 
7.1.2. Variation of Metal 
 
Figure 76. Plots showing the response of DLD-1, H460, cells following 6 day drug 
exposure and DLD-1 cells following 1 hour exposure to Metal
n+
chloride complexes of 
L
1
R with cisplatin curve shown for comparison. Each point represents the mean of three 
independent experiments. 
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Table 40. Cytotoxic activity of metal
n+
chloride complexes of L
1
Cy and L1PhMe for 
Ru
III
. Values are expressed as their mean IC50 values in M for three independant 
experiments ± standard deviation in brackets. 
 
 
Other than changing the ligand properties, a simple approach was to change the metal 
centre to identify which, (if any) metal would produce the most toxic species. The 
metals chosen in this study were the late first row transition metals. The metals Co
II
, 
Ni
II
, Cu
II
 and the non transition metal Zn
II
 were utilised in this study and the IC50 values 
for their dichloride complexes of ligand L
1
Cy are given in Table 40, along with the 
complex [RuCl3L
1
PhMe] and cisplatin for comparison. Figure 76 shows more distance 
between profiles than for complexes of the same metal salt. None of the complexes can 
better cisplatin for its cytotoxic potency against DLD-1 and H460 cell lines, though the 
most potent of the series was [RuCl3(L
1
PhMe)], being ~5 times less toxic to the DLD-1 
cell line and ~14 times less toxic to the H460 cell line than cisplatin. The remaining first 
row complexes showed moderate toxicity to the two cell lines. The chemosensitivity 
data show toxicities in the order Ru
III≈CoII>CuII≈ZnII>NiII, with CuII and ZnII having 
comparable values, with their toxicities towards the H460 cell line within experimental 
error the same 21.8 and 20.8 M respectively, but towards the DLD-1 cell line CuII 
shows slightly higher toxicity 10.0 M, where ZnII is 16.7 M. CoII, was shown also to 
Compound DLD-1 H460 1Hr Exposure DLD-1
Cisplatin 1.08 (0.05) 0.52 (0.05) 2.5 (0.5)
[RuCl3(L
1
PhMe)] 4.6 (0.7) 7.5 (1.2) 20.4 (3.5)
[CoCl2(L
1
Cy)] 6.4 (0.5) 8.0 (1.2) >100
[CuCl2(L
1
Cy)] 10.0 (1.7) 21.8 (0.7) -
[ZnCl2(L
1
Cy)] 16.7 (1.2) 20.8 (2.7) -
[NiCl2(L
1
Cy)] 34.0 (2.4) 31.9 (6.3) >100
IC50 M
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have not too dissimilar values to the Ru
III
 complex, being the most potent complexes of 
this series, their H460 cell toxicities of 7.5 and 8.0 M for the RuIII and CoII complexes 
respectively, again being within experimental error of each other. The least potent 
metal, Ni
II
, was some 7.6 times less toxic than Ru
III
 towards DLD-1 cells, and 4.3 times 
less toxic than Ru
III
 and Co
II
 towards H460 cells, though the complexes were still 
moderately toxic at 34.0 and 31.9 M, against the DLD-1 and H460 cells lines 
respectively. 
 
The observations for complexes [MCl2(L
1
Cy)] are also true for the average values of all 
ligands with the exception of H460 cells where Zn
II
 shows the greatest potency for the 
first row transition metals (Table 41). When the HT29 average is introduced the order is 
reversed form DLD-1 selectivity to Zn
II
>Cu
II
>Ni
II≈CoII, it must be noted however this 
series is an approximation from the results obtained. 
 Table 41. Average Cytotoxic activity of metal
n+
chloride complexes of L
1
R. 
 
 
Unfortunately for this series of complexes the results of a 1 hour exposure to the full 
panel of cell lines were not obtained and just a handful of complexes were tested for 
their acute toxicities against DLD-1 cell lines. In Table 40 the acute toxicities, (in the 
form of a 1 hour exposure), are reported for a few complexes of each metal complex. It 
is clear that none of the first row transition metal complexes show any acute toxicity 
Compound DLD-1 H460 HT29
Cisplatin 1.08 (0.05) 0.52 (0.05) 2.6 (0.6)
[CoCl2(L
1
R)] 9.7 22.5 22.4
[NiCl2(L
1
R)] 32 47.5 20.1
[CuCl2(L
1
R)] 14.0 28.3 15.7
[ZnCl2(L
1
R)] 15.2 17.9 7.4
IC50 M
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toward the two cell lines to which they were exposed, with none showing any cell kill in 
the concentration range used for this assay.  However [RuCl3(L
1
PhMe)] interestingly 
exhibited moderate potency (20.4 µM) in a 1 hour exposure to DLD-1 cells, which 
although it is 10 fold to that of cisplatin this result shows promise. It could also be a 
reasonable assumption that the mechanism could be associated with DNA alkylation, 
since those complexes that bind to DNA would remain within the cellular compartments 
upon washing after the 1 hour exposure, (see experimental), whereas those complexes 
that do not bind, are more likely be washed out in the media and have a lower 
concentration intracellularly. The bound complexes could then still carry out their 
cytotoxic effect. Therefore the acute toxicities would be controlled by the DNA binding 
affinities of the complexes and the cells ability to process the DNA in their presence. 
This is also corroborated by an observation made during the experiment. It was visually 
observed that after washing the cells after a 1 hour exposure to [RuCl3(L
1
PhMe)] a deep 
red colour remained within the cellular mass which followed an intensity proportional 
to the concentration gradient.  
 
The fact that the acute toxicities of the first row complexes are nowhere near the values 
for their longer exposure, implies that these complexes do not work via a DNA 
alkylating mechanism, or at least if they do, their DNA binding is particularly labile and 
can be processed easily by the cellular repair mechanism’s, or their cell membrane 
permeabilities are poor.  So if it is likely that these first row complexes are not operating 
via a DNA binding mechanism or at least a co-ordinating mechanism to produce 
macromolecular dysfunctions, how else can they produce their cytotoxic activity?  
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One explanation to this could be that they may act via a redox mechanism. The metals, 
could perhaps get into the cells and enter a catalytic redox cycling, which could lead to 
the production of reactive oxygen species and inevitably cause oxidative stress within 
the cellular environment. The oxidative stress could lead to all sorts of disruptions to 
cellular processes; one in particular would be DNA damage by the radical species 
produced during oxidative stress. But however, if this hypothesis were to be true, why 
do the redox inactive Zn
II
 complexes show comparable toxicities to the redox active 
complexes of Co
II
 and Cu
II
? The answer to this could be that either the complexes all 
work by the same mechanism that does not involve a redox process, or that the Zn
II
 
complexes work via a different mechanism. This latter statement could be a reasonable 
one and is weakly supported when considering the average toxicities from Table 41 
since Zn
II
 complexes show a selectivity to the three cell lines in the order DLD-1 ≈ 
H460 < HT29, whereas the Co
II
 Ni
II
 and Cu
II
 complexes seem to have a similar 
selectivity profile being approximately DLD-1≥HT29>H460 for the most of the 
complexes in each series. However this explanation is by no means exclusive. 
  
236 
7.1.3. Variation of Anion 
 
Figure 77. Plots showing the response of DLD-1, H460, HT29, cells following 6 day 
drug exposure to CoX2 complexes of L
1
R with cisplatin and curve shown for 
comparison. Each point represents the mean of three independent experiments. 
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Figure 78. Plots showing the response of DLD-1, H460, HT29, cells following 6 day 
drug exposure to NiX2 complexes of L
1
R with cisplatin and curve shown for 
comparison. Each point represents the mean of three independent experiments. 
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Figure 79. Plots showing the response of DLD-1, H460, HT29, cells following 6 day 
drug exposure to CuX2 complexes of L
1
R with cisplatin and curve shown for 
comparison. Each point represents the mean of three independent experiments. 
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Figure 80. Plots showing the response of DLD-1, H460, HT29, cells following 6 day 
drug exposure to ZnX2 complexes of L
1
R with cisplatin and curve shown for 
comparison. Each point represents the mean of three independent experiments. 
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Table 42. Average Cytotoxic activity of MX2 complexes of L
1
R, expressed as their 
mean IC50 values in M for three independant experiments ± standard deviation in 
brackets. 
 
 
The third series of structural changes, involved the systematic variation of the metal salt 
used to prepare the complexes. The idea behind this was to incorporate a systematic 
variation in the anionic coordinating ligands around the metal centre, to produce 
complexes of the general formula [MX2(L
1
R)], (M = Co
II
, Ni
II
, Cu
II
, Zn
II
; R = aryl, alkyl 
group; X = anionic coordinating ligand), for a fixed R group. It was also possible to 
introduce anions of differing coordinating power and denticity, which could result in 
differences in coordination geometry about the metal centre. Using this concept and 
Compound DLD-1 H460 HT29
Cisplatin 1.08 (0.05) 0.52 (0.05) 2.6 (0.6)
[CuCl2(L
1
Pr
n
)] 18.2 (1.8) 31.1 (5.3) 26.5 (2.7)
[Cu(NO3)2(L
1
Pr
n
)] 13.2 (3.0) 25.6 (7.7) -
[CuBr2(L
1
Pr
n
)] 16.3 (3.4) 15.2 (7.2) -
[Cu(L
1
Pr
n
)2][BF4]2 5.4 (1.1) 13.8 (0.3) 4.0 (0.4)
[Cu(L
1
Cy)2][BF4]2 10.0 (0.2) 22.9 (1.5) -
[CoCl2(L
1
Cy)] 6.4 (0.5) 8.0 (1.2) -
[CoBr2(L
1
Cy)] 3.8 (0.2) 7.8 (0.3) 4.4 (0.4)
[Co(AcO)2(L
1
Cy)] 16.8 (2.1) 30.3 (1.5) -
[Co(L
1
Cy)2][Co(NCS)4]* 9.8 (0.3) 22.5 (2.5) -
[Co(L
1
Cy)2][NO3]2 8.9 (0.9) 17.8 (2.0) -
[Co(L
1
Cy)2][BF4]2 8.4 (0.5) 16.9 (1.9) -
[ZnCl2(L
1
Bu
t
)] 11.5 (1.7) 18.3 (3.1) -
[Zn(NO3)2(L
1
Bu
t
)] 14.7 (0.8) 18.5 (0.5) -
[Zn(AcO)2(L
1
Bu
t
)] 15.1 (2.5) 18.9 (1.5) -
[NiCl2(L
1
Cy)] 34.0 (2.4) 31.9 (6.3) -
[Ni(AcO)2(L
1
Cy)] 29.3 (1.8) 29.8 (1.3) -
Copper
Zinc
Nickel
Cobalt
IC50 M
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based on structural reports of similar structures, several complexes with a ligand to 
metal stoichiometry of 2:1 were obtained with the general formula [M(L
1
R)2][X]n, (M = 
Cu
II
, Co
II
; R = aryl, alky group; X = spectator anion). The preparation of this class of 
compound provided an interesting addition to the structural variation of these 
complexes, namely coordinative saturation. Here the metals are now coordinatively 
saturated by the bis-terdentate pyridine Schiff base ligands, and would result in a greater 
chelative effect than for monodentate or bidentate ligands and so in vivo would provide 
less ability for binding to donor sites, since the metal is fully chelated and in the form of 
a stable complex. As mentioned in the introduction, the mechanism of cisplatin requires 
lability at the platinum centre, which is provided by hydrolysis, which can then facilitate 
DNA binding. Hydrolysis can only happen however, if there is a relatively labile ligand 
attached to the metal centre and in the case of cisplatin, chloride provides this 
prerequisite. So to back up the argument provided in the previous subsection that DNA 
binding is less likely to be involved in the mechanism, this class of complex could 
potentially provide the answer. If this class of complex could provide comparable 
toxicities to the cell lines as their analogous 1:1 complexes, then it could be argued that 
this class of complex does not deliver it’s toxicity through a DNA binding or for that 
fact any chelating mode of action.   
 
If we look firstly at the cytotoxicity data for the complexes of type [CuX2(L
1
Pr
n
)], 
(where X = acido ligand), we can observe no real difference in activity for the DLD-1 
cell lines, and likewise we can also say the same is mostly true for the H460 cell line. 
However the bromide complex does show a lower value than the chloride and nitrato 
towards H460, but this value is pretty erroneous, with a standard deviation that could 
take it almost to within the values for the chloride and nitrato complexes.  So for the 
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copper complexes we can conclude that for this class of compound, these particular 
coordinating anions have no effect on activity. 
 
For the Co
II
 complexes of type [CoX2(L
1
Cy)], (where X = acido ligand), we can 
observe that the chloride and bromide have very similar IC50 values, which both are 
relatively potent with regard to the rest of the IC50 values observed so far. In fact the 
bromide complex is more active against DLD-1 cell lines than any other complex  and 
shows an IC50 value 3.5 times less than cisplatin. The acetate complex however shows a 
marked difference in toxicity from the chloride and bromide complexes with a 2.6 fold 
higher IC50 toward DLD-1 than its analogous chloride complex and a 3.9 fold higher 
IC50 against H460. This order of activity resembles that of the spectrochemical series, 
which is also a good indicator for the order of stability:   
 
Carboxylate>>Cl
-
>Br
- 
 
Here the carboxylate ligand, which is kinetically less labile would be expected to show 
less activity if DNA binding was the mechanism of action for this compound class, 
since hydrolysis would be the activation step. However hydrolysis could also be the first 
step in formation of the bis complex (ligand:metal, 2:1), since the complex 
[Co(L
1
Cy)2][BF4]2, was isolated by accident from an attempted aqueous ligand 
metathesis with AgBF4. Which could then lead to the bis-complex being the active 
species in vitro, where a redox mechanism of action could be involved.   
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7.1.4. Variation of Ligand ‘Head’ Group 
Figure 81. Plots A-C showing the response of DLD-1 (A), H460 (B) cells following 6 
day drug exposure to Copper
II
chloride complexes of L
1
Bu
i
 and L
3
Bu
i
 with cisplatin 
curve shown for comparison. Each point represents the mean of three independent 
experiments. 
 
 
 
Table 43. Average Cytotoxic activity of Copper
II
chloride complexes of L
1
Bu
i
 and 
L
3
Bu
i
, expressed as their mean IC50 values in M for three independant experiments ± 
standard deviation in brackets. 
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DLD-1 H460
Cisplatin 1.08 (0.05) 0.52 (0.05) - 2.07
[CuCl2(L
3
Bu
i
)] 4.3 (0.1) 2.9 (0.1) 4.26 1.5
[CuCl2(L
1
Bu
i
)] 9.8 (0.7) 17.3 (0.4) 4.4 0.6
Compound
Selectivity Ratio            
DLD-1 : H460
IC50 M
cLogP of Ligand
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The final series of complexes was not as comprehensive as had been hoped, owing to 
solubility issues of the L
2
R and L
3
R complexes. The IC50 data of only one complex of 
this ligand class was obtained, and even this is a maximum IC50 due to incomplete 
dissolution in DMSO to produce the stock solution prior to dilution. Therefore the IC50 
value for this complex would actually be lower than the one stated in Table 43, but to 
what degree is unknown.  
 
The concept of varying the ligand head group was for the intention that some structural 
and chemical features of the complexes could be systematically altered from one head 
group to another, (see section 1.9), and that correlations could hopefully be 
distinguished from the chemosensitivity assays. Because only one complex was able to 
be tested, this plan was not as successful. However the points raised from this single 
result are informative and somewhat intriguing.  
 
Table 43, shows this lone result for [CuCl2(L
3
Bu
i)], along with it’s L1Bui analogue and 
cisplatin for comparison. Though only this single complex was able to be tested, it can 
be seen that it’s IC50 value is as toxic as any complex shown previously, and in fact was 
the most potent complex of the whole study. [CuCl2(L
3
Bu
i
)], is Ca. 4 fold less toxic to 
DLD-1 cell lines than cisplatin and Ca. 6 fold less toxic to H460 cell lines, these values 
show that this complex is not largely different from cisplatin in terms of cell line 
sensitivity. 
 
The analogous [CuCl2(L
1
Bu
i
)] complex is 2.3 fold less potent to the DLD-1 cell line 
than its L
3
Bu
i
 analogue and 6 fold less toxic to H460 cells. Clearly the L
3
 complex has a 
more promising profile than any of the L
1
R complexes. Not only does it show greater 
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cytotoxicity, but there is also a clear reversal in the selectivity toward the two cell lines 
compared to the L
1
R complexes. Although the difference is not too significant, the 
complex [CuCl2(L
3
Bu
i
)] has higher toxicity to H460 than to DLD-1. This difference in 
selectivity between cell lines, leads to the tentative conclusion that this complex cannot 
be acting by the same mechanism as with its L
1
R analogues. The selectivity ratio toward 
H460 for [CuCl2(L
3
Bu
i
)] is 1.5 and is closer to cisplatin with a ratio of 2.1 than it is to 
its L
1
Bu
i
 analogue at 0.6.  These figures may indicate that from the presumptions we 
have made so far and the facts we already know, that if L
1
R complexes are not working 
via a DNA binding mechanism and that cisplatin does, then perhaps the H460 cell line 
is more chemosensitive to drugs whose mechanism of action is DNA binding than the 
DLD-1 cell line. It could then be argued that the L
3
Bu
i
 complex could be working via a 
DNA binding mechanism owing to it’s selectivity toward the H460 cell line.   
 
This conclusion bodes well with the initial rationale for altering the ligand head groups, 
which was to increase the planar aromatic portion and therefore enable intercalative 
capabilities. This could then afford a foothold to covalent binding of the metal centre 
and as a result lead to cellular dysfunctions and ultimately cell death. Alternatively, if 
this is not the case and the L
3
Bu
i
 complex does not exert it’s toxicity through DNA 
binding, the ligand must somehow be playing a part in the increased toxicity from its 
L
1
Bu
i
 analogue. From the crystal structure, the coordination geometry of the metal has 
slight differences between the two structures. The L
1
Bu
i
 complex favours the distorted 
square based pyramid whereas the L
3
Bu
i
 complex prefers the distorted triganol 
bipyramidal geometry, however this slight difference will have little consequence on the 
toxicity seeing as though [CuCl2L
1
Bu
i
] is a rare case of distorted square based pyramid, 
since the majority of the [CuCl2(L
1
R)] complexes exhibit the distorted triganol 
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bipyramidal geometry, and moreover, these geometries are more likely to be a 
consequence of crystal packing and could possibly adopt anything in between triganol 
bipyramidal and square based pyramidal in solution. Also though both ligands are 
shown to be terdentate from the crystal structures, the [ZnCl2(L
3
R)] complexes are 
shown to be tetradentate at room temperature in solution by NMR spectroscopy, (see 
section 5.2.5). This however is proposed to be an exchange process between the vacant 
and coordinated Schiff base N atoms, which is too fast to be resolved on the NMR 
timescale at ambient temperature and so a time averaged spectrum is observed.  This 
fluxionality between the two sites however may have an effect on the metal redox 
properties and as a consequence the cytotocitity of the complex.  
 
The cLogP’s of the ligands are almost identical (see section 1.9, Table 6) and so 
lipophilicity of the ligand cannot play a part in the enhanced toxicicity, however, there 
is clearly some difference in aqueous solubility between the two class of complex and 
this could be down to the effect the ligand has on hydrolysis rates at the metal. The 
majority of the L
1
R complexes are readily water soluble and as mentioned earlier the 
L
3
R complexes have very poor aqueous solubility, this gives an indication to the ionic 
nature of the two complexes (conductivity studies here could have been beneficial). 
From this crude observation it is possible that hydrolysis of the [CuCl2(L
1
R)] complexes 
is instantaneous in water to give either of the aqua complexes [CuCl(H2O)(L
1
R)]
+
 or 
[Cu(H2O)2(L
1
R)]
2+
 and also the more likely product from here would be [Cu(L
1
R)2]
2+
, 
and in contrast the [CuCl2(L
3
Bu
i
)] could remain as the neutral dichloride complex. This 
likelihood leads to the suggestion that the neutral [CuCl2(L
3
Bu
i
)] complex could have a 
greater chance of diffusion through the cell membrane where it can then carry out it’s 
mode of action, where it could possibly bind with DNA, or have at least a better chance 
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of this occurring. Again at this point it would have been very beneficial to have 
obtained the 1 hour exposures for this compound, to see if this reasoning could be 
backed up by a more acute chemosensitivity.   
  
7.2. DNA Damaging Assay 
 
After obtaining the chemosensitivity data for the majority of complexes in the 
compound matrix and proposing some potential mechanistic modes of action. One of 
the concepts was the potential for the complexes to be involved in redox cycling, which 
could lead to oxidative stress within the cell. This redox cycling could lead to the 
production of radicals and in particular the production of hydroxyl radicals in the close 
proximity to DNA to cause considerable damage. This damage can be monitored by a 
simple assay involving incubation of the compound under test, with supercoiled plasmid 
DNA and also H2O2 as an oxidant, (or any possible substrates) so redox cycling can 
occur. After incubation for 1 hour the DNA is then subject to agarose gel elecrophoresis 
to separate different fractions of DNA based on density of the DNA fragments. The gel 
can identify two types of DNA damage via this method. The highest band in the gel 
corresponds to undamaged supercoiled (SC) DNA. The second band observed is due to 
open circular (OC) DNA, which is caused by single strand breaks to the supercoiled 
plasmid DNA. The third band identifies that OC DNA undergoes breaking of a second 
strand, (called a double strand break), which gives rise to linear (L) DNA. Obviously 
the production of L DNA identifies quite significant DNA damage. This procedure can 
be used as a semi quantitative method by visual observation of the intensity of the bands 
produced on the gel.   
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Figure 82. DNA damaging assay of supercoiled plasmid DNA. All lanes contain 
Plasmid DNA. 1, DNA Control; 2, cisplatin; 3, EO9, NQO1, NADH positive control; 4, 
H2O2 control; 5, [CuCl2(L
1
Pr
n
)]; 6, [CuCl2(L
1
Pr
n
)], H2O2; 7, [CoCl2(L
1
Cy)]; 8, 
[CoCl2(L
1
Cy)], H2O2; 9, [ZnCl2(L
1
Cy)]; 10, [ZnCl2(L
1
Cy)], H2O2; 11, [CuCl2(L
3
Bu
i
)]; 
12, [CuCl2(L
1
Bu
i
)], H2O2. SC indicates band for supercoiled DNA; OC indicates band 
for open circular DNA; L indicates band for linear DNA; arrows indicate direction of 
mobile phase.  
 
 
From Figure 82, lanes 1 and 4 identify controls for plasmid DNA alone and plasmid 
DNA with peroxide respectively. Lane 2 is that of cisplatin, which identifies that 
cisplatin alone produces significant single strand breaks, it’s neighbour in lane 3 is a 
positive control consisting of EO9, NQO1 and NADH which also shows significant 
single strand breaks as was intended and some double strand breaks are also observed.  
All complexes incubated alone with plasmid DNA (lanes 5,7,9 and 11), produced no 
DNA damage on examination of the gel. However after incubation of the complexes 
with plasmid DNA in the presence of hydrogen peroxide, revealed DNA damage had 
occurred in all cases, except for the complex [ZnCl2(L
1
Cy)], which produced no DNA 
damage at all. This result is as expected as Zn
II
 has no redox activity. The remaining 
three compounds [CuCl2(L
1
Pr
n
)], [CoCl2(L
1
Cy)] and [CuCl2(L
3
Bu
i
)] all showed 
relatively large amounts of single strand breaks and double strand breaks can also be 
observed. Both the Cu
II
 complexes produced single strand breaks of approximately 
equal magnitude and are comparable to the positive control EO9 and cisplatin. The Co
II
 
complex however demonstrates greater amounts of single strand breaks due to the very 
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intense band of OC DNA on the gel and also a much more noticeable loss in intensity 
for the band of SC DNA. Also this complex provides much more damage than the 
control and any of the Cu
II
 complexes, which is evident from the more intense band for 
L DNA, which is associated with double strand breaks.    
 
These results show very clearly the impact of these complexes on DNA damage in the 
presence of an oxidant.  Based on a qualitative observation is is clear that the Co
II
 
complex causes the largest amount of DNA damage, even more than cisplatin and the 
positive control EO9. The complex [CuCl2(L
3
Bu
i
)] seems to show the second highest 
DNA damage, where single and double strand breaks are clearly exhibited. The 
intensity of both single and double strand bands of the Cu
II
 complex of L
3
Bu
i
 also 
appear to be considerably greater than its L
1
Bu
i
 counterpart. This observation fits well 
the chemosensitivity data and clearly demonstrates the enhancement the phenanthroline 
moiety can have on the chemistry of the metal. 
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8. Conclusions 
 
This work was aimed at preparing a library of novel Schiff base complexes with subtle 
structural variations to be screened against a panel of cancer cells in a cytotoxicity assay 
to obtain structure activity relationships. The synthetic work in this thesis has developed 
improved methods and routes from the literature and characterisation work has also 
exposed some of the co-ordination characteristics of these complexes in the solid state 
and in solution.  
 
From a synthetic point of view this thesis has been very productive and as well as 
successfully preparing compounds by know literature procedures, several routes and 
methods from the literature and previous PhD colleagues at the university have been 
improved to give either higher yields, better purity, or less steps and in some cases all 
three. The first synthesis to be improved in this thesis was the preparation of the 
precursor dialdehyde 2,2’-bipyridine-6,6’-dialdehyde P2. In the literature and from my 
predecessors, the final preparation of the dialdehyde often required two steps from 6,6’-
dimethyl-2,2’-bipyridine P2b isolating the bromomethyl intermediate and oxidising with 
DMSO. It has been shown in this thesis that the same transformation can be done in one 
step using a DMSO oxidation of the preformed methyliodide complex to give the 
desired dialdehyde in 71% yield. A significant improvement compared to an overall 
yield of 4% in one Bradford thesis.
193
  
 
A further literature synthesis was developed by applying well known principles of 
optimising yields by taking advantage of le Chateliers principle regarding systems in 
equilibria. It has been shown how yield and purity improvements can be achieved by 
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removal of water and using a slight excess of amine in Schiff base ligand syntheses, 
particularly regarding ligands containing aliphatic tail groups. 
 
An improved and novel template synthesis of co-ordination complexes of macroacyclic 
Schiff base ligands has also been demonstrated. The particular class of complex 
prepared in this thesis is exclusively reported as being prepared via a free ligand 
approach in the literature, which involves a step preparing and isolating the free Schiff 
base ligand, followed by further reaction in the second step with a metal salt to generate 
the Schiff base complex which is again isolated. Although template syntheses are very 
common, it is the first time that the template methodology has been utilised for this 
class of macroacyclic complex. A plausible mechanism for this transformation has also 
been proposed which clearly shows the role of the metal in speeding up the Schiff base 
reaction and stabilising the product. This reaction is a one pot, one step synthesis with 
easily isolable and highly pure products. Furthermore the reaction is visually observed 
as being complete at time of mixing at room temperature. Altogether this approach has 
afforded 80 novel complexes in moderate to quantitative yield. One particular advantage 
of this methodology is in the preparation of Schiff base complexes where the aniline 
precursor is not sufficiently nucleophilic. An example of this is the Schiff base ligand 
L
1
PhNO2, which could not be synthesised as the free ligand, but could be generated as 
the complex [MX2(L
1
PhNO2)] via the template approach. This particular methodology 
could be probed further by testing other poorly nucleophilic amines to see if they too 
can form the intact complexed ligand. This opens other routes to generate free amines 
by templating with a metal such as Ba
II
 and reducing the complexed ligand with 
borohydride for instance. 
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78 Schiff base complexes of late first row transition metal salts Co
II
, Ni
II
, Cu
II
, Zn
II
 and 
Ru
III
, with differing anionic co-ordinating and non-co-ordinating counterions were 
successfully prepared. A comprehensive structural study has been carried out by a 
variety of techniques in both the solid state and in solution. Of the 78 complexes it was 
possible to characterise 35 of them by single crystal X-ray diffraction. It has been 
possible to identify the major co-ordination characteristics of this class of complex and 
compare the impact of the subtle structural variation.  
 
It was evident and surprising that although the L
2
R and L
3
R ligands offer four donor 
atoms, they generally afford tridentate chelates analogous to the three donar L
1
R ligand. 
However in one bipyridine complex [Zn(NO3)(H2O)(L
1
PhMe)][NO3], it seems the 
anion dictates the denticity, where a four co-ordinate distorted octahedral complex is 
observed.  
 
The co-ordination geometry typically observed for nearly all complexes (with the 
exception of Ni
II
 and bis complexes) is five co-ordinate and distorted somewhere 
between trigonal-bipyramidal or square based pyramidal. 
 
N
M
N
N
X
X
M
N
N
X
N
X
distorted square-pyramidaldistorted triganal-bipyramidal
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Ni
II
 complexes on the other hand showed preference for 6 co-ordinate distorted 
octahedral geometries. An exceptional complex was [-Cl2{NiCl(L
1
Pr
n
)}2], where two 
monomeric complexes formed a dimer through bridging chloro ligands.  
 
Several L
1
R complexes were prepared with different counter ions. From their x-ray 
structures and vibrational spectroscopy it was possible to characterise the co-ordination 
modes of the majority of these ligands. One particularly interesting complex was the 
saline [Co(L
1
Cy)2][CoNCS4], which was intended to be the mono ligated metal with 
two co-ordinated isothicyanato anions. The x-ray crystal structure of this complex 
identified the bis ligated cation and a tightly bound tetra-isothiocyanato cobaltate 
spectator. The symmetry of this anion was also corroborated through the isothiocyanato 
stretching frequencies present in the infra-red and Raman spectra. Other bis complexes 
were prepared in this study. Copper(II) complexes generally formed monomeric species 
unless non-coordinating counter ions were used (BF4
-
 in this study), where bis 
complexes were observed as expected from the literature. As for Cobalt(II) complexes, 
bis ligated complexes were prepared even when relatively good co-ordinating anions 
were used, namely SCN
-
 and NO3
-
. In all bis ligated complexes the cations were 
isostructural exhibiting a 6-co-ordinate octahedral co-ordination geometry, with counter 
ions as spectators.  
 
The solution chemistry of both the diamagnetic and some paramagnetic complexes in 
this thesis were also studied by NMR spectroscopy. Several paramagnetic cobalt 
complexes of ligands L
1
R gave rise to isotropically shifted resonances which appeared 
as broad singlets. These signals were plausibly assigned on the basis of peak areas, 
proximity to the metal centre and comparison with spectra of similar paramagnetic 
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structures. Copper however only gave rise to tail group signals, these were only 
observed when the tails were aliphatic and their resonances retained the characteristics 
of diamagnetic signals. Zinc complexes were simple to characterise as these were all 
diamagnetic and gave ligand signals analogous to free ligand. Through NMR it became 
apparent that in all cases the metal and Schiff base ligand remain intact when in 
solution, showing C2 symmetric spectra in all cases. However it is possible that the co-
ordinated anions attached to the metal are substituted with solvent molecules or at least 
exchanging. It is highly likely that in D2O these complexes become aquated upon 
dissolution, becoming ionic which gives rise to their good aqueous solubility. 
  
All transition metal complexes Ni, Co and Cu are paramagnetic as identified by the 
Evans NMR magnetic susceptibility experiments. Based on the magnetic moments and 
anion counts from crystal structures and based on CHN data, all metals retained the +2 
oxidation state. Both Ni
II
 and Co
II
 complexes give rise to high spin magnetic moments 
which are slightly departed from spin only values, these values do not change with the 
varying ligands used within this study. Magnetic susceptibility could also be used as a 
tool to infer the co-ordination geometry about Co
II
. When Co
II
 complexes of L
1
R 
ligands contained co-ordinating anions, it was most likely that the metal centre had a co-
ordination number of 5. Since the spin state of the Co
II
 centre was high spin it could be 
inferred that the geometry is close to triganol bipyramidal. Cu
II
 on the other hand cannot 
permutate spin states and hence a magnetic moment for one unpaired electron is 
observed which is close to the spin only value and confirms Cu
II
 since Cu
I
 is 
diamagnetic. 
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Complexes of ligands L
2
R and L
3
R also exhibited NMR spectra of C2 symmetric 
complexes, indicative of symmetrical tetradentate chelates. However this was 
contradictory to their x-ray crystal structures, where they exhibited unsymmetrical 
terdentate complexes. Variable temperature NMR experiments down to -65°C could not 
resolve any plausible fast exchange at room temperature, indicating a symmetrical co-
ordination mode in the NMR solvent employed or an extremely low energy barrier to 
interconversion. 
 
The second part of this thesis concentrated on the evaluation of these complexes as 
potential new anti-cancer metallopharmaceuticals. This was carried out by screening the 
generated complex library against a panel of cancer cell lines, firstly to obtain the 
cytotoxic potency of these complexes against a leading standard cytostatic, cisplatin. 
Secondly versus each other to form structure activity relationships and thirdly to 
identify if the complexes act in a similar manner to cisplatin by comparing cell line 
selectivities of the test compounds versus cisplatin. 
 
The above aims were successfully achieved in this study, and a comprehensive screen of 
the L
1
R complexes was obtained. However L
2
R and L
3
R complexes which suffered 
from poor aqueous and even DMSO solubility, did not provide the same comprehensive 
screen. Despite this the most promising candidate came from the L
3
R series and a few 
promising candidates have emerged as potential leads requiring further study and 
development from the L
1
R series.  
 
Cytostatic figures for the complexes under test were obtained utilising the MTT assay. 
It was discovered that the ligand is indeed essential for activity of the metal salts against 
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the panel of cell lines and it was largely discovered that the variation in ‘tail group’ and 
anionic coordinating ligands played little role in providing a dramatic variation in 
activity of the metal salt. In general all L
1
R complexes displayed moderate cytotoxicity 
showing a trend in activity with respect to the metal in the order 
Ru
III≈CoII>CuII≈ZnII>NiII, over a 6 day exposure to the three cell panel. RuIII was shown 
to be the most potent metal of the L
1
R series providing IC50 values of 4.6 (0.7) and 7.5 
(1.2) μM against the DLD-1 and H460 cell lines respectively, which is Ca. 4.6 and 15 
times less potent than cisplatin to the same cell panel respectively. Ru
III
 was discovered 
to be the only metal to provide an IC50 value from a 1 hour exposure to the DLD-1 cell 
panel. The value of 20.4 (3.5) μM is a moderate figure but again Ca. 10 fold less potent 
than cisplatin for the same test. 
 
The L
2
R and L
3
R complexes could not be screened by the same comprehension due to 
their low solubilities. However the lone screen that was possible from the very sparingly 
soluble complex [CuCl2(L
3
Bu
i
)] gave the most exciting result and most potent complex 
of this thesis. After a 6 day exposure, [CuCl2(L
3
Bu
i
)] gave IC50 values of 4.3 (0.1) and 
2.9 (0.1) μM against the DLD-1 and H460 cell lines respectively. These values are 
merely 4 and 6 fold more than Cisplatin to the same cell lines respectively and 
demonstrate the potential of this class of complex as cytostatic agents. It would be 
worth pursuing the phenanthroline complexes based on this discovery and more water 
soluble alternatives would be a good way forward. This could be achieved by trying 
different copper salts. Alternatively the ligand itself could be modified to be more polar 
and hence water soluble. An example of this could be condensation of the dialdehyde 
with the aniline sulphonate. It would also be worth quickly screening one complex of 
each of the metals Co
II
, Ru
III
, Ni
II
 and Zn
II
 to check if the same activity order as L
1
R 
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complexes is observed in L
3
R complexes. Since L
3
R complexes provided better activity 
than L
1
R complexes, it would also be beneficial to prepare a few water soluble 
complexes of L
2
R ligands to see if any enhanced potency is observed. 
 
Further studies utilising a semi-quantitative DNA damaging assay, demonstrated that all 
first row complexes can damage DNA when in the presence of hydrogen peroxide, with 
the exception of Zn
II
 complexes. Co
II
 appeared to afford the greatest DNA damage with 
the most intsense bands for double strand breaks. The Cu
II
 complex of the ligand L
3
Bu
i
 
also demonstrated a greater DNA damage as opposed to its L
1
Bu
i
 analogue. This along 
with observations that co-ordinatively saturated bis complexes gave rise to similar 
potency as their mono ligated counterparts does indicate a DNA binding mechanism is 
not part of the L
1
R complexes mode of action. This is also given some support by the 
observation of opposite cell line selectivity for L
1
R complexes to that of cisplatin.  
 
The observation that these complexes can operate via a redox pathway (exception of 
Zinc) does give hope to their moderate potencies, since this may not be a negative 
result. Indeed cisplatin is an exceptional anti-cancer metallopharmaceutical; however 
some drawbacks of cisplatin are related to its cytostatic potency and lack of selectivity 
for cancer and normal cells which leads to severe side effects during treatment. An area 
of opportunity of this class of redox active complex may be in their lack of potency in 
oxygenated cellular environemts. It may be that in a reductive environment, i.e. in 
hypoxic tissue (relatively specific to areas of cancerous tissue), these complexes could 
become activated upon reduction, to give more potent species. 
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9. Further Work 
 
It would therefore be worth identifying if potency of one L
1
R, L
2
R and L
3
R complex of 
each metal, (except Zinc) is enhanced in an anaerobic MTT assay or an assay utilising 
cellular spheroids which mimic hypoxic tissue.
194
 
 
Clearly when progressing or carrying out further studies of these complexes any 
alterations to tail groups should avoid many subtle variations as was used in this study, 
but less and more dramatic changes should be tried instead. If any future work based on 
these complexes progresses, and further structure activity relationships are saught, it 
may be worth generating ligands with substituted head groups, since it was the 
difference in these substituents which provided the greatest difference in activity of the 
complexes. 
 
Some experiments which were not carried out in this study due to either time, or 
hindsight after writing up this thesis would have been the following: 
 
 To screen one complex of each ligand and metal against a cisplatin resistant cell 
line to identify if any complexes can overcome the resistance problem of 
cisplatin. 
 To measure the 1 hour exposure MTT assay for the complex [CuCl2(L
3
Bu
i
)] to 
identify its acute potency 
 To measure DNA binding affinities for one complex of each ligand and metal 
and compare to cisplatin to identify if DNA binding could be a plausible mode 
of action for these complexes. 
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11. Appendix 
11.1. Madonna Model for the Simulation of Reaction Profiles 
 
The following models were used to obtain simulated reaction profiles of various Schiff 
base condensation reactions under various conditions. It was assumed in all cases that 
the forward rate constants, k1f and k2f of both steps was the same and vice versa for the 
backward rate constants k1r and k2r. The rate constants were estimated from a 
conversion time of 30 minutes (time to see 100% consumption of dialdehyde) and from 
the 5% residual monoimine observed at the end of reaction. The starting concentration 
of dialdehyde in all reactions was 74mM and hence rate constants of 7.5 M
-1
 min
-1
  for 
k1f and k2f  and 0.025 M
-1
 min
-1
 for k1r and k2r were used. 
11.1.1. Stoichiometric Reaction 
 
Dialdehyde Monoimine Diimine
k2f RNH2k1f RNH2
k1r H2O k2r H2O  
METHOD RK4 
 
STARTTIME = 0 
STOPTIME=80 
DT = 0.002 
 
k1f=7.5 
K1r=0.025 
k2f=7.5 
k2r=0.025 
k3=0 
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d/dt(dialdehyde)=-k1f*dialdehyde*RNH2+k1r*monoimine*H2O 
d/dt(monoimine)=k1f*dialdehyde*RNH2-k1r*monoimine*H2O-
k2f*monoimine*RNH2+k2r*diimine*H2O 
d/dt(diimine)=k2f*monoimine*RNH2-k2r*diimine*H2O 
d/dt(H2O)=k1f*dialdehyde*RNH2-k1r*monoimine*H2O+k2f*monoimine*RNH2-k2r*diimine*H2O-
k3*H2O 
d/dt(RNH2)=-k1f*dialdehyde*RNH2+k1r*monoimine*H2O-
k2f*monoimine*RNH2+k2r*diimine*H2O 
 
init(dialdehyde)=0.074  
init(monoimine)=0   
init(diimine)=0 
init(RNH2)=0.148 
init(H2O)=0 
11.1.2. Stoichiometric Reaction with Simulated Molecular Seives (Removal 
of Water) 
 
Dialdehyde Monoimine Diimine
k2f RNH2k1f RNH2
k1r H2O k2r H2O
k3 k3
 
METHOD RK4 
 
STARTTIME = 0 
STOPTIME=80 
DT = 0.002 
 
k1f=7.5 
K1r=0.025 
  
275 
k2f=7.5 
k2r=0.025 
k3=100 
 
d/dt(dialdehyde)=-k1f*dialdehyde*RNH2+k1r*monoimine*H2O 
d/dt(monoimine)=k1f*dialdehyde*RNH2-k1r*monoimine*H2O-
k2f*monoimine*RNH2+k2r*diimine*H2O 
d/dt(diimine)=k2f*monoimine*RNH2-k2r*diimine*H2O 
d/dt(H2O)=k1f*dialdehyde*RNH2-k1r*monoimine*H2O+k2f*monoimine*RNH2-k2r*diimine*H2O-
k3*H2O 
d/dt(RNH2)=-k1f*dialdehyde*RNH2+k1r*monoimine*H2O-
k2f*monoimine*RNH2+k2r*diimine*H2O 
 
init(dialdehyde)=0.074  
init(monoimine)=0   
init(diimine)=0 
init(RNH2)=0.148 
init(H2O)=0 
11.1.3. 0.1eq Excess of Amine and Simulated Water Removal 
 
METHOD RK4 
 
STARTTIME = 0 
STOPTIME=80 
DT = 0.002 
 
k1f=7.5 
K1r=0.025 
k2f=7.5 
k2r=0.025 
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k3=100 
 
d/dt(dialdehyde)=-k1f*dialdehyde*RNH2+k1r*monoimine*H2O 
d/dt(monoimine)=k1f*dialdehyde*RNH2-k1r*monoimine*H2O-
k2f*monoimine*RNH2+k2r*diimine*H2O 
d/dt(diimine)=k2f*monoimine*RNH2-k2r*diimine*H2O 
d/dt(H2O)=k1f*dialdehyde*RNH2-k1r*monoimine*H2O+k2f*monoimine*RNH2-k2r*diimine*H2O-
k3*H2O 
d/dt(RNH2)=-k1f*dialdehyde*RNH2+k1r*monoimine*H2O-
k2f*monoimine*RNH2+k2r*diimine*H2O 
 
init(dialdehyde)=0.074  
init(monoimine)=0   
init(diimine)=0 
init(RNH2)=0.155 
init(H2O)=0 
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11.2. Tables of Bond lengths and Angles for CuII Complexes of Ligand L1R. 
 
Table 44. Bond lengths for complexes of [CuX2(L
1R)], Symmetry codes: (i) −x+1, −y, z. 
N(1)—Cu 1.959 (2) 1.957 (2) 1.9265 (17) 1.9238 (16) 1.982 (4) 1.989 (3) 
N(2)—Cu 2.065 (3) 2.088 (3) 2.0829 (17) 2.0905 (17) 2.108 (3) 2.137 (3) 
N(3)—Cu 2.085 (3) 2.060 (2) 2.0673 (16) 2.0960 (18) N(2i)—Cu N(2i)—Cu 
X(1)—Cu 2.3414 (10) 2.4615 (5) 2.2399 (14) 2.2054 (15) 2.3265 (8) 2.3216 (9) 
X(2)—Cu 2.2839 (9) 2.4333 (4) 1.9443 (14) 1.9549 (14) X(1i)—Cu X(1i)—Cu 
C(11)—N(2) 1.267 (4) 1.255 (4) 1.263 (3) 1.270 (2) 1.275 (4) 1.300 (3) 
C(17)—N(3) 1.274 (4) 1.272 (3) 1.270 (3) 1.266 (3) C(11i)—N(2i) C(11i)—N(2i) 
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Table 45. Bond angles and geometrical parameters for complexes of [CuX2(L
1R)], Symmetry codes: (i) −x+1, −y, z. 
 [CuCl2(L
1
Pr
n
)] [CuBr2(L
1
Pr
n
)] 
[Cu(NO3)2(L
1
Pr
n
)]
a 
[Cu(NO3)2(L
1
Pr
n
)]
b 
[CuCl2(L1PhMe)] [CuCl2(L
1
PhCl)] 
N(1)—Cu—N(2) 77.83 (10) 78.02 (10) 79.11 (7) 78.57 (7) 77.75 (8) 77.49 (6) 
N(1)—Cu—N(3) 78.01 (11) 78.12 (9) 79.10 (7) 79.19 (7) 77.75 (8) 77.49 (6) 
N(2)—Cu—N(3) 155.45 (11) 155.77 (10) 156.84 (7) 157.52 (7) 155.51 (16) 154.97 (12) 
N(1)—Cu—X(1) 113.80 (7) 116.18 (7) 103.84 (6) 102.62 (7) 124.73 (3) 124.99 (3) 
N(1)—Cu—X(2) 135.69 (7) 131.22 (7) 171.00 (6) 167.05 (6) 124.73 (3) 124.99 (3) 
N(2)—Cu—X(1) 92.70 (8) 101.20 (8) 92.21 (6) 86.25 (6) 91.63 (7) 92.63 (7) 
N(2)—Cu—X(2) 97.72 (7) 95.90 (8) 99.12 (7) 100.31 (7) 91.63 (7) 92.63 (7) 
N(3)—Cu—X(1) 100.98 (9) 93.04 (7) 100.55 (6) 101.83 (7) 91.63 (7) 92.63 (7) 
N(3)—Cu—X(2) 96.46 (8) 96.61 (7) 101.17 (7) 100.60 (7) 91.63 (7) 92.63 (7) 
X(1)—Cu—X(2) 110.42 (4) 112.497 (18) 85.00 (6) 90.14 (6) 110.53 (5) 110.01 (5) 
N(2)—C(11)—C(12) 115.7 (3) 117.3 (3) 117.94 (19) 116.89 (18) 117.1 (3) 117.1 (3) 
N(3)—C(17)—C(16) 116.9 (3) 116.2 (2) 117.07 (19) 117.1 (2) 117.1 (3) 117.1 (3) 
N(2)—C(11)—C(12)—N(1) 1.6 (4) 5.0 (4) 1.6 (3) 2.8 (3) 0.5 (4) 0.2 (4) 
N(3)—C(17)—C(16)—N(1) 4.7 (4) 1.5 (4) 2.6 (3) 2.2 (3) 0.5 (4) 0.2 (4) 
τ 0.33 0.41 0.24 0.16 0.51 0.50 
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11.3. Tables of Bond lengths and Angles for NiII Complexes of Ligand L1R. 
 
Table 46. Bond lengths for Ni
(II)
 complexes of L
1
R, Symmetry codes: (i) –x+2, -y+2, -z+2. 
 [Ni(AcO)2(L
1
Cy)] [-Cl2{NiCl(L
1
Pr
n
)}2] [NiCl(H2O)2(L
1
Et)]Cl 
N(1)—Ni 1.969 (3) 1.9819 (18) 1.9909 (17) 
N(2)—Ni 2.190 (3) 2.1211 (19) 2.175 (4) 
N(3)—Ni 2.190 (3) 2.1222 (19) 2.133 (4) 
X(1)—Ni O(51) - 1.961 (3) Cl(1) - 2.4159 (7) O(1) - 2.099 (4) 
X(2)—Ni O(41) - 2.111 (3) Cl(2) - 2.3313 (10) Cl(1) - 2.3443 (5) 
X(3)—Ni O(42) - 2.110 (3) Cl(1i) - 2.5981 (7) O(2) - 2.097 (4) 
C(11)—N(2) 1.265 (4) 1.265 (3) 1.191 (7) 
C(17)—N(3) 1.258 (5) 1.268 (3) 1.352 (8) 
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Table 47. Bond angles and geometrical parameters for Ni
II
 complexes of L
1
R, Symmetry codes: (i) –x+2, -y+2, -z+2. 
 [Ni(AcO)2(L
1
Cy)] [-Cl2{NiCl(L
1
Pr
n
)}2] [NiCl(H2O)2(L
1
Et)]Cl 
N(1)—Ni—N(2) 77.16 (11) 77.38 (8) 76.9 (2) 
N(1)—Ni—N(3) 76.77 (11) 77.87 (8) 78.0 (2) 
N(2)—Ni—N(3) 153.90 (11) 155.17 (8) 154.85 (9) 
N(1)—Ni—X(1) 106.23 (12) 93.77 (5) 90.51 (19) 
N(1)—Ni—X(2) 97.16 (11) 167.09 (5) 178.99 (19) 
N(1)—Ni—X(3) 159.00 (11) 83.61 (5) 91.79 (19) 
N(2)—Ni—X(1) 96.27 (12) 87.78 (5) 89.47 (17) 
N(2)—Ni—X(2) 91.10 (11) 102.61 (5) 103.81 (15) 
N(2)—Ni—X(3) 101.63 (11) 89.63 (5) 91.38 (16) 
N(3)—Ni—X(1) 91.96 (13) 91.92 (5) 91.74 (15) 
N(3)—Ni—X(2) 91.11 (12) 101.95 (6) 101.33 (13) 
N(3)—Ni—X(3) 102.31 (11) 89.54 (5) 88.41 (16) 
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Table 48. Bond angles and geometrical parameters for Ni
II
 complexes of L
1
R, continued  Symmetry codes: (i) –x+2, -y+2, -z+2. 
 [Ni(AcO)2(L
1
Cy)] [-Cl2{NiCl(L
1
Pr
n
)}2] [NiCl(H2O)2(L
1
Et)]Cl 
X(1)—Ni—X(2) 156.49 (12) 99.13 (2) 88.80 (9) 
X(1)—Ni—X(3) 94.76 (12) 176.66 (2) 177.67 (6) 
X(2)—Ni—X(3) 61.83 (10) 89.54 (5) 88.89 (10) 
N(2)—C(11)—C(12) 118.4 (3) 117.1 (2) 118.6 (5) 
N(3)—C(17)—C(16) 119.0 (3) 118.1 (2) 117.7 (4) 
N(2)—C(11)—C(12)—N(1) 4.0 (5) 5.0 (3) 7.1 (8) 
N(3)—C(17)—C(16)—N(1) 3.2 (5) 3.3 (3) 3.1 (8) 
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11.4. Tables of Bond lengths and Angles for ZnII Complexes of Ligand L1R. 
 
Table 49. Bond lengths for complexes of [ZnX2(L
1
R)], Symmetry codes (i) −x, −y, z. 
 [Zn(NO3)2(L
1
Bu
t
)] [ZnCl2(L
1
Bu
t
)].CH3CN [ZnCl2(L
1
Ph)].CH3CN [ZnCl2(L
1
PhMe)] [ZnCl2(L
1
PhCl)] 
N(1)—Zn 2.0261 (7) 2.0671 (17) 2.058 (4) 2.0499 (12) 2.080 (4) 
N(2)—Zn 2.2253 (7) 2.3700 (18) 2.304 (4) 2.3405 (12) 2.324 (3) 
N(3)—Zn 2.3488 (7) 2.3522 (17) 2.336 (4) 2.3416 (13) 2.324 (3) 
X(1)—Zn 2.0162 (6) 2.2428 (7) 2.2437 (15) 2.2398 (4) 2.2296 (10) 
X(2)—Zn 2.0251 (6) 2.2328 (7) 2.2529 (16) 2.2408 (4) 2.2296 (10) 
C(11)—N(2) 1.2684 (11) 1.261 (3) 1.271 (6) 1.2750 (19) 1.281 (4) 
C(17)—N(3) 1.2716 (11) 1.264 (3) 1.279 (6) 1.2705 (19) 1.281 (4) 
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Table 50. Bond angles and geometrical parameters for complexes of [ZnX2(L
1
R)], Symmetry codes (i) −x, −y, z. 
 [Zn(NO3)2(L
1
Bu
t
)] [ZnCl2(L
1
Bu
t
)] [ZnCl2(L
1
Ph)].CH3CN [ZnCl2(L
1
PhMe)] [ZnCl2(L
1
PhCl)] 
N(1)—Zn—N(2) 76.81 (3) 73.58 (7) 74.66 (15) 74.36 (5) 73.99 (8) 
N(1)—Zn—N(3) 74.63 (3) 74.15 (6) 74.36 (15) 74.28 (5) N(1)—Cu—N(2i) 
N(2)—Zn—N(3) 151.28 (3) 147.54 (6) 149.01 (15) 148.64 (4) 147.97 (16) 
N(1)—Zn—X(1) 138.09 (3) 114.32 (5) 121.68 (13) 120.76 (4) 120.65 (3) 
N(1)—Zn—X(2) 130.71 (3) 123.74 (5) 118.78 (12) 120.90 (4) N(1)—Cu—X(1i) 
N(2)—Zn—X(1) 106.85 (3) 96.91 (5) 100.36 (11) 96.77 (3) 94.35 (7) 
N(2)—Zn—X(2) 100.90 (3) 98.87 (5) 94.31 (11) 99.18 (3) 101.86 (7) 
N(3)—Zn—X(1) 92.55 (3) 99.32 (5) 96.30 (12) 99.05 (3) N(2i)—Cu—X(1) 
N(3)—Zn—X(2) 99.91 (3) 96.08 (5) 99.94 (12) 96.85 (3) N(2i)—Cu—X(1i) 
X(1)—Zn—X(2) 90.37 (3) 121.94 (3) 119.53 (6) 118.340 (18) 118.69 (6) 
N(2)—C(11)—C(12) 119.20 (8) 119.20 (19) 119.2 (5) 119.49 (13) 120.2 (3) 
N(3)—C(17)—C(16) 119.55 (8) 118.98 (18) 119.4 (5) 119.64 (14) 
N(2
i
)—C(11i)—
C(12
i
) 
N(2)—C(11)—C(12)—N(1) 0.63 (12) 0.3 (3) 3.3 (7) −2.0 (2)  
N(3)—C(17)—C(16)—N(1) 1.74 (13) 0.1 (3) 1.6 (8) −1.7 (2)  
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11.5. Tables of Bond lengths and Angles for CoII Complexes of Ligand 
L
1
R 
 
Table 51. Bond lengths for Co
II
 complexes with bis L
1
R ligands. 
 
[Co(L
1
Cy)2][BF4]2. 
CH3CN. 2H2O 
[Co(L
1
Cy)2][NO3]2. 
CH3CN. 2H2O 
[Co(L
1
Cy)2] 
[CoNCS4].CH3CN 
N(1)—Co 1.968 (2) 1.959 (2) 1.942 (6) 
N(2)—Co 2.109 (2) 2.116 (2) 2.233 (7) 
N(3)—Co 2.143 (3) 2.154 (4) 2.270 (6) 
N(4)—Co 1.9924 (19) 1.991 (2) 1.882 (6) 
N(5)—Co 2.198 (2) 2.232 (3) 2.021 (6) 
N(6)—Co 2.304 (2) 2.281 (3) 2.010 (6) 
C(11)—N(2) 1.278 (4) 1.275 (4) 1.246 (8) 
C(17)—N(3) 1.267 (5) 1.258 (5) 1.262 (8) 
C(41)—N(5) 1.277 (3) 1.267 (4) 1.269 (9) 
C(47)—N(6) 1.268 (3) 1.270 (4) 1.274 (9) 
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Table 52. Bond angles and geometrical parameters for Co
II
 complexes with bis L
1
R ligands. 
 
[Co(L
1
Cy)2][BF4]2. 
CH3CN. 2H2O 
[Co(L
1
Cy)2][NO3]2. 
CH3CN. 2H2O 
[Co(L
1
Cy)2] 
[CoNCS4].CH3CN 
N(1)—Co—N(2) 77.99 (9) 76.16 (10) 77.4 (3) 
N(1)—Co—N(3) 77.29 (10) 75.87 (10) 75.4 (3) 
N(1)—Co—N(4) 179.55 (8) 178.42 (10) 176.3 (3) 
N(1)—Co—N(5) 103.75 (8) 102.11 (10) 102.1 (3) 
N(1)—Co—N(6) 104.28 (8) 103.19 (11) 98.1 (3) 
N(2)—Co—N(3) 155.07 (10) 152.03 (10) 152.8 (2) 
N(2)—Co—N(4) 102.32 (9) 105.38 (10) 99.4 (3) 
N(2)—Co—N(5) 86.21 (9) 88.51 (10) 87.0 (2) 
N(2)—Co—N(6) 97.00 (9) 95.37 (11) 95.1 (2) 
N(3)—Co—N(4) 102.42 (10) 102.58 (10) 107.7 (3) 
N(3)—Co—N(5) 96.59 (10) 96.81 (9) 99.1 (2) 
N(3)—Co—N(6) 92.11 (9) 91.46 (10) 88.3 (2) 
N(4)—Co—N(5) 76.62 (8) 77.69 (10) 79.5 (3) 
N(4)—Co—N(6) 75.37 (8) 77.08 (11) 80.3 (3) 
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Table 53. Bond angles and geometrical parameters for Co
II
 complexes with bis L
1
R ligands continued. 
N(5)—Co—N(6) 151.84 (8) 154.60 (11) 159.7 (3) 
N(2)—C(11)—C(12) 117.5 (3) 118.3 (3) 117.8 (8) 
N(3)—C(17)—C(16) 118.0 (3) 119.5 (3) 119.1 (8) 
N(5)—C(41)—C(42) 117.4 (2) 117.5 (3) 117.1 (9) 
N(6)—C(47)—C(46) 120.4 120.7 117.5 (8) 
N(2)—C(11)—C(12)—N(1) 3.9 (4) 2.4 (4) 3.6 (12) 
N(3)—C(17)—C(16)—N(1) 0.4 (4) 0.1 (4) 0.1 (12) 
N(5)—C(11)—C(12)—N(4) 5.3 (4) 3.0 (4) 3.6 (11) 
N(6)—C(11)—C(12)—N(4) 0.4 (4) 2.0 (5) 2.2 (11) 
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Table 54. Bond lengths for Co
II
 complexes [Co(NCS)4]
2- 
and [CoCl2(L
1
PhCl)], Symmetry codes (i) −x, −y+1, z. 
[CoCl2(L
1
PhCl)] [Co(NCS)4]
2-
 
N(1)—Co 2.042 (8) N(7)—Co 1.967 (8) 
N(2)—Co 2.257 (7) N(8)—Co 1.962 (8) 
N(2
i
)—Co 2.257 (7) N(9)—Co 1.910 (9) 
X(1)—Co 2.266 (2) N(10)—Co 1.962 (8) 
X(1
i
)—Co 2.266 (2) C—N 1.136 (10) 
C(11)—N(2) 1.290 (9) C—S 1.637 (10) 
C(11
i
)—N(2i) 1.290 (9)   
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Table 55. Bond angles and geometrical parameters for Co
II
 complexes [Co(NCS)4]
2- 
and [CoCl2(L
1
PhCl)], Symmetry codes (i) −x, −y+1, z. 
 [CoCl2(L
1
PhCl)] [Co(NCS)4]
2-
 
N(1)—Co—N(2) 75.03 (16) N(7)—Co—N(10) 111.4 (3) 
N(1)—Co—N(3) N(1)—Co—N(2i) N(7)—Co—N(9) 106.8 (3) 
N(2)—Co—N(3) 150.1 (3) N(7)—Co—N(8) 108.0 (3) 
N(1)—Co—X(1) 122.06 (6) N(9)—Co—N(8) 115.8 (3) 
N(1)—Co—X(2) N(1)—Co—X(1i) N(10)—Co—N(9) 109.6 (3) 
N(2)—Co—X(1) 93.43 (18) N(10)—Co—N(8) 105.2 (3) 
N(2)—Co—X(2) N(2)—Co—X(1i)   
N(3)—Co—X(1) 102.38 (18)   
N(3)—Co—X(2) N(2i)—Co—X(1i)   
X(1)—Co—X(2) 115.87 (13)   
N(2)—C(11)—C(12) 118.9 (8)   
N(3)—C(17)—C(16) N(2i)—C(11i)—C(12i)   
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11.6. Tables of Bond lengths and Angles for Complexes of Ligand L2R and L3R. 
 
Table 56. Bond lengths for complexes of L
2
R and L
3
R. 
 [ZnCl2(L
2
Cy)] 
[Zn(NO3)(H2O)(L
2
PhMe)] 
[NO3] 
[ZnCl2(L
3
PhMe)]. 2DMF [CuCl2(L
3
Bu
i
)].CH3CN.H2O 
N(1)—M 2.259 (9) 2.235 (2) 2.284 (3) 2.0972 (13) 
N(2)—M 2.072 (9) 2.1085 (18) 2.053 (3) 1.9641 (12) 
N(3)—M 2.325 (9) 2.1215 (19) 2.338 (3) 2.2061 (12) 
N(4)—M - 2.326 (2) - - 
X(1)—M 2.254 (3) 2.067 (2) 2.2296 (8) 2.4064 (4) 
X(2)—M 2.240 (3) 2.0449 (15) 2.2485 (9) 2.2599 (4) 
C(11)—N(1) 1.278 (14) 1.288 (3) 1.269 (4) 1.277 (2) 
C(21)—N(4) 1.260 (15) 1.283 (3) 1.266 (5) 1.256 (2) 
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Table 57. Bond angles and geometrical parameters for complexes of L
2
R and L
3
R 
 [ZnCl2(L
2
Cy)] 
[Zn(NO3)(H2O)(L
2
PhMe)] 
[NO3] 
[ZnCl2(L
3
PhMe)]. 2DMF [CuCl2(L
3
Bu
i
)].CH3CN.H2O 
N(1)—M—N(2) 75.6 (4) 74.68 (7) 74.85 (10) 77.48 (5) 
N(1)—M—N(3) 148.7 (4) 148.89 (7) 149.34 (10) 154.80 (5) 
N(1)—M—N(4) - 138.01 (7) - - 
N(2)—M—N(3) 73.1 (4) 74.21 (8) 74.49 (11) 77.98 (5) 
N(2)—M—N(4) - 146.96 (8) - - 
N(3)—M—N(4) - 73.01 (7) - - 
N(1)—M—X(1) 100.3 (3) 84.87 (9) 96.82 (7) 100.53 (4) 
N(1)—M—X(2) 100.0 (3) 89.81 (7) 100.40 (6) 95.77 (4) 
N(2)—M—X(1) 122.9 (3) 95.67 (8) 118.97 (7) 107.62 (4) 
N(2)—M—X(2) 119.0 (3) 111.74 (6) 121.13 (7) 144.38 (4) 
N(3)—M—X(1) 95.1 (3) 98.39 (8) 98.17 (6) 92.26 (3) 
N(3)—M—X(2) 96.6 (2) 101.43 (7) 95.07 (7) 100.83 (3) 
N(4)—M—X(1) - 85.11 (8) - - 
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Table 58. Bond angles and geometrical parameters for complexes of L
2
R and L
3
R continued. 
 [ZnCl2(L
2
Cy)] 
[Zn(NO3)(H2O)(L
2
PhMe)] 
[NO3] 
[ZnCl2(L
3
PhMe)]. 2DMF [CuCl2(L
3
Bu
i
)].CH3CN.H2O 
N(4)—M—X(2) - 79.00 (6) - - 
X(1)—M—X(2) 117.80 (14) 149.61 (7) 119.85 (4) 107.995 (16) 
N(1)—C(11)—C(12) 118.0 (11) 118.0 (2) 117.8 (3) 117.22 (13) 
N(4)—C(21)—C(22) 121.7 (12) 117.4 (2) 121.5 (3) 121.38 (15) 
N(1)—C(11)—C(12)—N(2) 0.7 (16) 4.0 (3) 3.4 (4) 1.1 (2) 
N(3)—C(26)—C(16)—N(2) 0.6 (14) 1.9 (3) 0.9 (4) 1.05 (18) 
N(3)—C(22)—C(21)—N(4) 161.3 (12) 1.5 (3) 173.2 (3) 170.70 (15) 
 
